{"meta":{"query_hash":"af7a8fbc2407","filters":{"venue":"Expert Opinion on Investigational Drugs"},"cohort_total":130,"direct_labels_cover":0,"predictions_cover":130,"exported":130,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/af7a8fbc2407","api":"https://metacan.xera.ac/api/v1/cohort?venue=Expert+Opinion+on+Investigational+Drugs"},"results":[{"id":"W1574978600","doi":"10.1517/13543784.2015.1057675","title":"Evidence to support peripheral and central IL-6 signaling targets to treat depression","year":2015,"lang":"en","type":"letter","venue":"Expert Opinion on Investigational Drugs","topic":"Tryptophan and brain disorders","field":"Neuroscience","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; St. Michael's Hospital","funders":"Canadian Institutes of Health Research","keywords":"Depression (economics); Medicine; Peripheral; Investigational Drugs; Psychology; Bioinformatics; Psychiatry; Biology; Internal medicine; Clinical trial","score_opus":0.08810745822753124,"score_gpt":0.3210609034709742,"score_spread":0.23295344524344297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1574978600","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.029939326,0.001209043,0.00027966473,0.9606346,0.003416184,0.0015882908,0.0003418365,0.0003206551,0.0022704394],"genre_scores_gemma":[0.027946424,0.00022319653,0.0017200344,0.9631507,0.0041488423,0.00026326827,0.00029635432,0.00010255513,0.0021486462],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99585176,0.0003075837,0.00043753258,0.0012914342,0.0014142827,0.000697434],"domain_scores_gemma":[0.99806327,0.0005661776,0.00014212799,0.00040063396,0.000102551865,0.0007252535],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016467679,0.00052930455,0.00037748384,0.00029410355,0.00027947332,0.00022168377,0.0005328806,0.00039689324,0.0003670817],"category_scores_gemma":[0.0015056398,0.00048385764,0.0001048273,0.0003278147,0.00022154761,0.0003568568,0.00021158939,0.0007088984,0.0002592827],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000077559685,0.000026084721,0.000046893005,0.00003524073,0.000003395301,0.00003164662,0.0033109293,0.00028004605,0.034319576,0.00016413425,0.959238,0.0024665087],"study_design_scores_gemma":[0.00045523304,0.00035036344,0.00031213684,0.0007468007,0.0000016783148,0.00002716012,0.00009857786,0.00012236767,0.056386426,0.00090636447,0.9398834,0.0007095004],"about_ca_topic_score_codex":0.000051202634,"about_ca_topic_score_gemma":8.961016e-7,"teacher_disagreement_score":0.022066848,"about_ca_system_score_codex":0.00025982442,"about_ca_system_score_gemma":0.00041695274,"threshold_uncertainty_score":0.9997613},"labels":[],"label_agreement":null},{"id":"W1622189727","doi":"10.1517/13543784.2015.1052403","title":"Development of experimental and early investigational drugs for the treatment of Ebola virus infections","year":2015,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Viral Infections and Outbreaks Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Public Health Agency of Canada","funders":"","keywords":"Investigational Drugs; Ebola virus; Medicine; Ebola vaccine; Virology; Ebolavirus; Intensive care medicine; Drug development; Biology; Virus; Pharmacology; Drug; Clinical trial; Internal medicine","score_opus":0.1577441369498381,"score_gpt":0.43332750397849157,"score_spread":0.2755833670286535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1622189727","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022406715,0.9934874,0.00009695565,0.00031997502,0.00050354964,0.0025027355,0.00019879025,0.000033435834,0.0006164464],"genre_scores_gemma":[0.00069941423,0.98955005,0.004643261,0.00011531301,0.0006868966,0.0028639585,0.00087151554,0.00007328566,0.0004962828],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99749374,0.00012298182,0.00097507675,0.00041859742,0.00075353525,0.00023607528],"domain_scores_gemma":[0.9979459,0.0006424124,0.00041531568,0.0002974033,0.0003871296,0.00031183352],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038677282,0.00040926645,0.0010325891,0.000417037,0.0003355543,0.000030354395,0.00012061129,0.00023648239,0.000055172502],"category_scores_gemma":[0.00010683732,0.00026733926,0.00037277554,0.0003698863,0.00066751125,0.0000941733,0.00005507556,0.00019216773,0.000016189884],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018103248,0.002640641,0.000055507728,0.0025398703,0.0015444816,7.972189e-7,0.015783068,0.000012398651,0.0014337779,0.024354523,0.007228508,0.9442254],"study_design_scores_gemma":[0.0012143729,0.001135635,0.00009013113,0.0023346792,0.00006224998,0.000016698477,0.00031441092,0.00007054805,0.004783217,0.00018659387,0.98956615,0.00022534182],"about_ca_topic_score_codex":0.00015819844,"about_ca_topic_score_gemma":0.0000022762551,"teacher_disagreement_score":0.9823376,"about_ca_system_score_codex":0.000503521,"about_ca_system_score_gemma":0.002262012,"threshold_uncertainty_score":0.9999779},"labels":[],"label_agreement":null},{"id":"W1814864706","doi":"10.1517/13543784.2011.562190","title":"Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes","year":2011,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Rivaroxaban; Apixaban; Medicine; Edoxaban; Dosing; Clinical trial; Intensive care medicine; Anticoagulant; Fondaparinux; Dabigatran; Pharmacodynamics; Atrial fibrillation; Discovery and development of direct thrombin inhibitors; Thrombosis; Pharmacokinetics; Pharmacology; Warfarin; Internal medicine; Venous thromboembolism; Thrombin","score_opus":0.2905933212457546,"score_gpt":0.4304623271137995,"score_spread":0.1398690058680449,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1814864706","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018779575,0.98866105,0.000054681677,0.0043482315,0.0021487607,0.003273841,0.0004976824,0.00020514622,0.00062282494],"genre_scores_gemma":[0.000059925704,0.98529595,0.0046076537,0.001586178,0.0022579767,0.0002781763,0.0046291333,0.00012333758,0.0011616953],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970843,0.00012916015,0.0010172778,0.00079953216,0.0006287721,0.00034095673],"domain_scores_gemma":[0.9976922,0.0007763278,0.00055869826,0.0003602711,0.00016529771,0.0004471858],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022371268,0.0006936693,0.0015458447,0.00052847445,0.0002837263,0.00006754553,0.00018485074,0.00046531405,0.00027676637],"category_scores_gemma":[0.0002752829,0.00056836754,0.00066411245,0.0003254817,0.00041951396,0.0002700205,0.00013143283,0.0003075911,0.00013074596],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002095117,0.00012406429,0.004178991,0.013504374,0.005084295,0.0000070652727,0.002371528,0.000003062605,0.000022951801,0.23744541,0.16385989,0.57318884],"study_design_scores_gemma":[0.00090276264,0.00026909017,0.0020474312,0.0065998393,0.0002246848,0.000029907353,0.000043824904,0.000024486675,0.000012521849,0.0021599445,0.98712534,0.0005601697],"about_ca_topic_score_codex":0.000011692097,"about_ca_topic_score_gemma":2.5532526e-7,"teacher_disagreement_score":0.82326543,"about_ca_system_score_codex":0.00020977622,"about_ca_system_score_gemma":0.00062290137,"threshold_uncertainty_score":0.99967676},"labels":[],"label_agreement":null},{"id":"W1897302030","doi":"10.1517/13543784.2015.1051220","title":"Targeting of cancer stem cells by inhibitors of DNA and histone methylation","year":2015,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"China Scholarship Council","keywords":"Histone; DNA methylation; Epigenetics; Cancer; Biology; Cancer research; Cancer epigenetics; Cancer stem cell; Stem cell; DNA; Genetics; Histone methyltransferase; Computational biology; Gene; Gene expression","score_opus":0.04232140536129853,"score_gpt":0.3578750581984829,"score_spread":0.3155536528371844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1897302030","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013405434,0.99725205,0.00008102204,0.000052413357,0.00058220857,0.00033091975,0.00023902656,0.000005086658,0.00011671555],"genre_scores_gemma":[0.00062603585,0.9967802,0.00047333416,0.00003216281,0.00039691356,0.000072180526,0.0014183631,0.000040071573,0.00016071051],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99822307,0.00020571264,0.0007062614,0.0003824296,0.00035819234,0.00012433692],"domain_scores_gemma":[0.9986408,0.00006237811,0.00075649814,0.00019808141,0.00022515628,0.00011710474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040752825,0.00026247685,0.000579398,0.00010936167,0.000042082946,0.000008318583,0.00012246206,0.00033455505,0.000008627576],"category_scores_gemma":[0.00005190377,0.00024078402,0.00012969135,0.00013186295,0.00021398671,0.000005870799,0.00007063229,0.00010918376,0.0000015112699],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028825347,0.00011110786,0.00002342358,0.002901022,0.00021676645,1.1331708e-7,0.00059485645,0.00021616396,0.29858223,0.00056231907,0.026266392,0.67049676],"study_design_scores_gemma":[0.00015418729,0.00009883266,0.0000010372117,0.0010167581,0.000014833253,1.3756964e-7,0.000025983509,0.000022971311,0.19560152,0.00009561131,0.80277777,0.00019037658],"about_ca_topic_score_codex":0.00005867912,"about_ca_topic_score_gemma":6.1204827e-7,"teacher_disagreement_score":0.7765114,"about_ca_system_score_codex":0.000057363435,"about_ca_system_score_gemma":0.00036296283,"threshold_uncertainty_score":0.9818888},"labels":[],"label_agreement":null},{"id":"W1965251241","doi":"10.1517/13543780902905848","title":"New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Canadian Institutes of Health Research; Amgen","keywords":"Thrombocytopenic purpura; Medicine; Immunology; Platelet","score_opus":0.1256630411908193,"score_gpt":0.3862692893222556,"score_spread":0.2606062481314363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965251241","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000027295617,0.99249554,0.000043963366,0.0016081319,0.0007486258,0.0028847666,0.00010627938,0.00014932547,0.0019360993],"genre_scores_gemma":[0.00002799764,0.984648,0.004849017,0.0021773588,0.0011505471,0.0006697573,0.0028539828,0.00013123355,0.0034920962],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968351,0.00012944345,0.0008932083,0.0009166884,0.00074695406,0.00047856726],"domain_scores_gemma":[0.99801785,0.00039233448,0.0004969909,0.00052632723,0.00010014762,0.00046633958],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020773968,0.0008326527,0.0023321507,0.00033770443,0.00028678245,0.00008335483,0.0002686287,0.00057268335,0.00010105758],"category_scores_gemma":[0.00027075378,0.00062873465,0.00088807003,0.00032623083,0.00009729303,0.00016623824,0.000041596777,0.00041904283,0.00026591113],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000074383664,0.00034264367,0.000003766594,0.0012112745,0.0009143089,0.000039278544,0.0005387372,0.0000011089239,0.000002918262,0.008619248,0.023114713,0.9651376],"study_design_scores_gemma":[0.0023929814,0.0008025897,0.00003159872,0.027139641,0.00031305407,0.00016963459,0.00002117433,0.000011541314,0.00003114116,0.01277192,0.9557974,0.00051734195],"about_ca_topic_score_codex":0.00006618028,"about_ca_topic_score_gemma":0.000001157429,"teacher_disagreement_score":0.9646203,"about_ca_system_score_codex":0.00059649505,"about_ca_system_score_gemma":0.001632544,"threshold_uncertainty_score":0.9996164},"labels":[],"label_agreement":null},{"id":"W1970919362","doi":"10.1517/13543784.11.8.1061","title":"Cytokine modulation in sepsis and septic shock","year":2002,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Macrophage Migration Inhibitory Factor","field":"Immunology and Microbiology","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Sepsis; Medicine; Septic shock; Cytokine; Proinflammatory cytokine; Tumor necrosis factor alpha; Immunology; Inflammation","score_opus":0.05579661714413267,"score_gpt":0.3200596065372179,"score_spread":0.26426298939308523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970919362","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013060268,0.9965344,0.000015435804,0.0003206638,0.0013822891,0.0006959109,0.00016436291,0.00007943133,0.0006768935],"genre_scores_gemma":[0.00058267044,0.9933694,0.00016886705,0.0004691197,0.00028996172,0.00033797233,0.002536925,0.000060258935,0.0021848327],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975308,0.0005201619,0.0008463448,0.00067617,0.00013058595,0.000295929],"domain_scores_gemma":[0.9987375,0.0004626587,0.00034637284,0.000328814,0.00005931202,0.000065313914],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0001926834,0.000500125,0.0009106357,0.00053762866,0.0001740712,0.000038324666,0.00019483818,0.00067545584,0.0015222039],"category_scores_gemma":[0.0001774067,0.00045149768,0.00019340887,0.0003274351,0.0002634296,0.00014781952,0.00007590075,0.0005832886,0.0011635417],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030038464,0.0003110913,0.000056911806,0.0023411224,0.00029980208,0.0000062386307,0.0032533905,0.00006612932,0.0005257384,0.010838201,0.12148792,0.8607834],"study_design_scores_gemma":[0.0005102434,0.000059305345,0.00007214534,0.0034818365,0.000009959909,0.0000260719,0.000032619075,0.00007178788,0.00006694023,0.00019977715,0.9950562,0.00041309965],"about_ca_topic_score_codex":0.000036321228,"about_ca_topic_score_gemma":0.0000031107675,"teacher_disagreement_score":0.8735683,"about_ca_system_score_codex":0.00024343385,"about_ca_system_score_gemma":0.00014510805,"threshold_uncertainty_score":0.99979365},"labels":[],"label_agreement":null},{"id":"W1972990589","doi":"10.1517/13543784.16.9.1315","title":"Discontinued drugs in 2006: cardiovascular drugs translational medicine perspective","year":2007,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Health and Medical Research Impacts","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Translational medicine; Perspective (graphical); Medicine; Intensive care medicine; Translational research; Pipeline (software); Pharmacology; Computer science; Pathology; Artificial intelligence","score_opus":0.21975101929612723,"score_gpt":0.48077113902438307,"score_spread":0.26102011972825584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972990589","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000085286,0.95037675,0.00009009754,0.02696141,0.0010152871,0.0026195033,0.00013158933,0.000094040995,0.018702772],"genre_scores_gemma":[0.00005231603,0.98300254,0.00054391165,0.0076619894,0.0046594986,0.00048297868,0.002394034,0.00013631345,0.0010664036],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99001193,0.00084771303,0.0017939071,0.0012487072,0.00457946,0.0015182548],"domain_scores_gemma":[0.99109524,0.0021405057,0.0003294774,0.0008038252,0.0005216478,0.0051093153],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005206557,0.00087954244,0.0030830638,0.0016554109,0.00019814425,0.000031270494,0.0003951826,0.00084043335,0.00067115633],"category_scores_gemma":[0.012514204,0.0006608807,0.0011147377,0.0015891868,0.0010541303,0.0002025478,0.00006129613,0.002299596,0.0003064935],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019021038,0.0003206497,0.0000103276225,0.004559184,0.00059597724,0.000056836914,0.0090846,0.0000049052524,8.9127116e-7,0.016409954,0.074877225,0.89388925],"study_design_scores_gemma":[0.0031069203,0.00030471166,0.00010150684,0.033335444,0.00007375011,0.0000538139,0.0011226109,0.000036039557,0.0000031209645,0.0010474909,0.96030563,0.00050893356],"about_ca_topic_score_codex":0.00091561204,"about_ca_topic_score_gemma":0.0000053737017,"teacher_disagreement_score":0.8933803,"about_ca_system_score_codex":0.0019209592,"about_ca_system_score_gemma":0.012813795,"threshold_uncertainty_score":0.99958426},"labels":[],"label_agreement":null},{"id":"W1974617095","doi":"10.1517/13543784.2012.668882","title":"ENMD-2076 for hematological malignancies","year":2012,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hematology; Multiple myeloma; Oncology; Internal medicine; Myeloid leukemia; Cancer research; Leukemia; Aurora inhibitor; Expert opinion; Clinical trial; Lymphoma; Kinase; Cancer; Intensive care medicine; Biology; Cell cycle","score_opus":0.07468509289997952,"score_gpt":0.3500534612008316,"score_spread":0.2753683683008521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974617095","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000018302924,0.99665695,0.00049371895,0.00020843341,0.0009901919,0.000793692,0.00026048007,0.00002636299,0.00055186934],"genre_scores_gemma":[0.000016149928,0.9848566,0.0029706208,0.0011646212,0.002035371,0.0010400658,0.0070555,0.00007061949,0.0007904722],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982224,0.000114786366,0.00051229366,0.0005677779,0.0002143442,0.00036837044],"domain_scores_gemma":[0.99893504,0.00010816924,0.00026826755,0.00039985366,0.000094577874,0.00019406689],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020855914,0.00045179663,0.0006776525,0.000086422544,0.00014485727,0.000030075074,0.00034198057,0.0006532438,0.000043641892],"category_scores_gemma":[0.00014136094,0.00036858924,0.0005248823,0.00008683478,0.00017416533,0.000005476821,0.00012146619,0.00016782041,0.00008887245],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007893366,0.0005623099,0.000012379,0.007379482,0.0006658363,0.0000014772095,0.0003325941,0.000009391028,0.0030771035,0.13640952,0.26368597,0.587785],"study_design_scores_gemma":[0.00018671583,0.00010765908,0.0000010854587,0.0012773892,0.000020303047,0.000029885883,0.000015300802,0.0000054849947,0.0009020221,0.00035447348,0.9966588,0.00044088936],"about_ca_topic_score_codex":0.000002461434,"about_ca_topic_score_gemma":4.1700298e-7,"teacher_disagreement_score":0.7329728,"about_ca_system_score_codex":0.000046585825,"about_ca_system_score_gemma":0.0003255586,"threshold_uncertainty_score":0.9998766},"labels":[],"label_agreement":null},{"id":"W1988024888","doi":"10.1517/13543784.2013.822485","title":"Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia","year":2013,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Canadian Institutes of Health Research","keywords":"PCSK9; Ezetimibe; Alirocumab; Proprotein convertase; Evolocumab; Pharmacology; Tolerability; Kexin; Niacin; Medicine; Statin; Familial hypercholesterolemia; Dyslipidemia; Adverse effect; Internal medicine; Cholesterol; Endocrinology; Apolipoprotein B; Lipoprotein; LDL receptor; Disease; Apolipoprotein A1","score_opus":0.09729688680475103,"score_gpt":0.4063385413648205,"score_spread":0.3090416545600695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988024888","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000072096234,0.9844021,0.00016260995,0.0020126642,0.0023424805,0.010339938,0.00038832935,0.00016202629,0.000117746036],"genre_scores_gemma":[0.000017791783,0.97182864,0.0021371932,0.001413322,0.007823632,0.010527184,0.005626117,0.00018305234,0.00044303972],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951373,0.0004010095,0.0014189885,0.0010971404,0.0013376297,0.0006079596],"domain_scores_gemma":[0.9967956,0.00036112915,0.0006347814,0.0010321714,0.0004429064,0.00073339633],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010141691,0.00090676465,0.0024449648,0.0003942066,0.0004646463,0.00007370433,0.00029425218,0.0005712226,0.0002917562],"category_scores_gemma":[0.0006984058,0.0006552871,0.0015684587,0.00030929036,0.00032471598,0.00019084412,0.00010389981,0.00086626364,0.0002178936],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007295289,0.0005412515,5.8203165e-7,0.010326036,0.00038221112,0.0000014115355,0.0004927114,2.913446e-7,0.0000107474825,0.0048232106,0.0724687,0.9108799],"study_design_scores_gemma":[0.003429172,0.0011063238,0.0000018386374,0.022287123,0.0001020055,0.000025003346,0.000055918048,0.00005983491,0.00019816039,0.00063524925,0.9714728,0.00062654994],"about_ca_topic_score_codex":0.000060048314,"about_ca_topic_score_gemma":4.5703146e-7,"teacher_disagreement_score":0.91025335,"about_ca_system_score_codex":0.0005220485,"about_ca_system_score_gemma":0.0026367242,"threshold_uncertainty_score":0.99958986},"labels":[],"label_agreement":null},{"id":"W1988565068","doi":"10.1517/13543784.10.11.1937","title":"An update on the status of endothelin receptor antagonists for hypertension","year":2001,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Nitric Oxide and Endothelin Effects","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Endothelin receptor; Context (archaeology); Endothelin receptor antagonist; Clinical trial; Damages; Pulmonary hypertension; Intensive care medicine; Blood pressure; Drug; Pharmacology; Receptor; Internal medicine; Cardiology; Biology","score_opus":0.09096548893189195,"score_gpt":0.37419146824180255,"score_spread":0.2832259793099106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988565068","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012511009,0.99152875,0.000046176596,0.0026274088,0.0013936778,0.0026302151,0.0007807952,0.0000883084,0.00077956246],"genre_scores_gemma":[0.000038374284,0.9869597,0.0021445318,0.0047292765,0.001757016,0.000598935,0.0032526618,0.00011849578,0.00040103533],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970075,0.00035397298,0.0008148134,0.00059734256,0.00070572237,0.0005206877],"domain_scores_gemma":[0.9962292,0.0018770848,0.00048835494,0.0007418959,0.00022428526,0.00043919182],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048328986,0.0005156812,0.0012801435,0.0003032042,0.0001781316,0.000026457248,0.0002659356,0.0003314384,0.0002249539],"category_scores_gemma":[0.00090301613,0.00031160528,0.0005094406,0.00034022183,0.00023241028,0.00007078928,0.000029303945,0.00043639398,0.00024017149],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004310875,0.00062243885,0.0000068677364,0.003165735,0.00027499694,0.0000050991607,0.0002879045,0.000008768821,0.00063970865,0.021796016,0.08594211,0.88681924],"study_design_scores_gemma":[0.00097312545,0.00077789044,0.0000039565157,0.009328885,0.00005273633,0.000030558793,0.00005747862,0.00010400246,0.0010281561,0.0004775331,0.9868679,0.0002977889],"about_ca_topic_score_codex":0.000042047035,"about_ca_topic_score_gemma":2.673087e-7,"teacher_disagreement_score":0.90092576,"about_ca_system_score_codex":0.00023826543,"about_ca_system_score_gemma":0.00089292094,"threshold_uncertainty_score":0.9999336},"labels":[],"label_agreement":null},{"id":"W1993494094","doi":"10.1517/13543784.16.10.1627","title":"Omega-3 fatty acid eicosapentaenoic acid. A new treatment for psychiatric and neurodegenerative diseases: a review of clinical investigations","year":2007,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Fatty Acid Research and Health","field":"Nursing","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"The Scarborough Hospital; University of Toronto; University of Prince Edward Island","funders":"","keywords":"Eicosapentaenoic acid; Clinical trial; Schizophrenia (object-oriented programming); Disease; Medicine; Depression (economics); Neuroprotection; Omega 3 fatty acid; Psychiatry; Placebo; Polyunsaturated fatty acid; Internal medicine; Docosahexaenoic acid; Fatty acid; Biology; Alternative medicine; Pathology; Biochemistry","score_opus":0.2169775897946894,"score_gpt":0.49454567394869875,"score_spread":0.27756808415400935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993494094","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000007555645,0.9820108,0.00035391632,0.009259427,0.0022238153,0.0048905597,0.0010101855,0.000078860554,0.00016492578],"genre_scores_gemma":[0.000002337127,0.96445864,0.019555949,0.007608238,0.0026733796,0.0010759255,0.0044366512,0.00011472194,0.00007416815],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99324036,0.0011256428,0.002727323,0.0012478505,0.0010014117,0.00065739284],"domain_scores_gemma":[0.99404615,0.0019653137,0.00133009,0.00072844076,0.00030449813,0.0016254875],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010180731,0.0008320408,0.0026748092,0.0006406368,0.00046203542,0.000071692644,0.0004488929,0.00044377468,0.00007037439],"category_scores_gemma":[0.002196029,0.0006561935,0.0011322204,0.0009772597,0.0006482539,0.0002243806,0.000090294736,0.00065746455,0.00005856452],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019216613,0.00051475264,0.000042663356,0.034402642,0.00020680485,0.0000011913061,0.0003010131,9.799486e-7,0.000005467267,0.00559085,0.0999348,0.85880667],"study_design_scores_gemma":[0.0017510026,0.001703486,0.00008137762,0.045449547,0.00016212337,0.000012742769,0.00002342715,0.00004775788,0.00011426097,0.001307403,0.9488345,0.0005123868],"about_ca_topic_score_codex":0.000081669226,"about_ca_topic_score_gemma":0.000010358708,"teacher_disagreement_score":0.8582943,"about_ca_system_score_codex":0.00041633428,"about_ca_system_score_gemma":0.0036406904,"threshold_uncertainty_score":0.9995889},"labels":[],"label_agreement":null},{"id":"W2000128451","doi":"10.1517/13543784.2014.907272","title":"Recent and current Phase II clinical trials in endometrial cancer: review of the state of art","year":2014,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical trial; Tolerability; Endometrial cancer; Context (archaeology); Disease; Drug development; Quality of life (healthcare); MEDLINE; Intensive care medicine; Cancer; Alternative medicine; Oncology; Bioinformatics; Internal medicine; Pharmacology; Drug; Pathology","score_opus":0.29065493866975994,"score_gpt":0.5403879654482976,"score_spread":0.24973302677853765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000128451","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000028583434,0.9912193,0.0000019416066,0.0023001223,0.0029600563,0.0028930667,0.00036302104,0.000008468101,0.00022544037],"genre_scores_gemma":[0.000005808273,0.99660414,0.000071060356,0.0011128316,0.00109661,0.00053306064,0.00048435733,0.000027994323,0.00006411386],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99166805,0.00276234,0.003955317,0.000490748,0.00093109417,0.0001924689],"domain_scores_gemma":[0.99191207,0.004767007,0.002390754,0.00043426876,0.00022783133,0.0002680752],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005750399,0.00038009253,0.004741459,0.00037162026,0.000045945773,0.0000057133034,0.00021307709,0.00016169396,0.00037960935],"category_scores_gemma":[0.014854867,0.00021164777,0.0010264444,0.0011962326,0.00032936377,0.000035695288,0.00012869404,0.0005349114,0.000007910973],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025765368,0.0006661311,0.000014704958,0.021060344,0.00020060952,2.7944873e-7,0.00003862914,2.3393312e-7,4.540501e-7,0.00022857804,0.00841364,0.9691187],"study_design_scores_gemma":[0.0073078936,0.00073349284,0.00001735104,0.16198388,0.00017033187,0.0000021845276,0.0000012465989,0.000002665802,0.000019297628,0.00019286596,0.82943535,0.00013344843],"about_ca_topic_score_codex":0.00003081514,"about_ca_topic_score_gemma":0.000001073435,"teacher_disagreement_score":0.9689853,"about_ca_system_score_codex":0.00021772542,"about_ca_system_score_gemma":0.0014080573,"threshold_uncertainty_score":0.9934434},"labels":[],"label_agreement":null},{"id":"W2000370942","doi":"10.1517/13543784.9.9.2051","title":"Animal models in xenotransplantation","year":2000,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Xenotransplantation and immune response","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"Medical Research Council; Physicians' Services Incorporated Foundation","keywords":"Xenotransplantation; Biology; Animal model; Computational biology; Transplantation; Medicine; Internal medicine; Endocrinology","score_opus":0.09810914091250716,"score_gpt":0.38366950857728577,"score_spread":0.2855603676647786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000370942","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004455794,0.9885048,0.000039121383,0.0007029649,0.00030771634,0.0010652767,0.00015118138,0.00010455823,0.0090798205],"genre_scores_gemma":[0.000113606715,0.99158293,0.0006108765,0.0014774364,0.00033792455,0.00033059498,0.0049612476,0.00008866508,0.00049672386],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970217,0.00034781103,0.0010148489,0.0005957028,0.0006922422,0.00032774263],"domain_scores_gemma":[0.99879444,0.00038381372,0.00019707668,0.0003275768,0.00005526901,0.00024183036],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002658814,0.0005188962,0.001183544,0.00077286636,0.00008780126,0.000035738598,0.00017643104,0.0004433009,0.00050195487],"category_scores_gemma":[0.000035315185,0.00045648267,0.00038949808,0.000556024,0.00013903702,0.00021965276,0.000009631313,0.00064564304,0.00049436965],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018062672,0.0006139648,0.000004236057,0.008642924,0.00022741767,0.00008961998,0.0041509913,0.00022790024,0.00002955325,0.0402645,0.004911303,0.9390313],"study_design_scores_gemma":[0.0012684595,0.00021277045,0.000053118445,0.025391791,0.000039048773,0.0001737841,0.000039927476,0.00039701417,0.000024815221,0.0005493318,0.9714026,0.00044737436],"about_ca_topic_score_codex":0.000046045876,"about_ca_topic_score_gemma":8.7851697e-7,"teacher_disagreement_score":0.9664913,"about_ca_system_score_codex":0.00027010313,"about_ca_system_score_gemma":0.0010981489,"threshold_uncertainty_score":0.9997887},"labels":[],"label_agreement":null},{"id":"W2002307343","doi":"10.1517/13543784.2011.549125","title":"AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer","year":2011,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; Amgen (Canada)","funders":"","keywords":"Angiopoietin 2; Ovarian cancer; Medicine; Angiogenesis; Malignancy; Cancer; Oncology; Antagonist; Internal medicine; Disease; Tumor progression; Overall survival; Cancer research; Receptor; VEGF receptors; Vascular endothelial growth factor","score_opus":0.0426732515451642,"score_gpt":0.31938400671454525,"score_spread":0.27671075516938104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002307343","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005095742,0.99664074,0.000041671225,0.00006111561,0.0003840597,0.0007572261,0.0007250849,0.000008738372,0.0008717791],"genre_scores_gemma":[0.00045950335,0.99250823,0.0014304329,0.00033571527,0.00052459294,0.0006561367,0.003745301,0.00007899902,0.00026108266],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99837875,0.00007426866,0.00050415314,0.0005440677,0.00027351966,0.00022525078],"domain_scores_gemma":[0.99896777,0.000019319934,0.00041331735,0.00034818682,0.00014668748,0.00010469387],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011651178,0.00036394564,0.00058441545,0.00012808535,0.000054391192,0.0000119723245,0.00027175792,0.00031640698,0.0001111351],"category_scores_gemma":[0.000027081143,0.00028318263,0.00022027387,0.00021542594,0.0002081039,0.0000060611897,0.00008031088,0.00012744516,0.000007925712],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001420163,0.004621421,0.010653553,0.009651144,0.0020533237,0.0000022076074,0.001662528,0.00015027986,0.0008986826,0.021023707,0.096872345,0.85099065],"study_design_scores_gemma":[0.0008606376,0.00022203081,0.0013464229,0.0040084817,0.000013389983,8.850783e-7,0.0000109484845,0.000003889654,0.00039455685,0.000007980599,0.99274766,0.00038313522],"about_ca_topic_score_codex":0.00018861447,"about_ca_topic_score_gemma":0.000008725935,"teacher_disagreement_score":0.8958753,"about_ca_system_score_codex":0.00007297711,"about_ca_system_score_gemma":0.00083483336,"threshold_uncertainty_score":0.99996203},"labels":[],"label_agreement":null},{"id":"W2003487329","doi":"10.1517/13543784.16.4.519","title":"Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent","year":2007,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Cardiac electrophysiology and arrhythmias","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Cardiome Pharma Corp.","keywords":"Medicine; Atrial fibrillation; Cardiology; Sinus rhythm; Internal medicine; Exacerbation; Ranolazine; Anti-Arrhythmia Agents","score_opus":0.08118196522207384,"score_gpt":0.38167944945452537,"score_spread":0.30049748423245154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003487329","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007116547,0.9915122,0.000032214193,0.00039352296,0.002996741,0.0012857069,0.0001236542,0.00014689578,0.0034379407],"genre_scores_gemma":[0.00006300014,0.9864345,0.0005063521,0.0018637291,0.008278114,0.00010699,0.0019370043,0.00011525432,0.0006950576],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965562,0.00021388881,0.0009238647,0.0009485418,0.0008112214,0.0005462879],"domain_scores_gemma":[0.9976316,0.0007050167,0.00049080595,0.00055481127,0.00018990059,0.00042783841],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004301833,0.0007086266,0.0020020006,0.0005099154,0.00024125741,0.00002713355,0.00016338777,0.00072767714,0.000106997904],"category_scores_gemma":[0.00033237675,0.00058536837,0.0015723787,0.0005919575,0.00037390474,0.000076782126,0.00008330193,0.0009829309,0.0006506368],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000597849,0.00027066655,0.000009999947,0.0038578403,0.0027470603,0.0001826076,0.00081133365,0.0000435647,0.00018747212,0.024212882,0.123165436,0.8439133],"study_design_scores_gemma":[0.00082798273,0.00037674385,0.000058549525,0.008119796,0.00010172342,0.0005783351,0.000012780197,0.000011242007,0.00008582317,0.00017086887,0.9891187,0.00053744984],"about_ca_topic_score_codex":0.00002495883,"about_ca_topic_score_gemma":2.5411327e-7,"teacher_disagreement_score":0.86595327,"about_ca_system_score_codex":0.0006788185,"about_ca_system_score_gemma":0.0018806509,"threshold_uncertainty_score":0.9996598},"labels":[],"label_agreement":null},{"id":"W2004668464","doi":"10.1517/13543784.16.8.1183","title":"Looking for novel ways to treat the hallmarks of Alzheimer's disease","year":2007,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Alzheimer's disease research and treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Association of Nurses in Oncology","funders":"","keywords":"Disease; Medicine; Population ageing; Intensive care medicine; Population; Public health; Pathology","score_opus":0.1889479930650907,"score_gpt":0.4335896363934577,"score_spread":0.24464164332836702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004668464","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000003792103,0.9917553,0.00039385085,0.0015038503,0.000322355,0.0038142602,0.000859164,0.00004552721,0.0013018723],"genre_scores_gemma":[0.00011639002,0.988397,0.0023409564,0.0015982009,0.0012300411,0.0019195711,0.004205054,0.00012634072,0.0000664578],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99678254,0.00007229182,0.0008246318,0.0006603037,0.0011640666,0.0004961895],"domain_scores_gemma":[0.99649984,0.0009820131,0.00032204387,0.0006946976,0.00030092246,0.0012004918],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000415987,0.00055627176,0.0011502757,0.00043024044,0.00024498397,0.000033909775,0.0003048145,0.0002050959,0.00009159163],"category_scores_gemma":[0.00041444096,0.0003489844,0.0008829614,0.00041840345,0.00031049713,0.00007465481,0.00010026799,0.0002889696,0.00009996531],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096346013,0.0017944473,0.000027896165,0.006251709,0.01136967,0.000024783792,0.00053166284,0.000017977958,0.0000038510043,0.05558707,0.052985568,0.8704419],"study_design_scores_gemma":[0.0012664094,0.0003118081,0.000087447865,0.013052269,0.0007668864,0.000011017893,0.00003363239,0.00004426358,0.000049743347,0.0005186755,0.9835229,0.00033497936],"about_ca_topic_score_codex":0.000039962037,"about_ca_topic_score_gemma":4.1506146e-7,"teacher_disagreement_score":0.9305373,"about_ca_system_score_codex":0.00022931358,"about_ca_system_score_gemma":0.0018322645,"threshold_uncertainty_score":0.9998962},"labels":[],"label_agreement":null},{"id":"W2005370593","doi":"10.1517/13543784.2012.646081","title":"Apaziquone as an intravesical therapeutic agent for urothelial non-muscle-invasive bladder cancer","year":2011,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Victoria Hospital; London Health Sciences Centre; Western University","funders":"","keywords":"Urothelial carcinoma; Bladder cancer; Mitomycin C; Medicine; Urothelial cancer; Urology; Cancer; Cancer research; Urothelium; Cytotoxic T cell; Urinary bladder; Oncology; Internal medicine; Biology; Surgery; In vitro","score_opus":0.11641905106193319,"score_gpt":0.4085934940975326,"score_spread":0.2921744430355994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005370593","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000033885553,0.98817223,0.0001351327,0.0011628837,0.0024977745,0.004452755,0.0006522949,0.00012960522,0.0027634266],"genre_scores_gemma":[0.0000790867,0.9754831,0.00092870684,0.008919803,0.004790031,0.0057632755,0.0021567845,0.0002431231,0.0016360759],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965942,0.0001918237,0.0008618969,0.0010996083,0.00069584453,0.0005566448],"domain_scores_gemma":[0.99771965,0.00034562172,0.00038850083,0.0006669468,0.00025318415,0.000626074],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019261814,0.0008935282,0.0015891608,0.00029948074,0.00024329234,0.00005735604,0.0003524519,0.0005848862,0.0011404948],"category_scores_gemma":[0.00009965266,0.0006824022,0.0007481881,0.0002528081,0.00033556705,0.00015702611,0.00005235823,0.0005168484,0.0003846923],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000320853,0.0008566932,0.0000041191893,0.0026913383,0.0013915594,0.000008985083,0.0025656435,0.0000013410943,0.000036035,0.010454796,0.016781608,0.964887],"study_design_scores_gemma":[0.0020227549,0.0015540012,0.000058152957,0.008069192,0.0003430067,0.000037064194,0.000075523705,0.000017656814,0.00025342783,0.0021561438,0.9847498,0.0006633039],"about_ca_topic_score_codex":0.00032340825,"about_ca_topic_score_gemma":0.0000069118128,"teacher_disagreement_score":0.96796817,"about_ca_system_score_codex":0.00055132696,"about_ca_system_score_gemma":0.0042285617,"threshold_uncertainty_score":0.9997726},"labels":[],"label_agreement":null},{"id":"W2008784330","doi":"10.1517/13543780902752463","title":"Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Monoclonal antibody; Apoptosis; Medicine; Cancer; Radiation therapy; Chemotherapy; Cancer research; Cancer cell; Immunology; Pharmacology; Oncology; Antibody; Internal medicine; Biology","score_opus":0.06154890020905902,"score_gpt":0.39466437696634865,"score_spread":0.33311547675728964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008784330","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009849112,0.9871044,0.0007183216,0.00018840561,0.0009261748,0.0009188043,0.000053583823,0.000063303036,0.0001778548],"genre_scores_gemma":[0.0019149061,0.9794078,0.010182416,0.00047934637,0.0028207314,0.00017358018,0.0047758,0.000096494594,0.00014891688],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957644,0.000525794,0.0013327503,0.0014059325,0.0005451605,0.00042599317],"domain_scores_gemma":[0.9981207,0.00013639328,0.00067950704,0.0004587396,0.00015003169,0.0004545925],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00077556306,0.0006522981,0.0009959614,0.00011375091,0.0003845187,0.00015790122,0.00036754194,0.0008163939,0.000021956754],"category_scores_gemma":[0.00022958466,0.00051913346,0.0003324616,0.0001640796,0.00047053408,0.000035225683,0.000117678246,0.0005339016,0.000009974421],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034638378,0.00075449946,0.00033175742,0.001012505,0.00034940796,0.000007069545,0.0013419414,0.000112665744,0.0037414413,0.00426362,0.00451886,0.98321986],"study_design_scores_gemma":[0.0006556853,0.0013491731,0.00031089818,0.002496504,0.000032348216,0.000023645565,0.00015057904,0.00022437327,0.00032240205,0.00018509362,0.9933603,0.00088901934],"about_ca_topic_score_codex":0.000018284067,"about_ca_topic_score_gemma":4.3496559e-7,"teacher_disagreement_score":0.9888414,"about_ca_system_score_codex":0.00003699696,"about_ca_system_score_gemma":0.00045015564,"threshold_uncertainty_score":0.999726},"labels":[],"label_agreement":null},{"id":"W2009085459","doi":"10.1517/13543780903336050","title":"Antivascular agents for non-small-cell lung cancer: current status and future directions","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bevacizumab; Medicine; Oncology; Targeted therapy; Lung cancer; Clinical trial; Internal medicine; Vascular endothelial growth factor; Chemotherapy; Monoclonal antibody; Cancer; Intensive care medicine; VEGF receptors; Immunology; Antibody","score_opus":0.03724310527637133,"score_gpt":0.35748955878031713,"score_spread":0.3202464535039458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009085459","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007857347,0.99613625,0.00011657769,0.00021935916,0.0019079346,0.00096357765,0.00041338068,0.000015486004,0.0001488731],"genre_scores_gemma":[0.000005436737,0.98924094,0.0005576722,0.00046692003,0.00508075,0.0010491922,0.003271062,0.000062909385,0.00026512364],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982912,0.00008392687,0.00038727187,0.00070388167,0.00021388044,0.0003198491],"domain_scores_gemma":[0.9990687,0.0000340935,0.0002484977,0.00030289576,0.00012041227,0.00022539854],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011338841,0.0004378407,0.0005468751,0.00010769496,0.00024059913,0.00004529313,0.00017645667,0.00033836122,0.00002286874],"category_scores_gemma":[0.000017956454,0.0003801451,0.00047609978,0.0001387409,0.000079994716,0.000005888939,0.00006354951,0.00015352941,0.000003627593],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010290872,0.000091075875,0.00003459326,0.0017727577,0.00019308073,1.5506319e-7,0.00011933287,0.0000066020143,0.000039738927,0.00038451742,0.068778634,0.9285692],"study_design_scores_gemma":[0.0003622063,0.00007286276,0.000066410845,0.002054203,0.00005579372,0.0000017917021,0.000018771063,0.000031987864,0.00018344066,0.00002306962,0.9966926,0.0004368384],"about_ca_topic_score_codex":0.000019321997,"about_ca_topic_score_gemma":0.0000017023702,"teacher_disagreement_score":0.9281324,"about_ca_system_score_codex":0.00009955793,"about_ca_system_score_gemma":0.00067290047,"threshold_uncertainty_score":0.99986506},"labels":[],"label_agreement":null},{"id":"W2011994674","doi":"10.1517/13543780903184591","title":"Discontinued psychiatric drugs in 2008","year":2009,"lang":"en","type":"article","venue":"Expert Opinion on Investigational Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Mental illness; Psychiatry; Mood disorders; Medicine; Disease; Mood; Psychology; Mental health; Anxiety","score_opus":0.025545702541629953,"score_gpt":0.32921201957993546,"score_spread":0.3036663170383055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011994674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78407764,0.005059541,0.00002080224,0.19146222,0.000753902,0.0011133467,0.00002553472,0.00015553091,0.017331492],"genre_scores_gemma":[0.9877162,0.00053123623,0.0055714147,0.0042914427,0.00074243423,0.00010255256,0.00034336402,0.000018807861,0.00068257534],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99824274,0.000073140836,0.00031136523,0.00036943195,0.00068386097,0.00031943736],"domain_scores_gemma":[0.9991622,0.00009816486,0.00005831493,0.00027251738,0.000050876006,0.00035791905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001627027,0.00019084869,0.00022863838,0.00036261175,0.00009082895,0.000027103115,0.000103848164,0.000081783895,0.00018802003],"category_scores_gemma":[0.00011971475,0.00015557141,0.000101797814,0.0004775778,0.00009113966,0.00011781398,0.000015161846,0.00024934587,0.00026750984],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0116331065,0.0047734906,0.040822882,0.00004985526,0.00018184938,0.00008911585,0.007677481,0.00014318015,0.0014396617,0.4657429,0.2907752,0.17667128],"study_design_scores_gemma":[0.013217058,0.0013661222,0.91002506,0.00037059924,0.000004633039,0.00003535528,0.0004050117,0.0011147485,0.0027285672,0.040525593,0.02977323,0.00043402988],"about_ca_topic_score_codex":0.00005196912,"about_ca_topic_score_gemma":0.000005123319,"teacher_disagreement_score":0.8692022,"about_ca_system_score_codex":0.00017852962,"about_ca_system_score_gemma":0.00037998677,"threshold_uncertainty_score":0.6344018},"labels":[],"label_agreement":null},{"id":"W2013917368","doi":"10.1517/13543784.13.2.139","title":"Current and investigational treatment of psoriatic arthritis","year":2004,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Medicine; Psoriatic arthritis; Leflunomide; Psoriasis; Rheumatoid arthritis; Disease; Arthritis; Clinical trial; Antirheumatic drugs; Internal medicine; Oncology; Antirheumatic Agents; Immunology","score_opus":0.07521642956042679,"score_gpt":0.3736866971312487,"score_spread":0.2984702675708219,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013917368","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007857731,0.99634075,0.0000034244288,0.000663842,0.0010124273,0.001250146,0.0003130235,0.000044785695,0.00029302927],"genre_scores_gemma":[0.00005792363,0.99461037,0.0010709065,0.00016740197,0.00075730594,0.0007322519,0.002479017,0.00005995729,0.00006484933],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99746466,0.000095273324,0.0008949735,0.00062077044,0.000656319,0.00026802183],"domain_scores_gemma":[0.9984921,0.00025828058,0.0004318532,0.00032155172,0.00012916845,0.00036699467],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000074269825,0.00060017506,0.001687124,0.0003147363,0.00016511473,0.00002179324,0.00007356536,0.0002079159,0.00009004686],"category_scores_gemma":[0.00012039905,0.00047061575,0.00042724118,0.00028388153,0.00047829511,0.000066584864,0.000041525844,0.00017590482,0.00007549288],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020489215,0.0005529316,0.00002994666,0.0023976183,0.00040802464,0.000008728452,0.000579738,0.0000012348208,3.4407734e-7,0.014382035,0.0011492696,0.98046964],"study_design_scores_gemma":[0.0031587186,0.000973936,0.00016299158,0.044485904,0.00009976495,0.00010385682,0.00003125106,0.000004100694,0.000013648854,0.0021629557,0.94848967,0.00031321598],"about_ca_topic_score_codex":0.00007664904,"about_ca_topic_score_gemma":0.0000018714273,"teacher_disagreement_score":0.9801564,"about_ca_system_score_codex":0.00055794645,"about_ca_system_score_gemma":0.0012356174,"threshold_uncertainty_score":0.9997746},"labels":[],"label_agreement":null},{"id":"W2015553616","doi":"10.1517/13543784.11.7.937","title":"Novel therapies in the treatment of spondyloarthritis","year":2002,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Ankylosing spondylitis; Psoriatic arthritis; Observational study; Adalimumab; Clinical trial; Inflammatory arthritis; Intensive care medicine; Placebo; Tumor necrosis factor alpha; Arthritis; Internal medicine; Alternative medicine; Pathology","score_opus":0.11037823578546131,"score_gpt":0.3657993861203648,"score_spread":0.2554211503349035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015553616","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000079586105,0.9946898,9.2743807e-7,0.0010750829,0.00043758503,0.0013225282,0.00022284934,0.000021328318,0.0021502697],"genre_scores_gemma":[0.00006641278,0.9963769,0.00045368905,0.00046658292,0.00051861856,0.0009888854,0.0007853134,0.00004454415,0.00029905266],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979471,0.00012847826,0.00068130984,0.00041569545,0.00057938806,0.00024806024],"domain_scores_gemma":[0.998692,0.00046850173,0.00025766657,0.00043630923,0.000058407837,0.000087152985],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010404193,0.00046868855,0.0013305197,0.00027517646,0.000109454086,0.000017730988,0.00014526227,0.00019218223,0.00020168486],"category_scores_gemma":[0.00004340977,0.00027702472,0.0005273966,0.0004067861,0.00027088673,0.000041561023,0.000014847795,0.00016453555,0.00008468991],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029974119,0.0019727864,0.000030590203,0.0005036691,0.00033352495,0.000026592406,0.005105075,4.6322165e-7,0.0000011766189,0.005095347,0.0027183031,0.9841825],"study_design_scores_gemma":[0.0023270363,0.0011638483,0.00016654383,0.009064827,0.000038835176,0.00011417781,0.00028586196,0.0000021609508,0.0000038483972,0.000093174545,0.9865436,0.00019610039],"about_ca_topic_score_codex":0.00010409579,"about_ca_topic_score_gemma":0.000005947784,"teacher_disagreement_score":0.9839864,"about_ca_system_score_codex":0.00024913272,"about_ca_system_score_gemma":0.00016294456,"threshold_uncertainty_score":0.9999682},"labels":[],"label_agreement":null},{"id":"W2017150135","doi":"10.1517/13543784.14.8.1019","title":"Angiotensin-(1-7) and its receptor as a potential targets for new cardiovascular drugs","year":2005,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Renin-Angiotensin System Studies","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute","funders":"","keywords":"Angiotensin II receptor type 1; Renin–angiotensin system; Angiotensin II; Receptor; Angiotensin receptor; Angiotensin-converting enzyme; Pharmacology; Internal medicine; Biology; Chemistry; Endocrinology; Medicine; Blood pressure","score_opus":0.06479758894437689,"score_gpt":0.35178939358215555,"score_spread":0.2869918046377787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017150135","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008743563,0.9864373,0.0000840868,0.006522428,0.0024108433,0.0036233487,0.00015512774,0.0001723386,0.00058576744],"genre_scores_gemma":[0.000021872213,0.974024,0.0078043165,0.0016423853,0.010661841,0.00050327287,0.0017229561,0.00022718901,0.0033921874],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950603,0.00028206897,0.0012233338,0.001368126,0.0014465282,0.0006196365],"domain_scores_gemma":[0.99700886,0.000425583,0.00049966876,0.0007283095,0.0005553566,0.00078221835],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005973031,0.0010330945,0.0032789211,0.0005138678,0.00034583936,0.000085077874,0.00023888334,0.00072753365,0.00008829096],"category_scores_gemma":[0.0008013818,0.00085932243,0.00222394,0.00039538328,0.00022358856,0.00016084564,0.00015978447,0.0004795308,0.0004719324],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008953478,0.00007082307,9.489318e-7,0.0014153293,0.003298676,0.000010190363,0.0012615754,0.0000132063815,0.000013343919,0.0023576205,0.35717157,0.6342972],"study_design_scores_gemma":[0.0015800587,0.00025228862,0.000015065477,0.013706615,0.000438235,0.00028191932,0.00005268915,0.000058480957,0.000040315233,0.00013909367,0.9826729,0.000762291],"about_ca_topic_score_codex":0.00005754739,"about_ca_topic_score_gemma":2.4680568e-7,"teacher_disagreement_score":0.6335349,"about_ca_system_score_codex":0.0004255775,"about_ca_system_score_gemma":0.0014882658,"threshold_uncertainty_score":0.9993858},"labels":[],"label_agreement":null},{"id":"W2020509695","doi":"10.1517/13543784.16.3.397","title":"3<sup>rd</sup>PacRim Breast and Prostate Cancer Meeting","year":2007,"lang":"en","type":"article","venue":"Expert Opinion on Investigational Drugs","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Androgen receptor; Breast cancer; Context (archaeology); Estrogen; Medicine; Estrogen receptor; Cancer; Prostate; Oncology; Internal medicine; Gynecology; Cancer research; Biology","score_opus":0.03216663827553005,"score_gpt":0.34997464406226947,"score_spread":0.3178080057867394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020509695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8941841,0.012471223,0.000029397605,0.074412584,0.00053042494,0.0012890365,0.00014938031,0.00021176333,0.016722063],"genre_scores_gemma":[0.98029536,0.004841684,0.0018182604,0.005847954,0.0017301695,0.00023343806,0.00051514816,0.00006895667,0.0046490463],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99822927,0.00004280922,0.0002837259,0.00039284065,0.00064746616,0.00040388803],"domain_scores_gemma":[0.9989748,0.00016071762,0.00006906489,0.00016756103,0.00018635947,0.00044150028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004057131,0.00020417313,0.00020575729,0.00018407353,0.00023455221,0.000039555292,0.000066350665,0.000091140995,0.00015407712],"category_scores_gemma":[0.000076166405,0.00016004188,0.000054594973,0.00024338135,0.0003428538,0.0001428504,0.0000499661,0.00023442882,0.00003997033],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071612983,0.00137688,0.31033778,0.0007788292,0.0009664636,0.00018806945,0.07373097,0.00070199254,0.04578388,0.032771606,0.25237685,0.27382538],"study_design_scores_gemma":[0.016884465,0.0012943529,0.28287768,0.0045768977,0.00003438853,0.00039502323,0.008319644,0.006416813,0.07689859,0.004905835,0.5959671,0.0014292008],"about_ca_topic_score_codex":0.0003601155,"about_ca_topic_score_gemma":0.0000036627684,"teacher_disagreement_score":0.34359026,"about_ca_system_score_codex":0.0002727177,"about_ca_system_score_gemma":0.0003672478,"threshold_uncertainty_score":0.6526318},"labels":[],"label_agreement":null},{"id":"W2021916888","doi":"10.1517/13543784.12.7.1067","title":"Potential new drugs for therapy of chronic obstructive pulmonary disease","year":2003,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Bern; University of Saskatchewan; Eli Lilly and Company","keywords":"Medicine; Inflammation; Chemokine; COPD; Immunology; Pulmonary disease; Monocyte; Lung; Disease; Internal medicine","score_opus":0.05510405966884598,"score_gpt":0.3654987197261629,"score_spread":0.3103946600573169,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021916888","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003487903,0.9901237,0.000115980016,0.0010633295,0.0015773054,0.004698946,0.0009816163,0.00008082149,0.0013234328],"genre_scores_gemma":[0.00007027977,0.9847142,0.0010494433,0.00046881408,0.003511355,0.0013590071,0.005719543,0.00024397609,0.002863362],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945551,0.00038264546,0.0012640598,0.0013521389,0.0017091903,0.00073686946],"domain_scores_gemma":[0.9958424,0.0005389482,0.0006991386,0.0009998587,0.0004756437,0.0014440074],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029985048,0.00096027605,0.0019366258,0.00066724955,0.0002347629,0.000041950876,0.0005231859,0.00045333797,0.00083735614],"category_scores_gemma":[0.00027097896,0.00083739293,0.0015619564,0.00067330775,0.0007994954,0.00021440149,0.00011979414,0.0007030453,0.0000999277],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006145661,0.00070165,0.000013353146,0.010905738,0.0005756599,0.000025233858,0.0002204704,0.000027222004,0.000017560436,0.01198398,0.016268969,0.9586456],"study_design_scores_gemma":[0.001995786,0.00022315574,0.00042274353,0.009059961,0.00010049562,0.000046822435,0.00008136529,0.0002840965,0.000032995285,0.0050861184,0.981982,0.0006844655],"about_ca_topic_score_codex":0.0000432787,"about_ca_topic_score_gemma":1.348864e-7,"teacher_disagreement_score":0.965713,"about_ca_system_score_codex":0.0017258517,"about_ca_system_score_gemma":0.011889126,"threshold_uncertainty_score":0.9994077},"labels":[],"label_agreement":null},{"id":"W2024461486","doi":"10.1517/13543784.2011.566862","title":"Aromatase inhibition: a potential target for the management of recurrent or metastatic endometrial cancer by letrozole: more questions than answers?","year":2011,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Letrozole; Medicine; Aromatase; Metastatic breast cancer; Tamoxifen; Endometrial cancer; Hormonal therapy; Oncology; Internal medicine; Clinical trial; Breast cancer; Aromatase inhibitor; Anastrozole; Disease; Cancer","score_opus":0.047020588754872035,"score_gpt":0.35858271814898407,"score_spread":0.31156212939411204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024461486","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004149437,0.99290806,0.0008946942,0.00031857446,0.0014016969,0.0018704332,0.0025027615,0.000015621006,0.000046671707],"genre_scores_gemma":[0.00007925092,0.98530406,0.0022540805,0.00014424602,0.0006460873,0.0023394118,0.008939406,0.000055225963,0.0002382352],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981048,0.00020761362,0.0005993755,0.0005062516,0.00033002536,0.0002519258],"domain_scores_gemma":[0.9987951,0.00012253922,0.00046141632,0.00037878338,0.000098395976,0.00014374797],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002776674,0.000410878,0.0005521744,0.00013641958,0.00019495438,0.000026173435,0.0002852014,0.00024495542,0.00006304578],"category_scores_gemma":[0.000068281275,0.0002610865,0.00047952693,0.0002794141,0.00027065404,0.000009071996,0.0000984795,0.00021980374,0.000008586617],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015417914,0.0011853931,8.964217e-7,0.009296811,0.007651971,0.000013063993,0.00037963505,0.000188456,0.0009140601,0.010370132,0.45495585,0.51350194],"study_design_scores_gemma":[0.0010829405,0.00054669165,7.699396e-7,0.0035938264,0.00022378392,0.000013634039,0.000057121102,0.0000371508,0.0017556592,0.000097526296,0.992269,0.00032192134],"about_ca_topic_score_codex":0.000029478708,"about_ca_topic_score_gemma":3.9632195e-7,"teacher_disagreement_score":0.5373131,"about_ca_system_score_codex":0.00005835633,"about_ca_system_score_gemma":0.00034327185,"threshold_uncertainty_score":0.99998415},"labels":[],"label_agreement":null},{"id":"W2033435813","doi":"10.1517/13543784.12.11.1855","title":"Experimental and clinical studies show that the probucol derivative AGI-1067 prevents vascular growth","year":2003,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Probucol; Restenosis; Medicine; Internal medicine; Endocrinology; Lipoprotein; Cholesterol; Stent","score_opus":0.16570150015299992,"score_gpt":0.43428749972595293,"score_spread":0.26858599957295304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033435813","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018039314,0.9927738,0.00002443542,0.0010597282,0.0011551789,0.0042657936,0.000023098666,0.000056283665,0.00046134114],"genre_scores_gemma":[0.00012584924,0.9914713,0.00090416626,0.0034252612,0.0015124638,0.0019360123,0.00028966402,0.00009625081,0.00023906805],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99483234,0.0014081299,0.0010047797,0.0009478457,0.0014229316,0.00038395025],"domain_scores_gemma":[0.9975439,0.00063451706,0.0004576095,0.00076430023,0.00019715459,0.00040256712],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001668705,0.00067619194,0.0020780286,0.00014629003,0.00040639978,0.00005578086,0.00023969622,0.00040206884,0.00004472474],"category_scores_gemma":[0.0006460256,0.00040674862,0.0011990442,0.00029600732,0.0008118152,0.0001328856,0.00017481904,0.0008212353,0.0000377563],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013604181,0.0020412838,0.0004091001,0.021517375,0.018941287,0.00006375169,0.008462123,0.0000013087359,0.0000078453995,0.028967092,0.08855631,0.8308965],"study_design_scores_gemma":[0.0012160626,0.00038165148,0.00012747859,0.012056906,0.00018687123,0.00012375397,0.0007849767,0.000004769533,0.00007658917,0.00033833933,0.98427504,0.00042754656],"about_ca_topic_score_codex":0.000025586998,"about_ca_topic_score_gemma":2.2654187e-7,"teacher_disagreement_score":0.89571875,"about_ca_system_score_codex":0.00036705926,"about_ca_system_score_gemma":0.0009694178,"threshold_uncertainty_score":0.9998384},"labels":[],"label_agreement":null},{"id":"W2034340607","doi":"10.1517/13543784.2010.532123","title":"Na <sup>+</sup> /H <sup>+</sup> exchanger-1: a link with atherogenesis?","year":2010,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Ion Transport and Channel Regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Biogen Idec","keywords":"Dyslipidemia; Inflammation; Medicine; Intracellular; Diabetes mellitus; Vascular smooth muscle; Sodium–hydrogen antiporter; Internal medicine; Endocrinology; Chemistry; Pharmacology; Bioinformatics; Cell biology; Sodium; Biochemistry; Smooth muscle; Biology","score_opus":0.03270307871499557,"score_gpt":0.29272651002668293,"score_spread":0.26002343131168737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034340607","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015905498,0.9937474,0.00048076568,0.0009974663,0.000592945,0.0013762433,0.00030500608,0.00011363871,0.0007960017],"genre_scores_gemma":[0.0006841802,0.970567,0.001543936,0.0012398555,0.0058107935,0.000935149,0.017064001,0.00026839762,0.0018866941],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996219,0.00023383464,0.00086342514,0.0012676249,0.0008465872,0.000569573],"domain_scores_gemma":[0.9978354,0.000081512684,0.00047342712,0.00089496345,0.0002901268,0.0004245839],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00035402458,0.0009811609,0.0010216088,0.00028817903,0.00032443245,0.00008691899,0.00059197994,0.0013373647,0.0002072677],"category_scores_gemma":[0.0000649867,0.0008051383,0.00061491027,0.000381563,0.00040852075,0.000023845918,0.00008738544,0.000614876,0.00018119336],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003364514,0.00052613666,0.000060647337,0.0040166588,0.0010504335,0.000018850216,0.0034013584,0.0036120005,0.00061084033,0.0053337333,0.025173044,0.95585984],"study_design_scores_gemma":[0.00063833944,0.00030253897,0.000008676433,0.0027483967,0.000050144088,0.000048672668,0.0001039329,0.000523914,0.0009735943,0.00012277452,0.99353504,0.00094395137],"about_ca_topic_score_codex":0.000021510336,"about_ca_topic_score_gemma":0.0000023632294,"teacher_disagreement_score":0.96836203,"about_ca_system_score_codex":0.00008998953,"about_ca_system_score_gemma":0.0008950991,"threshold_uncertainty_score":0.9999591},"labels":[],"label_agreement":null},{"id":"W2035153450","doi":"10.1517/13543784.15.4.335","title":"Optimal antimicrobial therapy: the balance of potency and exposure","year":2006,"lang":"en","type":"editorial","venue":"Expert Opinion on Investigational Drugs","topic":"Urinary Tract Infections Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Royal University Hospital","funders":"","keywords":"Antimicrobial; Medicine; Intensive care medicine; Pharmacotherapy; Antibiotics; Clinical trial; Drug; Antimicrobial drug; Internal medicine; Pharmacology; Biology; Microbiology","score_opus":0.01338367502739927,"score_gpt":0.2792595564198222,"score_spread":0.2658758813924229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035153450","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019217314,0.008113972,0.0001397751,0.019496826,0.93841976,0.002202376,0.0004824148,0.00022217857,0.01170536],"genre_scores_gemma":[0.01522302,0.010921929,0.0039049438,0.0024712535,0.9575223,0.000322241,0.004567129,0.00015871506,0.0049084686],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977205,0.00011688819,0.0005117583,0.00046003045,0.00097326667,0.00021758399],"domain_scores_gemma":[0.9983015,0.00051488075,0.00033590317,0.00046385717,0.0002885731,0.00009529628],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031268556,0.00035022758,0.00041210666,0.000208196,0.00019060116,0.000040075094,0.0001971749,0.0003901051,0.00006602589],"category_scores_gemma":[0.0002301864,0.00025815723,0.00014484437,0.0002103513,0.00046364605,0.00010061032,0.00007705526,0.0006614483,0.000018715937],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016856554,0.00057314173,0.00013869427,0.000077604745,0.00011805185,0.0000029859634,0.00034483118,0.00017567449,0.00030901202,0.0009234996,0.99655163,0.0006162903],"study_design_scores_gemma":[0.0015243198,0.0010918347,0.0017688847,0.00048744061,0.000011845407,0.000010426919,0.00004257836,0.00008293635,0.0006893904,0.00013355866,0.99392325,0.00023355747],"about_ca_topic_score_codex":0.00023125381,"about_ca_topic_score_gemma":7.956372e-7,"teacher_disagreement_score":0.019102518,"about_ca_system_score_codex":0.000108126675,"about_ca_system_score_gemma":0.000418123,"threshold_uncertainty_score":0.99998707},"labels":[],"label_agreement":null},{"id":"W2037261747","doi":"10.1517/13543780903143753","title":"Rosiglitazone maleate + metformin hydrochloride extend: review of an emerging compound","year":2009,"lang":"en","type":"article","venue":"Expert Opinion on Investigational Drugs","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Credit Valley Hospital; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Rosiglitazone; Metformin Hydrochloride; Metformin; Medicine; Glycemic; Type 2 diabetes; Pill; Pharmacology; Diabetes mellitus; Endocrinology","score_opus":0.03459180608237115,"score_gpt":0.337369398605298,"score_spread":0.30277759252292685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037261747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.55488205,0.18548375,0.00044473197,0.12216338,0.0027435692,0.0057002916,0.00009501745,0.0008251922,0.12766202],"genre_scores_gemma":[0.7440834,0.08919315,0.04309995,0.11011967,0.002075674,0.00044382774,0.005466115,0.00013217145,0.0053860378],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99839044,0.00004839048,0.0004511588,0.00030640792,0.0005905755,0.00021302623],"domain_scores_gemma":[0.9991218,0.000053485855,0.0001608727,0.00034150068,0.00010148433,0.00022087105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030655312,0.0002058767,0.00037765224,0.0001641358,0.00007612314,0.000012172796,0.000114453345,0.000042319385,0.0002009533],"category_scores_gemma":[0.0000799371,0.00017458935,0.00012474893,0.00023061408,0.000084143925,0.00023903302,0.000023071827,0.00009328439,0.000052277137],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078327523,0.004822213,0.00068426796,0.004705368,0.0008379428,0.00008370105,0.0042244033,0.00020105901,0.02345848,0.38111508,0.17052673,0.40855747],"study_design_scores_gemma":[0.0063843145,0.0043360367,0.016089141,0.028902082,0.00013034373,0.000052137624,0.0005579481,0.002781141,0.07677747,0.018594407,0.8443496,0.001045335],"about_ca_topic_score_codex":0.000015688065,"about_ca_topic_score_gemma":1.9438625e-7,"teacher_disagreement_score":0.67382294,"about_ca_system_score_codex":0.000096804746,"about_ca_system_score_gemma":0.00006550236,"threshold_uncertainty_score":0.7119547},"labels":[],"label_agreement":null},{"id":"W2039029105","doi":"10.1517/13543784.13.3.245","title":"The therapeutic potential of angiotensin II receptor blockers in the treatment of heart failure","year":2004,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Heart Failure Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"","keywords":"Angiotensin II; Heart failure; Medicine; Renin–angiotensin system; Aldosterone; Clinical trial; Internal medicine; Angiotensin Receptor Blockers; Cardiology; Angiotensin-converting enzyme; Angiotensin II receptor type 1; Pharmacology; Angiotensin receptor; Endocrinology; Receptor; Blood pressure","score_opus":0.043718400046902015,"score_gpt":0.33794365659088843,"score_spread":0.2942252565439864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039029105","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008796718,0.9345944,0.0000025235058,0.062581755,0.00041441212,0.0022092625,0.000028750004,0.000019703333,0.00006124348],"genre_scores_gemma":[0.00023903378,0.9951859,0.0024278024,0.0005353305,0.00037500384,0.00038169953,0.0005301647,0.00003747318,0.00028760912],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99767077,0.00028701348,0.0007508825,0.00033709937,0.0007051479,0.00024909613],"domain_scores_gemma":[0.9986857,0.0003145386,0.00029221887,0.0005345498,0.000085123334,0.00008783055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028982508,0.00039617522,0.0009671961,0.00021897294,0.00017874732,0.000016135333,0.00018386992,0.00019469431,0.000050845756],"category_scores_gemma":[0.00003076925,0.00019421888,0.000625618,0.0004047956,0.00034492646,0.00003417318,0.000026149006,0.00017845964,0.000030521656],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028136134,0.0045416127,0.000032371052,0.0028782478,0.0023796742,0.000013795839,0.009984685,0.00004779864,0.00008420723,0.033825275,0.2522182,0.6937128],"study_design_scores_gemma":[0.0011115687,0.0011254149,0.000032498006,0.0052680396,0.00010479935,0.000013754895,0.0002971513,0.0000054508328,0.0000699762,0.00022090418,0.99160624,0.00014418483],"about_ca_topic_score_codex":0.00011791411,"about_ca_topic_score_gemma":0.000004952656,"teacher_disagreement_score":0.73938805,"about_ca_system_score_codex":0.00035109307,"about_ca_system_score_gemma":0.0006863993,"threshold_uncertainty_score":0.7920016},"labels":[],"label_agreement":null},{"id":"W2043656098","doi":"10.1517/13543784.12.7.1143","title":"Clinically tested drugs for Alzheimer’s disease","year":2003,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Alzheimer's disease research and treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Neuroinflammation; Disease; Medicine; Oxidative stress; Acetylcholinesterase; Clinical trial; Forebrain; Drug; Cholinergic neuron; Cholinergic; Pathological; Neuroscience; Pharmacology; Internal medicine; Psychology; Central nervous system; Biology","score_opus":0.1734363243478155,"score_gpt":0.45406705170395134,"score_spread":0.2806307273561358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043656098","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000018636692,0.98990667,0.000011789814,0.0015391833,0.0007976094,0.004417718,0.00097614335,0.00015104275,0.002197986],"genre_scores_gemma":[0.00001646754,0.9761117,0.0020047058,0.003163022,0.001322837,0.0038266964,0.012985816,0.0002021759,0.00036656234],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949196,0.00040198147,0.0013661651,0.0012137641,0.0013852285,0.000713276],"domain_scores_gemma":[0.99415046,0.0016201766,0.0005177049,0.00091912533,0.00041708938,0.0023754216],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047259647,0.0008744405,0.0017723971,0.00040824324,0.00032031702,0.00007970755,0.0003293416,0.00042518615,0.00033037396],"category_scores_gemma":[0.00088457024,0.0006843325,0.0014339028,0.00046205206,0.00044870927,0.00013836128,0.000078382654,0.0005581345,0.00088451436],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009937473,0.0029611913,0.0001019117,0.0060332734,0.0198996,0.000068852874,0.00021832681,0.0000022703894,1.2570518e-7,0.016896203,0.21462218,0.73820233],"study_design_scores_gemma":[0.0022062026,0.00048596066,0.000041735402,0.0108686425,0.000968289,0.000013796946,0.000023111772,0.000038579754,0.0000015432009,0.0014278289,0.98334044,0.0005838602],"about_ca_topic_score_codex":0.000008666906,"about_ca_topic_score_gemma":6.862192e-8,"teacher_disagreement_score":0.76871824,"about_ca_system_score_codex":0.00031188334,"about_ca_system_score_gemma":0.0053066625,"threshold_uncertainty_score":0.9998934},"labels":[],"label_agreement":null},{"id":"W2045036128","doi":"10.1517/13543784.2014.974803","title":"Ticagrelor for the treatment of peripheral arterial disease","year":2014,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Ticagrelor; Medicine; Clopidogrel; Intensive care medicine; Expert opinion; Clinical trial; Disease; Adverse effect; Arterial disease; Cardiology; Pharmacology; Internal medicine; Myocardial infarction; Vascular disease","score_opus":0.0663237658817336,"score_gpt":0.3664681768823458,"score_spread":0.3001444110006122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045036128","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000020755513,0.9957109,0.0002746063,0.00073728623,0.001056498,0.0018376746,0.0002353676,0.000031862997,0.000095037634],"genre_scores_gemma":[0.000045128054,0.99231815,0.00021881862,0.0005556648,0.0034065503,0.0012795719,0.0018081167,0.00005606369,0.0003119175],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984157,0.00013847345,0.00047375815,0.00035673063,0.00043650018,0.00017884797],"domain_scores_gemma":[0.99845994,0.00048560175,0.00020148991,0.00050376833,0.000088108005,0.0002610939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012217383,0.00036108054,0.0011388878,0.000073390496,0.00013943763,0.000020170632,0.00013059814,0.00013331336,0.00014801102],"category_scores_gemma":[0.00008541988,0.0002031744,0.0018138237,0.00009375917,0.00027977838,0.00002734094,0.000009508109,0.000071361785,0.000028455524],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047474558,0.0003734969,0.0000019017206,0.0022267106,0.0014385222,0.0000019415334,0.00025441428,0.000009874081,8.427565e-7,0.006615261,0.0068370127,0.9817653],"study_design_scores_gemma":[0.001585768,0.00046170168,0.000029972818,0.003487207,0.00037796912,0.00000790067,0.000020671652,0.000095592375,0.0000057792613,0.00018461481,0.9935486,0.00019425216],"about_ca_topic_score_codex":0.000004061068,"about_ca_topic_score_gemma":5.7114786e-8,"teacher_disagreement_score":0.98671156,"about_ca_system_score_codex":0.00012860112,"about_ca_system_score_gemma":0.00061169174,"threshold_uncertainty_score":0.82852113},"labels":[],"label_agreement":null},{"id":"W2047633734","doi":"10.1517/13543784.17.7.1029","title":"Heparin as an anticancer therapeutic","year":2008,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Proteoglycans and glycosaminoglycans research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences","funders":"","keywords":"Heparin; Pharmacology; Intensive care medicine; Medicine; Anticancer drug; Drug; Internal medicine","score_opus":0.07779585488762812,"score_gpt":0.4086712590680824,"score_spread":0.33087540418045425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047633734","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006920949,0.99530834,0.000047980477,0.00026037786,0.00047553028,0.00072442606,0.000097641125,0.00003097399,0.0029855033],"genre_scores_gemma":[0.00008782826,0.99094045,0.00037713448,0.0015757394,0.001729631,0.0006184388,0.003320496,0.00010069524,0.0012495847],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99711,0.00036042352,0.0004891382,0.00092031294,0.00067965366,0.00044044908],"domain_scores_gemma":[0.9984831,0.000059859674,0.00018685812,0.00077372586,0.00012935734,0.00036709046],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017109889,0.00052403886,0.0006548263,0.0001858203,0.0002474935,0.00006262983,0.0006390374,0.0005228477,0.00014912008],"category_scores_gemma":[0.00010708454,0.0004411837,0.00035386244,0.00024370546,0.00041314107,0.00001137039,0.00014365512,0.00040956325,0.00025630198],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059939117,0.0001957874,0.0000045097645,0.00041233352,0.0002182041,0.0000070644455,0.00013237368,0.0000070704536,0.00022168447,0.006883292,0.021658244,0.9701995],"study_design_scores_gemma":[0.0002581311,0.00042785978,0.000007877628,0.00096466165,0.0000051212264,0.00008248819,0.000014465607,0.00002086939,0.0005640895,0.00038128725,0.99675864,0.0005145271],"about_ca_topic_score_codex":0.00010798969,"about_ca_topic_score_gemma":0.0000032355838,"teacher_disagreement_score":0.9751004,"about_ca_system_score_codex":0.00009763207,"about_ca_system_score_gemma":0.0016790364,"threshold_uncertainty_score":0.999804},"labels":[],"label_agreement":null},{"id":"W2047925472","doi":"10.1517/13543780903282759","title":"Darinaparsin: a novel organic arsenical with promising anticancer activity","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Arsenic trioxide; Acute promyelocytic leukemia; In vivo; Cancer research; Arsenic; Pharmacology; Broad spectrum; Leukemia; In vitro; Chemistry; Medicine; Biology; Biochemistry; Immunology; Retinoic acid; Combinatorial chemistry","score_opus":0.044893318701998634,"score_gpt":0.3385623228525425,"score_spread":0.29366900415054387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047925472","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004945318,0.9952095,0.001080206,0.00033030493,0.00035680243,0.000609131,0.000041688374,0.000041091258,0.0018367538],"genre_scores_gemma":[0.00066947046,0.99319154,0.0024650125,0.000644755,0.0013753738,0.00013320784,0.001042377,0.000087906345,0.000390333],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977517,0.00012757677,0.0003973622,0.0008928243,0.0004986683,0.00033183917],"domain_scores_gemma":[0.9987446,0.000064543216,0.00033538128,0.0005334974,0.00012226481,0.00019972482],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018569523,0.0005367465,0.0007195987,0.00008380691,0.00019022798,0.00007729958,0.00038182896,0.0005093581,0.000035044337],"category_scores_gemma":[0.00015737647,0.0004187434,0.00022976224,0.00025968606,0.00035092226,0.0000112828075,0.00009373004,0.0004367243,0.000028939392],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026055187,0.00081358466,0.0000110707015,0.0036496576,0.0005624914,0.000010079792,0.00021531327,0.000034650042,0.01813963,0.0041242926,0.01367728,0.9585014],"study_design_scores_gemma":[0.00040580778,0.00034300706,0.000008960059,0.004055108,0.000024174898,0.0000895238,0.000008452489,0.0000144602955,0.006419908,0.00007832107,0.98798466,0.0005676348],"about_ca_topic_score_codex":0.00000573086,"about_ca_topic_score_gemma":7.37697e-7,"teacher_disagreement_score":0.97430736,"about_ca_system_score_codex":0.00013739063,"about_ca_system_score_gemma":0.0019150533,"threshold_uncertainty_score":0.99982643},"labels":[],"label_agreement":null},{"id":"W2053907476","doi":"10.1517/13543780902897623","title":"Spinal cord injury and neural repair: focus on neuroregenerative approaches for spinal cord injury","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Spinal Cord Injury Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto Western Hospital; University Health Network","funders":"","keywords":"Medicine; Spinal cord injury; Clinical trial; Spinal cord; Intensive care medicine; Physical medicine and rehabilitation; Pathology","score_opus":0.2504881047520121,"score_gpt":0.46319645090178946,"score_spread":0.21270834614977735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053907476","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005291987,0.98468983,0.00007280158,0.0057474882,0.0014026491,0.005639902,0.00044467626,0.0003516212,0.0011218389],"genre_scores_gemma":[0.00079611,0.97791636,0.006194107,0.004524616,0.005058013,0.0025015215,0.0018308434,0.00027815034,0.00090030354],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99360114,0.0005943866,0.001410697,0.001879742,0.0016626681,0.00085133326],"domain_scores_gemma":[0.99672574,0.000420858,0.0006304731,0.0009503521,0.00038496987,0.0008875795],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007446899,0.0012439627,0.0022415684,0.001023303,0.00048769292,0.00014061554,0.00048090715,0.0006528641,0.000054943448],"category_scores_gemma":[0.0010327819,0.0010363462,0.0010029887,0.00077591464,0.00081229483,0.00023680806,0.00018974369,0.0016761351,0.000077945624],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023229046,0.00028759777,0.000004947891,0.0023415063,0.00018509373,0.000015355312,0.000026250224,6.5067917e-7,0.000011975861,0.0235582,0.0348562,0.9154832],"study_design_scores_gemma":[0.00097049604,0.092636585,0.00018067502,0.012381199,0.00010347206,0.00017358588,0.0000516571,0.0004513387,0.0001274579,0.001625159,0.8903496,0.0009487449],"about_ca_topic_score_codex":0.000027894625,"about_ca_topic_score_gemma":8.516671e-7,"teacher_disagreement_score":0.91453445,"about_ca_system_score_codex":0.0005678316,"about_ca_system_score_gemma":0.0014641791,"threshold_uncertainty_score":0.9992087},"labels":[],"label_agreement":null},{"id":"W2054297512","doi":"10.1517/13543780902980171","title":"Sunitinib in solid tumors","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Sunitinib; GiST; Medicine; Sorafenib; Everolimus; Renal cell carcinoma; Imatinib; Tyrosine-kinase inhibitor; Bevacizumab; Oncology; Pharmacology; Internal medicine; Cancer; Stromal cell; Hepatocellular carcinoma; Chemotherapy","score_opus":0.11988726613130786,"score_gpt":0.4374837508832138,"score_spread":0.31759648475190594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054297512","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000031247226,0.98870957,0.000002206533,0.0019820323,0.00016613006,0.001287245,0.000049253384,0.000081403916,0.00769089],"genre_scores_gemma":[0.000061266124,0.9932092,0.001486298,0.0010757981,0.0006829968,0.0004268965,0.0023557718,0.000065283566,0.00063652406],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99689204,0.00023890476,0.000837638,0.0006077697,0.0009011715,0.0005225027],"domain_scores_gemma":[0.99826294,0.00037831822,0.00023439486,0.00041040004,0.00011750817,0.00059642777],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029343533,0.0005359888,0.0014417191,0.0007125794,0.000084812506,0.000039202045,0.00020562725,0.00015100367,0.00022130701],"category_scores_gemma":[0.00059284834,0.00041770094,0.00040249678,0.00053957937,0.0001948186,0.00007055863,0.00005156886,0.0008179904,0.00064236595],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000089749585,0.000924706,0.000048030604,0.0026452949,0.000109208304,0.00054014503,0.00021552852,0.0000042591255,0.000002038604,0.011236348,0.018669238,0.96551543],"study_design_scores_gemma":[0.00087089214,0.0008190931,0.00024824508,0.04875133,0.000012679346,0.000552902,0.00003928864,0.000017545195,0.000013016343,0.00080884364,0.94757575,0.0002904282],"about_ca_topic_score_codex":0.000050833307,"about_ca_topic_score_gemma":0.0000012274957,"teacher_disagreement_score":0.96522504,"about_ca_system_score_codex":0.00058392575,"about_ca_system_score_gemma":0.0015728628,"threshold_uncertainty_score":0.9998275},"labels":[],"label_agreement":null},{"id":"W2056360850","doi":"10.1517/13543780802528609","title":"Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer","year":2008,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Clusterin; Prostate cancer; Cancer; Medicine; Clinical trial; Cancer research; Internal medicine; Oncology; Biology; Apoptosis; Biochemistry","score_opus":0.1531090493367765,"score_gpt":0.425771464691668,"score_spread":0.2726624153548915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056360850","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00059777626,0.99214166,0.000035639274,0.00094059925,0.0018836927,0.0029847098,0.0012793142,0.000026684087,0.000109892724],"genre_scores_gemma":[0.00011702936,0.99100286,0.00094916794,0.00037822576,0.0024321422,0.0023938275,0.0018867383,0.000075024276,0.0007649895],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976133,0.00017847735,0.0010665506,0.0004895631,0.00043441085,0.00021770156],"domain_scores_gemma":[0.99753547,0.0007702848,0.0007269638,0.00054849137,0.00025659692,0.00016221753],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0000976335,0.00044716074,0.00144537,0.00024673625,0.00011729543,0.00000794254,0.00014417707,0.00029882343,0.00022802896],"category_scores_gemma":[0.00014716285,0.0002707005,0.0007080409,0.00023581691,0.00047075178,0.000040996198,0.00004028579,0.00012551885,0.000013270057],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035145695,0.0010029232,0.000024284098,0.008553217,0.0009962581,0.000010178321,0.00271815,0.00010601091,0.0006164716,0.000893315,0.06611922,0.91860855],"study_design_scores_gemma":[0.0014434559,0.000762563,0.000056898858,0.0050109266,0.00014242368,0.00007642354,0.0000399573,0.0004212456,0.0009412726,0.000019716388,0.9908547,0.00023045405],"about_ca_topic_score_codex":0.00006842179,"about_ca_topic_score_gemma":0.000011469824,"teacher_disagreement_score":0.9247354,"about_ca_system_score_codex":0.0003652848,"about_ca_system_score_gemma":0.0013384402,"threshold_uncertainty_score":0.9999745},"labels":[],"label_agreement":null},{"id":"W2057495794","doi":"10.1517/13543784.2011.565329","title":"Brivanib alaninate for cancer","year":2011,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cetuximab; Medicine; Pharmacodynamics; Pharmacology; Cancer; Regorafenib; Angiogenesis; Colorectal cancer; Pharmacokinetics; Oncology; Internal medicine","score_opus":0.11655984381337209,"score_gpt":0.41313203269809323,"score_spread":0.29657218888472114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057495794","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008168098,0.9964209,0.00007750361,0.00018018266,0.00082230574,0.0009777214,0.0005110877,0.00002454298,0.0009775634],"genre_scores_gemma":[0.0000067029428,0.98931986,0.0008278825,0.0005138509,0.0016722883,0.0016392526,0.004122655,0.000120767676,0.00177674],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99803174,0.00014340936,0.00042560828,0.00072663807,0.00029431234,0.00037828975],"domain_scores_gemma":[0.9988444,0.000094122246,0.00022399788,0.0004456502,0.00016564011,0.0002262139],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018898018,0.0004284642,0.00055224,0.00014303696,0.00012677006,0.000036128327,0.0004976683,0.00045381414,0.00013431875],"category_scores_gemma":[0.00020633539,0.00037512806,0.0003988579,0.00012956538,0.00018908392,0.0000057849047,0.0001563957,0.00023651634,0.00011130731],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009726823,0.00013172514,0.0000069766397,0.0044952016,0.00049727113,7.6573326e-7,0.00019647946,0.0000056667377,0.00084721786,0.019151505,0.33134213,0.6432278],"study_design_scores_gemma":[0.00023802,0.00019408985,0.0000041870258,0.0026444003,0.000007412995,0.0000047944154,0.000005072317,0.000005943354,0.0011347217,0.00029702162,0.995056,0.00040838867],"about_ca_topic_score_codex":0.00004504685,"about_ca_topic_score_gemma":0.0000024809833,"teacher_disagreement_score":0.6637138,"about_ca_system_score_codex":0.000084244726,"about_ca_system_score_gemma":0.00095221784,"threshold_uncertainty_score":0.99987006},"labels":[],"label_agreement":null},{"id":"W2057625697","doi":"10.1517/13543784.2013.831404","title":"Current Phase II clinical data for ridaforolimus in cancer","year":2013,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"PI3K/AKT/mTOR pathway; mTORC1; mTORC2; Everolimus; Cancer research; Medicine; Cancer; Protein kinase B; Clinical trial; Pharmacology; Signal transduction; Biology; Oncology; Internal medicine; Cell biology","score_opus":0.30661209334578565,"score_gpt":0.5347343585449083,"score_spread":0.2281222651991226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057625697","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008056458,0.9911999,0.00013837726,0.00040910632,0.0044599515,0.0014963058,0.002125671,0.000019659905,0.0000704563],"genre_scores_gemma":[0.000012796488,0.96855986,0.0010264767,0.0009060616,0.0059996303,0.0025100652,0.020730412,0.000093248695,0.00016145117],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965395,0.00025567567,0.0011681428,0.0012776817,0.00036784916,0.00039114789],"domain_scores_gemma":[0.99764055,0.00023161751,0.0005307656,0.00119828,0.00014543264,0.00025332844],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00068063475,0.00051191193,0.00091609533,0.00013845362,0.00013088949,0.000040477073,0.0011289053,0.00054366473,0.00010198469],"category_scores_gemma":[0.00057149533,0.00045222096,0.00034915356,0.00016187053,0.00025042502,0.000015870013,0.000494078,0.000447692,0.000040089177],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031995274,0.00031663448,0.0000037907992,0.0006946007,0.00009930077,2.0573934e-7,0.000026002259,0.000012071455,0.000030112848,0.00031891352,0.25484425,0.7436221],"study_design_scores_gemma":[0.0014740222,0.0004375114,0.0000014784343,0.004397554,0.000020295109,0.0000022864076,0.0000042930587,0.00023430407,0.00008090234,0.00015003751,0.9926892,0.0005081242],"about_ca_topic_score_codex":0.00004412021,"about_ca_topic_score_gemma":0.000005432901,"teacher_disagreement_score":0.743114,"about_ca_system_score_codex":0.00014293047,"about_ca_system_score_gemma":0.0021318716,"threshold_uncertainty_score":0.99979293},"labels":[],"label_agreement":null},{"id":"W2062518823","doi":"10.1517/13543784.14.8.1009","title":"Growth hormone therapy in heart failure: a novel therapy worthy of further consideration?","year":2005,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Heart Failure Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton General Hospital","funders":"","keywords":"Heart failure; Medicine; Cardiac function curve; Quality of life (healthcare); Hormone; Internal medicine; Growth hormone; Intensive care medicine; Cardiology","score_opus":0.08101180246770066,"score_gpt":0.3604330639189664,"score_spread":0.2794212614512657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062518823","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000068543224,0.960319,0.000018558336,0.036322962,0.00022544137,0.0025119807,0.000033550532,0.00007042009,0.00042952993],"genre_scores_gemma":[0.0001574592,0.9828723,0.009883647,0.0041657933,0.0007406815,0.00085295213,0.0009023814,0.00008719119,0.00033757958],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970995,0.00018449657,0.0010319937,0.00060442573,0.00076480483,0.0003147468],"domain_scores_gemma":[0.99858975,0.0002748628,0.0003187261,0.00044993358,0.00015694591,0.00020979712],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003586632,0.00058738486,0.0014854034,0.0006312951,0.0000700256,0.0000336034,0.00013562669,0.00032731154,0.0003383743],"category_scores_gemma":[0.000074921736,0.00044153794,0.0004522716,0.00054357725,0.00020645361,0.00014095713,0.00003334866,0.00038433386,0.00012513057],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026513805,0.0029791084,0.00017846705,0.0009859985,0.0011145532,0.000009152297,0.003267873,0.000009975179,0.0001466378,0.026669007,0.35784197,0.60653216],"study_design_scores_gemma":[0.0031166754,0.00049333804,0.00016386624,0.0035491132,0.000014130652,0.000017827046,0.000063058586,0.000009759498,0.000054574,0.0001875021,0.9919874,0.00034275942],"about_ca_topic_score_codex":0.000079774014,"about_ca_topic_score_gemma":0.0000058040314,"teacher_disagreement_score":0.63414544,"about_ca_system_score_codex":0.0002317607,"about_ca_system_score_gemma":0.00077768584,"threshold_uncertainty_score":0.99980366},"labels":[],"label_agreement":null},{"id":"W2063706444","doi":"10.1517/13543784.17.6.827","title":"Acetyl-<scp>L</scp>-carnitine and α-lipoic acid: possible neurotherapeutic agents for mood disorders?","year":2008,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Biochemical Acid Research Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Neurocognitive; Carnitine; Neuroprotection; Lipoic acid; Mood; Mood disorders; Cognition; Medicine; Acetylcarnitine; Pharmacology; Antidepressant; Apathy; Psychology; Psychiatry; Neuroscience; Antioxidant; Internal medicine; Biochemistry; Chemistry","score_opus":0.058678572561528315,"score_gpt":0.3597756872211676,"score_spread":0.3010971146596393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063706444","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019013655,0.996369,0.00007809316,0.00064692023,0.00036363615,0.0012717263,0.0002801283,0.000033514312,0.00076682295],"genre_scores_gemma":[0.0001154461,0.9923298,0.00072495174,0.0008118093,0.0011121939,0.0012141954,0.0026770988,0.00010470635,0.00090982637],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974588,0.00018748829,0.0004892275,0.00091962493,0.00045537992,0.0004894475],"domain_scores_gemma":[0.99861276,0.0003348685,0.00023774775,0.0003997035,0.00013254145,0.00028237587],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001344064,0.0005882541,0.0007087342,0.00014205226,0.0003313882,0.000054270164,0.0003943172,0.00048287713,0.000007508495],"category_scores_gemma":[0.0008726763,0.0004964321,0.0003836711,0.00020758496,0.000558,0.000009374795,0.00028691857,0.00034314443,0.000022752425],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009857809,0.00079537317,0.00006860581,0.008152462,0.0020096581,0.0000020230768,0.00095426536,0.000008920661,0.008596069,0.0026171913,0.34578833,0.6309085],"study_design_scores_gemma":[0.00059895904,0.00046401864,0.00002084717,0.00092241657,0.000013793357,0.000019662932,0.000038084236,0.0000155074,0.002701916,0.00034529992,0.9946078,0.00025166472],"about_ca_topic_score_codex":0.0000049431087,"about_ca_topic_score_gemma":0.0000010998801,"teacher_disagreement_score":0.6488195,"about_ca_system_score_codex":0.000045322646,"about_ca_system_score_gemma":0.0003124554,"threshold_uncertainty_score":0.9997487},"labels":[],"label_agreement":null},{"id":"W2066759481","doi":"10.1517/13543784.16.1.1","title":"Discontinued drugs in 2005: anti-infectives","year":2006,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Drug-Induced Adverse Reactions","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pyrogenesis (Canada)","funders":"","keywords":"Econazole; Medicine; Anthrax vaccines; Antiseptic; Pharmacology; Azole; Antifungal; Virology; Dermatology; Immunology; Immune system; Miconazole","score_opus":0.05939597517357224,"score_gpt":0.378497513004909,"score_spread":0.31910153783133677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066759481","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007661123,0.9451705,0.000008947134,0.0015538104,0.0018618251,0.0018401607,0.0001520345,0.00021826854,0.049117815],"genre_scores_gemma":[0.00017513121,0.98949754,0.00051403645,0.00050781615,0.0020454742,0.00067772635,0.0034817918,0.00016881856,0.0029316496],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958711,0.00032847375,0.0012270795,0.001024646,0.000924311,0.0006243344],"domain_scores_gemma":[0.9975884,0.0006554661,0.0005518358,0.0006735872,0.00011718398,0.00041352186],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039766694,0.0008285207,0.0020120258,0.0011917792,0.00015867739,0.000062419145,0.0002498863,0.0005839452,0.00006582453],"category_scores_gemma":[0.00034781534,0.00072069507,0.0007249802,0.00086126,0.00034117003,0.0002922804,0.00008840711,0.0011905553,0.00070891314],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010322146,0.0012114005,0.000116931966,0.0034171434,0.00037834112,0.000032989486,0.0011206542,0.000031557774,0.000029595862,0.018215604,0.03041486,0.9450206],"study_design_scores_gemma":[0.0009509436,0.000023166942,0.001525304,0.019491432,0.00004798616,0.000063006875,0.00013099507,0.000023369294,0.000020651087,0.00030658548,0.97679293,0.00062361965],"about_ca_topic_score_codex":0.00025271886,"about_ca_topic_score_gemma":0.000007665232,"teacher_disagreement_score":0.94637805,"about_ca_system_score_codex":0.0011184756,"about_ca_system_score_gemma":0.0016517342,"threshold_uncertainty_score":0.9995244},"labels":[],"label_agreement":null},{"id":"W2069838467","doi":"10.1517/13543784.12.1.65","title":"Recent developments in the psychobiology and pharmacotherapy of depression: optimising existing treatments and novel approaches for the future","year":2003,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health","funders":"","keywords":"Monoaminergic; Major depressive disorder; Tricyclic; Neuroscience; Psychology; Antidepressant; Monoamine neurotransmitter; Medicine; Psychiatry; Pharmacology; Psychotherapist; Serotonin; Mood; Receptor; Internal medicine","score_opus":0.27848004033976725,"score_gpt":0.43478211963056057,"score_spread":0.15630207929079332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069838467","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011170585,0.99541706,0.000058385296,0.0013912679,0.00044010344,0.0021770124,0.000039812545,0.00001162866,0.00035303592],"genre_scores_gemma":[0.000045137007,0.98776394,0.009513705,0.00083154265,0.00032060826,0.0009398339,0.00048359408,0.000038033515,0.00006359475],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983091,0.00020606913,0.00051849143,0.00048070698,0.00029766874,0.00018801038],"domain_scores_gemma":[0.99838483,0.00089763495,0.00035053922,0.00024385288,0.000042171236,0.00008095589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039620322,0.00037233226,0.00066178496,0.00013528754,0.00019538985,0.000021574495,0.00013956393,0.0002207923,0.00000951996],"category_scores_gemma":[0.000060937025,0.00018294388,0.00010091793,0.00017751173,0.00018458813,0.000048433747,0.000029917832,0.00023807403,6.4865975e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000085905354,0.0002498098,0.00016500444,0.00062190846,0.00022666539,6.119211e-7,0.0009942347,0.0000032400123,0.00001218236,0.00090231036,0.0010760799,0.99566203],"study_design_scores_gemma":[0.002664976,0.00011074642,0.0005706851,0.00555962,0.000073475385,0.00009069655,0.00027401673,0.000051110204,0.000037688795,0.00010686668,0.99029064,0.00016948253],"about_ca_topic_score_codex":0.0000035192297,"about_ca_topic_score_gemma":2.727841e-7,"teacher_disagreement_score":0.9954926,"about_ca_system_score_codex":0.00009626638,"about_ca_system_score_gemma":0.00020325638,"threshold_uncertainty_score":0.74602354},"labels":[],"label_agreement":null},{"id":"W2070483380","doi":"10.1517/13543784.2014.966900","title":"Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder","year":2014,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Centre; Western University","funders":"","keywords":"Receptor tyrosine kinase; Cancer research; Tyrosine kinase; Fibroblast growth factor receptor 3; Tyrosine-kinase inhibitor; Fibroblast growth factor receptor; In vivo; Fibroblast growth factor; Medicine; In vitro; Cancer; Receptor; Biology; Internal medicine; Biotechnology","score_opus":0.1606687305433176,"score_gpt":0.44059212969756373,"score_spread":0.27992339915424613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070483380","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0074525066,0.9882492,0.000017430231,0.00082688686,0.00092224614,0.0015277901,0.0005704832,0.000009139877,0.00042434133],"genre_scores_gemma":[0.0027097461,0.99193203,0.00048843795,0.00048507613,0.0019393212,0.00016485486,0.0019822118,0.00007272415,0.00022556708],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.995879,0.0011825251,0.0012112807,0.00089847867,0.0005933574,0.00023538567],"domain_scores_gemma":[0.9972607,0.00081825326,0.00042648346,0.0012297063,0.00010167717,0.00016320111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001279271,0.00031811127,0.0007503187,0.0001054748,0.00007071075,0.00003238812,0.0010562141,0.0005581609,0.000023895105],"category_scores_gemma":[0.0023727007,0.00022930242,0.00025598664,0.00017226307,0.0008051212,0.000011476967,0.0009134575,0.0005813504,0.000017571083],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008984862,0.0019072156,0.059068367,0.011384097,0.00142916,0.0000057725338,0.0007310152,0.000027803619,0.0008583555,0.027495489,0.19640186,0.6997924],"study_design_scores_gemma":[0.0005904099,0.00022884182,0.006381483,0.0017025486,0.000008212487,0.0000064833966,0.000005708346,0.00004610406,0.00007954876,0.00014167347,0.99056286,0.00024612085],"about_ca_topic_score_codex":0.000042172866,"about_ca_topic_score_gemma":0.0000075414373,"teacher_disagreement_score":0.794161,"about_ca_system_score_codex":0.000021937505,"about_ca_system_score_gemma":0.0011444002,"threshold_uncertainty_score":0.93506813},"labels":[],"label_agreement":null},{"id":"W2074643072","doi":"10.1517/13543784.10.2.213","title":"Clinical utility of the new fluoroquinolones for treating respiratory and urinary tract infections","year":2001,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Antibiotics Pharmacokinetics and Efficacy","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; St. Paul's Hospital; University of Saskatchewan","funders":"","keywords":"Medicine; Dosing; Antimicrobial; Urinary system; Intensive care medicine; Respiratory tract infections; Pharmacokinetics; Pharmacodynamics; Bioavailability; Pharmacology; Internal medicine; Respiratory system; Biology; Microbiology","score_opus":0.1632236923694076,"score_gpt":0.4521198595069692,"score_spread":0.2888961671375616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074643072","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005755524,0.99489474,0.000056970697,0.001197345,0.0009573608,0.0012823351,0.00006914105,0.000033645832,0.0009328809],"genre_scores_gemma":[0.00052537146,0.9957102,0.0008589866,0.00071941136,0.0016252553,0.000038665323,0.00015581447,0.000042273437,0.00032400445],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979985,0.00019837996,0.0009386143,0.00040656334,0.0002873942,0.00017055143],"domain_scores_gemma":[0.99779624,0.001047354,0.00046006372,0.0003512414,0.000110665846,0.00023444614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042480207,0.00028321057,0.00087613845,0.00012378038,0.00016826503,0.000013606294,0.00013226268,0.00030047423,0.000050425817],"category_scores_gemma":[0.0006972465,0.00019194694,0.00053941767,0.00024813597,0.00039647525,0.00003764195,0.000070444825,0.0004396981,0.0000055290107],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045696932,0.0011717129,0.0010591169,0.0021743255,0.00018254686,0.0000012478389,0.00017178821,0.0000016561565,0.000003856992,0.0025282975,0.035428334,0.9572314],"study_design_scores_gemma":[0.00078149757,0.00061972166,0.002889656,0.0068392553,0.0000970274,0.000044677632,0.000013965902,0.00010974225,0.000015264675,0.00021789617,0.98821,0.00016126205],"about_ca_topic_score_codex":0.000014311736,"about_ca_topic_score_gemma":1.6066052e-7,"teacher_disagreement_score":0.9570702,"about_ca_system_score_codex":0.00003764485,"about_ca_system_score_gemma":0.000889898,"threshold_uncertainty_score":0.7827369},"labels":[],"label_agreement":null},{"id":"W2079084305","doi":"10.1517/13543784.11.6.801","title":"Anti-emetics in development","year":2002,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Nausea and vomiting management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Hospital and Health Sciences Centre","funders":"","keywords":"Nausea; Vomiting; Medicine; Opioid; Anesthesia; Motion sickness; Aprepitant; Internal medicine; Antiemetic; Psychiatry; Receptor","score_opus":0.15195587789629997,"score_gpt":0.39209928240458025,"score_spread":0.24014340450828028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079084305","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000012034194,0.9878352,0.000010743585,0.0009761638,0.0006866669,0.00090797106,0.0000074358054,0.00007259574,0.009491184],"genre_scores_gemma":[0.000013346191,0.9916813,0.0034502763,0.0015069083,0.0006148925,0.00028010103,0.00075530546,0.000062997264,0.0016348703],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974808,0.00011800384,0.0008704027,0.00051855406,0.0007141711,0.00029807288],"domain_scores_gemma":[0.9989529,0.00019812278,0.00024077822,0.0003380591,0.000057967365,0.00021216384],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031522883,0.00041082138,0.0010895084,0.0006247753,0.000080913254,0.000028528535,0.00017981215,0.00024221608,0.0002657155],"category_scores_gemma":[0.00018156318,0.00034803455,0.00020310552,0.00047435157,0.00009159626,0.000044433174,0.00008504533,0.00044122245,0.0007308028],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000050728677,0.00031817085,0.00004459379,0.0047274674,0.00013984587,0.000022591028,0.0006203099,0.0000037528332,5.074354e-7,0.008380441,0.04857998,0.9371573],"study_design_scores_gemma":[0.0004951914,0.000044766006,0.00013040041,0.022511017,0.000015062703,0.00001280573,0.000023352746,0.000021866683,0.0000081939925,0.00006554446,0.976351,0.00032076312],"about_ca_topic_score_codex":0.0000061920523,"about_ca_topic_score_gemma":2.4106347e-7,"teacher_disagreement_score":0.9368365,"about_ca_system_score_codex":0.00045172792,"about_ca_system_score_gemma":0.00047965962,"threshold_uncertainty_score":0.9998972},"labels":[],"label_agreement":null},{"id":"W2079671777","doi":"10.1517/13543784.12.9.1471","title":"C-peptide and diabetic neuropathy","year":2003,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Advanced Glycation End Products research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; Diabetes Canada; National Institutes of Health; Canadian Diabetes Association; American Diabetes Association","keywords":"Medicine; Diabetes mellitus; Insulin; Diabetic neuropathy; Type 2 diabetes; Internal medicine; Type 1 diabetes; Endocrinology; Animal studies; Bioinformatics; Biology","score_opus":0.052835658344886655,"score_gpt":0.3660591950859705,"score_spread":0.31322353674108383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079671777","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000011623139,0.9964064,0.000062780404,0.00030676226,0.00047630988,0.00045123906,0.000050105045,0.0000172006,0.0022176031],"genre_scores_gemma":[0.0000064004767,0.9927548,0.0011929647,0.0010874222,0.0007430925,0.00024360593,0.0014247204,0.00007566618,0.0024713015],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978737,0.0003671089,0.0003783567,0.00076920504,0.00034701714,0.00026460574],"domain_scores_gemma":[0.99890256,0.00009351269,0.0001722971,0.0005055768,0.00010369973,0.00022233745],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022113492,0.0003578921,0.00042598095,0.00013668432,0.00013581302,0.000039881405,0.00023314643,0.00023071686,0.000046225487],"category_scores_gemma":[0.00048762545,0.00032221756,0.00012731447,0.00019659614,0.00026663355,0.0000068678696,0.000116431176,0.00028474713,0.000104387924],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016265125,0.00010176164,0.000005462998,0.0018969993,0.00011767154,0.0000025779318,0.00011580431,0.000028541646,0.00036528843,0.009688559,0.0709518,0.91670924],"study_design_scores_gemma":[0.00013563129,0.00010218405,0.0000036434694,0.0007674052,0.0000041191083,0.00002251699,0.000007984058,0.0000031664104,0.00023105486,0.00034733122,0.99805623,0.00031870583],"about_ca_topic_score_codex":0.0000016171052,"about_ca_topic_score_gemma":7.921154e-8,"teacher_disagreement_score":0.9271045,"about_ca_system_score_codex":0.0000376844,"about_ca_system_score_gemma":0.0004022398,"threshold_uncertainty_score":0.999923},"labels":[],"label_agreement":null},{"id":"W2085430830","doi":"10.1517/13543784.11.12.1795","title":"Novel therapies for sepsis: antiendotoxin therapies","year":2002,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Immune Response and Inflammation","field":"Immunology and Microbiology","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Health Sciences Centre; Manitoba Health","funders":"","keywords":"Sepsis; Lipopolysaccharide; Immune system; Lipid A; Monoclonal antibody; Immunology; Receptor; Septic shock; Biology; Antibody; Medicine; Internal medicine","score_opus":0.08159723834029357,"score_gpt":0.3380841695788234,"score_spread":0.25648693123852984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085430830","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008298737,0.9938639,0.00020878084,0.0011108688,0.002540842,0.0013428569,0.00020075466,0.00014111036,0.0005826156],"genre_scores_gemma":[0.000013194944,0.9893602,0.00070598157,0.0007918718,0.00044917045,0.0014364959,0.0035728356,0.0000890833,0.0035811616],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99760026,0.00039723836,0.0008788738,0.00057346316,0.00013099096,0.0004191614],"domain_scores_gemma":[0.99774367,0.0010762359,0.00055243215,0.00045079773,0.00013906586,0.00003782222],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00037603214,0.0006128828,0.0011111274,0.0004246805,0.00044655305,0.00006115008,0.0004429081,0.0007280853,0.0005691799],"category_scores_gemma":[0.00020020003,0.0004817537,0.0006438779,0.00023135981,0.00036691315,0.00019382098,0.00005410481,0.00042558764,0.00096528226],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008951822,0.0002190606,3.77326e-7,0.0010512546,0.001083329,2.7713696e-7,0.003350179,0.0000019729484,0.0026516567,0.032111943,0.09308983,0.8663506],"study_design_scores_gemma":[0.0008699226,0.0001678948,0.0000033053905,0.0040995413,0.000025433013,0.000026405545,0.000178659,0.000005251959,0.0012783495,0.0003886604,0.9924306,0.00052593666],"about_ca_topic_score_codex":0.000013158922,"about_ca_topic_score_gemma":2.069776e-7,"teacher_disagreement_score":0.8993408,"about_ca_system_score_codex":0.00012548544,"about_ca_system_score_gemma":0.00027967463,"threshold_uncertainty_score":0.9998126},"labels":[],"label_agreement":null},{"id":"W2091033733","doi":"10.1517/13543784.10.9.1687","title":"Therapeutic potential of angiotensin II receptor antagonists","year":2001,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Renin-Angiotensin System Studies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"","keywords":"Angiotensin II; Renin–angiotensin system; Blockade; Angiotensin receptor; Angiotensin II receptor type 1; Homeostasis; Medicine; Receptor; Internal medicine; Pharmacology; Endocrinology; Blood pressure","score_opus":0.07544061395837655,"score_gpt":0.3672220431966472,"score_spread":0.29178142923827066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091033733","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000028857816,0.9909941,0.000027089523,0.0036230898,0.0025396172,0.0013351431,0.00011090385,0.00011404941,0.001227146],"genre_scores_gemma":[0.00012796,0.99085164,0.002173689,0.001015764,0.0026484642,0.0001351443,0.0014400752,0.00014240437,0.0014648497],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957533,0.0003384023,0.0014322009,0.00079737784,0.0012564813,0.00042227682],"domain_scores_gemma":[0.9973364,0.0002729107,0.00088409707,0.00074475503,0.00047062832,0.00029121136],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035232733,0.00076246465,0.0026262973,0.00052386924,0.000280019,0.00002600949,0.0002685512,0.0005679273,0.00019559103],"category_scores_gemma":[0.0001982792,0.00059001264,0.0011147528,0.0007237448,0.00055205374,0.00007779177,0.00015402831,0.0004785486,0.00024452567],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001506392,0.00049033866,0.000039514005,0.0024219647,0.0021992098,0.000029737075,0.0013505921,0.000006137635,0.0002693651,0.0050341645,0.28567266,0.70233566],"study_design_scores_gemma":[0.0006172705,0.00037883827,0.00012326815,0.021515956,0.00013385028,0.00023753438,0.000036657635,0.0000142226545,0.00008351265,0.00011598194,0.9762759,0.00046696907],"about_ca_topic_score_codex":0.00003983649,"about_ca_topic_score_gemma":2.085117e-7,"teacher_disagreement_score":0.7018687,"about_ca_system_score_codex":0.00032655115,"about_ca_system_score_gemma":0.00089101045,"threshold_uncertainty_score":0.9996551},"labels":[],"label_agreement":null},{"id":"W2091130375","doi":"10.1517/13543780903066772","title":"EGFR-directed therapies to treat non-small-cell lung cancer","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Lung cancer; Medicine; Tyrosine kinase; Cancer research; Cancer; Angiogenesis; Epidermal growth factor receptor; Monoclonal antibody; Disease; Drug development; Targeted therapy; Drug; Oncology; Immunology; Pharmacology; Internal medicine; Receptor; Antibody","score_opus":0.04626132764116791,"score_gpt":0.3999452614262695,"score_spread":0.3536839337851016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091130375","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000023891042,0.9829099,0.000031500946,0.0046904013,0.0008840896,0.0024066395,0.00021494376,0.00021553766,0.008623056],"genre_scores_gemma":[0.000012588203,0.9753057,0.002475037,0.0051903785,0.0014968888,0.0022521482,0.0022719968,0.000108521475,0.010886775],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99759674,0.000109186425,0.0006266418,0.0007444241,0.0005555288,0.00036745906],"domain_scores_gemma":[0.9983598,0.00020531147,0.00026205223,0.00047346752,0.00019993055,0.0004994112],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008600707,0.00066042633,0.0012403086,0.00042999056,0.00021810865,0.000062679654,0.00019978423,0.000298427,0.00038614596],"category_scores_gemma":[0.00004181173,0.00044118523,0.00043137372,0.00059447484,0.00007426549,0.00007684004,0.000033247776,0.00032649277,0.00019929853],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003095024,0.0003182446,0.000019519284,0.0022925169,0.00042911488,0.00000811338,0.0032250204,0.000014127093,0.000008240037,0.00065267744,0.14637809,0.8466234],"study_design_scores_gemma":[0.0010352042,0.00022106641,0.000080768536,0.017016105,0.00027017356,0.000011064241,0.00006804941,0.0000343987,0.00004234562,0.00006197489,0.9807011,0.00045778957],"about_ca_topic_score_codex":0.00030326625,"about_ca_topic_score_gemma":0.000004283825,"teacher_disagreement_score":0.8461656,"about_ca_system_score_codex":0.0011227847,"about_ca_system_score_gemma":0.0023225395,"threshold_uncertainty_score":0.999804},"labels":[],"label_agreement":null},{"id":"W2094045238","doi":"10.1517/13543784.14.3.251","title":"Parathyroid hormone and leptin – new peptides, expanding clinical prospects","year":2005,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Institute for Biological Sciences","funders":"","keywords":"Teriparatide; Medicine; Leptin; Parathyroid hormone; Osteoporosis; Internal medicine; Osteoblast; Endocrinology; Anabolism; Hormone; Biology; Calcium","score_opus":0.12904821129417793,"score_gpt":0.42632336944373983,"score_spread":0.2972751581495619,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094045238","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030682865,0.99312246,0.000016656277,0.0015797919,0.00070894195,0.0014525829,0.0000390669,0.00018239177,0.0025912712],"genre_scores_gemma":[0.00013343229,0.9842083,0.00296629,0.0022290982,0.0066710836,0.0001932778,0.001310738,0.00014520308,0.0021425684],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952426,0.00023832728,0.0018371587,0.0011802237,0.00094680634,0.0005548941],"domain_scores_gemma":[0.9967594,0.0006060088,0.0006614617,0.00059899024,0.000116633695,0.0012575199],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005884503,0.00088301144,0.0022396564,0.00045902652,0.00023737465,0.000100819474,0.0002574116,0.00082864746,0.00008133342],"category_scores_gemma":[0.0006498371,0.0007151921,0.0006596723,0.0004792084,0.00040803038,0.00026339953,0.00014123238,0.0013016182,0.00050776114],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008424301,0.0002373055,0.000076482254,0.0006770341,0.00025087397,0.0000148932595,0.00059578294,3.6925286e-7,0.000019979729,0.0050928267,0.32073355,0.67221665],"study_design_scores_gemma":[0.0016330282,0.0006782533,0.0009209876,0.006090803,0.00008225085,0.00012055645,0.000053896114,0.000015233968,0.000012507576,0.0003262444,0.98938316,0.00068307674],"about_ca_topic_score_codex":0.000040335628,"about_ca_topic_score_gemma":5.335516e-7,"teacher_disagreement_score":0.6715336,"about_ca_system_score_codex":0.0002896645,"about_ca_system_score_gemma":0.001633599,"threshold_uncertainty_score":0.9995299},"labels":[],"label_agreement":null},{"id":"W2094081851","doi":"10.1517/13543784.2013.840289","title":"Investigational drugs for onychomycosis","year":2013,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Nail Diseases and Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mediprobe Research (Canada); University of Toronto","funders":"","keywords":"Terbinafine; Medicine; Adverse effect; Drug; Dermatology; Drug development; Pharmacology; Clinical trial; Intensive care medicine; Antifungal; Itraconazole; Internal medicine","score_opus":0.12005280775955049,"score_gpt":0.41042137815608937,"score_spread":0.29036857039653885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094081851","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000016742926,0.98854595,0.000027572938,0.0027033556,0.001324034,0.003963404,0.00084772834,0.00016773348,0.0024034837],"genre_scores_gemma":[0.000011279312,0.9610016,0.0061830585,0.0041221767,0.0022854528,0.0062837778,0.017220853,0.00018298041,0.0027088267],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99607444,0.00015473102,0.0010972765,0.0010449624,0.0011164463,0.00051215803],"domain_scores_gemma":[0.99655426,0.0008658801,0.0005701819,0.0006529879,0.00036093593,0.0009957736],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018951784,0.00088755245,0.00164962,0.0004967003,0.00031589426,0.000105495186,0.00029654862,0.00050855137,0.0007497022],"category_scores_gemma":[0.00042843464,0.0007044702,0.0011946491,0.00044020006,0.0003364539,0.00021012816,0.000076576696,0.00040217963,0.0013878121],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004920607,0.00052327,0.000026093347,0.00469287,0.0008327342,0.0000028223021,0.0002446454,0.0000017140095,0.000001263576,0.030239401,0.27882466,0.6845613],"study_design_scores_gemma":[0.0016766696,0.00026750853,0.00006552671,0.016168408,0.00020249558,0.000022424352,0.00003684399,0.000049900627,0.000011834148,0.004392047,0.97651297,0.00059336674],"about_ca_topic_score_codex":0.000046782,"about_ca_topic_score_gemma":1.8231249e-7,"teacher_disagreement_score":0.6976883,"about_ca_system_score_codex":0.0006155817,"about_ca_system_score_gemma":0.002051824,"threshold_uncertainty_score":0.9995406},"labels":[],"label_agreement":null},{"id":"W2095549754","doi":"10.1517/13543780903179294","title":"Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Neonatal Respiratory Health Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Business Development Bank of Canada","funders":"","keywords":"Medicine; Asthma; COPD; Disease; Inflammation; Intensive care medicine; Immunology; Internal medicine","score_opus":0.07718330351801966,"score_gpt":0.4155367821951554,"score_spread":0.3383534786771357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095549754","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000018303492,0.992791,0.000018527913,0.003462073,0.00045540594,0.0026055416,0.00018959306,0.00008290301,0.00037668357],"genre_scores_gemma":[0.000017006407,0.9919277,0.0010639197,0.0020852548,0.0021386142,0.0011468744,0.0010371432,0.00011283562,0.00047068906],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99681044,0.00022708961,0.00071083376,0.00085158244,0.00087384874,0.00052620895],"domain_scores_gemma":[0.997273,0.00080637797,0.000285667,0.0004527836,0.00020334187,0.0009787935],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003690807,0.0005463474,0.0010903486,0.00047548464,0.00033163044,0.000047825743,0.00021186483,0.00024106784,0.000086800705],"category_scores_gemma":[0.00059423485,0.00045506426,0.00035526472,0.00031620765,0.0003890998,0.00016009173,0.00007820483,0.00060877524,0.000051918905],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013044215,0.000063184685,0.0000030426481,0.011207634,0.00007483447,0.000013348907,0.00014665497,0.0000013125992,0.0000049598143,0.008891506,0.001624044,0.97783905],"study_design_scores_gemma":[0.00046614697,0.00027366052,0.00033485936,0.013742838,0.000019837325,0.000032088417,0.000039097926,0.00013063145,0.0000064115443,0.0019135784,0.9826828,0.00035800206],"about_ca_topic_score_codex":0.000009324468,"about_ca_topic_score_gemma":3.2456612e-7,"teacher_disagreement_score":0.9810588,"about_ca_system_score_codex":0.00071728067,"about_ca_system_score_gemma":0.0029174432,"threshold_uncertainty_score":0.99979013},"labels":[],"label_agreement":null},{"id":"W2095646768","doi":"10.1517/13543784.12.10.1655","title":"Targeting cellular energy production in neurological disorders","year":2003,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Coenzyme Q10 studies and effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"","keywords":"Coenzyme Q10; Neuroprotection; Oxidative stress; Ataxia; Medicine; Amyotrophic lateral sclerosis; Creatine; Neuroscience; Disease; Excitotoxicity; Mitochondrial disease; Bioinformatics; Pharmacology; Biology; Pathology; Internal medicine; Biochemistry; Glutamate receptor","score_opus":0.024588816499651073,"score_gpt":0.29465874988490354,"score_spread":0.2700699333852525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095646768","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006709907,0.9971924,0.000038520087,0.00046046532,0.0015297569,0.0003404374,0.000009576211,0.000016805081,0.00034494986],"genre_scores_gemma":[0.0001532595,0.99552804,0.00016509644,0.00076257496,0.0012816308,0.00038511766,0.0014113204,0.00004888747,0.0002640875],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978096,0.00040500896,0.00044539143,0.00078895706,0.00024893234,0.00030210154],"domain_scores_gemma":[0.99934316,0.00005984211,0.00018730249,0.00027775753,0.000035797977,0.00009616855],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023924545,0.00039983485,0.00051138125,0.00011874793,0.00013315541,0.000019527233,0.0001846742,0.00034616096,0.000019056268],"category_scores_gemma":[0.000302646,0.00034464174,0.00022778346,0.00023029566,0.00013518584,0.000004373851,0.00010593112,0.00024415326,0.000017258159],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000629336,0.00043502782,0.000053564097,0.0014425546,0.00017858973,0.0000054616926,0.00017727881,0.0006991712,0.00057962607,0.005808535,0.642805,0.34775227],"study_design_scores_gemma":[0.00013817083,0.00015288546,0.0000038770904,0.00057273766,0.0000042333195,0.0000036565884,0.000013181767,0.000024189096,0.00012971838,0.00017201742,0.9984373,0.00034806528],"about_ca_topic_score_codex":0.000024211447,"about_ca_topic_score_gemma":0.0000042129436,"teacher_disagreement_score":0.35563228,"about_ca_system_score_codex":0.00003218394,"about_ca_system_score_gemma":0.00015551089,"threshold_uncertainty_score":0.9999006},"labels":[],"label_agreement":null},{"id":"W2100771859","doi":"10.1517/13543784.2015.1009629","title":"Investigational drugs for the treatment of spinal cord injury: review of preclinical studies and evaluation of clinical trials from Phase I to II","year":2015,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Spinal Cord Injury Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto Western Hospital; University Health Network","funders":"AOSpine; Ontario Neurotrauma Foundation; European Commission; Acorda Therapeutics; Hadassah Medical Organization; Medtronic","keywords":"Medicine; Clinical trial; Riluzole; Spinal cord injury; Tolerability; Intensive care medicine; Neuroprotection; Pharmacology; Gabapentin; Adverse effect; Spinal cord; Disease; Internal medicine; Amyotrophic lateral sclerosis; Pathology; Alternative medicine","score_opus":0.7987099318314077,"score_gpt":0.7059770694690723,"score_spread":0.09273286236233536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100771859","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013451698,0.98090804,0.000018244265,0.0052322587,0.0010837294,0.009748873,0.001599501,0.000014985682,0.000049201557],"genre_scores_gemma":[0.000085134445,0.98721063,0.0048007723,0.00092083676,0.0018318582,0.0031256925,0.0019046513,0.000056035944,0.000064375],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9863154,0.0036817251,0.005782137,0.00087519357,0.003084703,0.00026079878],"domain_scores_gemma":[0.9770662,0.013161308,0.0035942309,0.0009882718,0.004567368,0.000622574],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.022179049,0.00058577734,0.0057845754,0.0003673082,0.0001299969,0.000010862118,0.00036925098,0.00037323232,0.00012633408],"category_scores_gemma":[0.043767955,0.00035517957,0.0012565928,0.0006192171,0.0013140431,0.00009154873,0.0001577323,0.00036897467,0.000009302649],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006080949,0.000929579,0.00000894619,0.012972166,0.0015586127,1.7224222e-7,0.00029878624,7.742445e-7,0.000009476485,0.0011567781,0.03026365,0.9467201],"study_design_scores_gemma":[0.004889542,0.03650551,0.000043242675,0.12122878,0.0015741787,0.0000029773012,0.0001616457,0.00013346707,0.0001414502,0.0021563822,0.83290875,0.00025410636],"about_ca_topic_score_codex":0.00005056382,"about_ca_topic_score_gemma":8.2719623e-7,"teacher_disagreement_score":0.946466,"about_ca_system_score_codex":0.00040175795,"about_ca_system_score_gemma":0.0061911964,"threshold_uncertainty_score":0.99989},"labels":[],"label_agreement":null},{"id":"W2100830152","doi":"10.1517/13543784.17.11.1761","title":"Clazosentan: an endothelin receptor antagonist for treatment of vasospasm after subarachnoid hemorrhage","year":2008,"lang":"en","type":"article","venue":"Expert Opinion on Investigational Drugs","topic":"Intracranial Aneurysms: Treatment and Complications","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"","keywords":"Subarachnoid hemorrhage; Endothelin receptor antagonist; Vasospasm; Medicine; Cerebral vasospasm; Endothelin receptor; Antagonist; Placebo; Clinical trial; Randomized controlled trial; Receptor antagonist; Anesthesia; Internal medicine; Receptor; Pathology","score_opus":0.04050734314660269,"score_gpt":0.30314685557252613,"score_spread":0.2626395124259234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100830152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831273,0.0008835137,0.00027434915,0.011857134,0.00054354477,0.0013938661,0.00045507366,0.0001296389,0.0013355697],"genre_scores_gemma":[0.974784,0.00029288037,0.017571485,0.0016395435,0.00097519567,0.001034245,0.0018039182,0.00004087359,0.0018578565],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99870443,0.000038821323,0.00036772655,0.00036842932,0.00031319255,0.0002074176],"domain_scores_gemma":[0.9990489,0.000111582995,0.0001145527,0.00034542402,0.00016522406,0.00021433452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000045339315,0.00023296969,0.00030098058,0.00011043873,0.0002299957,0.0000102824315,0.00008178855,0.000094415846,0.0002791209],"category_scores_gemma":[0.000026476528,0.00019211284,0.0001772549,0.00012395624,0.0002527964,0.0001060203,0.000008564194,0.00004784648,0.00009153729],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01752547,0.032726236,0.05576486,0.00054315134,0.00079025375,0.00017744373,0.042632714,0.00013837071,0.53463924,0.215066,0.023233179,0.07676306],"study_design_scores_gemma":[0.017581629,0.012867209,0.043165978,0.00016199426,0.00009093727,0.0006161062,0.0010251206,0.005114937,0.7021143,0.004783151,0.21132295,0.0011557032],"about_ca_topic_score_codex":0.00005882481,"about_ca_topic_score_gemma":0.0000017811116,"teacher_disagreement_score":0.21028285,"about_ca_system_score_codex":0.00016478845,"about_ca_system_score_gemma":0.00019353445,"threshold_uncertainty_score":0.78341347},"labels":[],"label_agreement":null},{"id":"W2101161401","doi":"10.1517/13543784.2010.515586","title":"Quetiapine: novel uses in the treatment of depressive and anxiety disorders","year":2010,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"AstraZeneca Canada","keywords":"Quetiapine; Tolerability; Anxiety; Psychiatry; Mania; Atypical antipsychotic; Bipolar disorder; Medicine; Psychology; Antipsychotic; Depression (economics); Schizophrenia (object-oriented programming); Clinical psychology; Adverse effect; Mood; Pharmacology","score_opus":0.05158241660745432,"score_gpt":0.3582140999012484,"score_spread":0.3066316832937941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101161401","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011875816,0.9960886,0.000005020781,0.001459163,0.00018378014,0.0012872616,0.000089167916,0.000015335,0.00075291493],"genre_scores_gemma":[0.00033113305,0.99720997,0.00043358028,0.00020923285,0.00019990814,0.0006743943,0.0008631396,0.000033629454,0.0000450042],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99853444,0.00010403088,0.00043746835,0.0003945854,0.00036427836,0.00016520292],"domain_scores_gemma":[0.9989478,0.00033423994,0.00020607367,0.00036874195,0.000037050573,0.00010608834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008955859,0.00038100436,0.0007914309,0.00017584696,0.000074166244,0.000016110107,0.00011283108,0.0002607293,0.000022443568],"category_scores_gemma":[0.00005179845,0.00021713681,0.0002644873,0.00020720127,0.00028852726,0.000043259603,0.000017816208,0.0002526973,0.000007722775],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022064827,0.0016010745,0.0011684254,0.00084241433,0.00018972236,5.9130815e-7,0.0030777836,8.0048414e-7,0.0000042949123,0.0070634377,0.00036996877,0.9856594],"study_design_scores_gemma":[0.0013119437,0.00037263735,0.0020852755,0.0025028025,0.000068790214,0.000031598345,0.000096446194,0.0000072494795,0.000014710834,0.0002858631,0.99304914,0.0001735626],"about_ca_topic_score_codex":0.0002531013,"about_ca_topic_score_gemma":0.000054343567,"teacher_disagreement_score":0.9926792,"about_ca_system_score_codex":0.000087947265,"about_ca_system_score_gemma":0.00032945347,"threshold_uncertainty_score":0.88545823},"labels":[],"label_agreement":null},{"id":"W2101906616","doi":"10.1517/13543784.16.10.1525","title":"Next-generation calcineurin inhibitors for ophthalmic indications","year":2007,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Ocular Diseases and Behçet’s Syndrome","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Institute for Nanotechnology","funders":"","keywords":"Calcineurin; Ciclosporin; Medicine; Tacrolimus; Pharmacology; Uveitis; Blepharitis; Transplantation; Ophthalmology; Immunology; Internal medicine","score_opus":0.23988800468594348,"score_gpt":0.4298117209830393,"score_spread":0.18992371629709584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101906616","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006666084,0.99273586,0.00013960841,0.0017906446,0.0017361299,0.0025304805,0.00026600956,0.000109750494,0.00062484137],"genre_scores_gemma":[0.00010895571,0.9726029,0.0022947376,0.0014226782,0.004872473,0.0012220602,0.016333966,0.00013320768,0.0010090187],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969868,0.00010285562,0.0010032885,0.0007722941,0.0007652547,0.0003695118],"domain_scores_gemma":[0.9979974,0.00029433056,0.00044245768,0.000526551,0.00020157787,0.00053766713],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003151525,0.0005465062,0.0010349283,0.0006577546,0.0002748036,0.00007454386,0.00020263903,0.00048975146,0.00024812904],"category_scores_gemma":[0.0003179521,0.00046613254,0.00081200915,0.0005154781,0.00017533888,0.00015526649,0.00004803901,0.00039165886,0.00023552672],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004161163,0.00078270544,0.000021247906,0.0060136905,0.0003923754,0.000016561726,0.0002760462,0.000008681088,0.000081871556,0.015822481,0.12802143,0.8485213],"study_design_scores_gemma":[0.0006314553,0.00025310126,0.000035040794,0.006709182,0.00010262897,0.00012936104,0.000023031687,0.00011315738,0.000057763962,0.00020214156,0.9913055,0.00043763974],"about_ca_topic_score_codex":0.000017858678,"about_ca_topic_score_gemma":4.1736158e-7,"teacher_disagreement_score":0.86328405,"about_ca_system_score_codex":0.00038681144,"about_ca_system_score_gemma":0.0012276095,"threshold_uncertainty_score":0.99977905},"labels":[],"label_agreement":null},{"id":"W2103370158","doi":"10.1517/13543784.13.3.199","title":"Recent advances in protein tyrosine phosphatase 1B inhibitors","year":2004,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Protein Tyrosine Phosphatases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Downregulation and upregulation; Leptin; Insulin resistance; Protein tyrosine phosphatase; Insulin; Type 2 diabetes; Diabetes mellitus; Obesity; Insulin receptor; Biology; Phosphatase; Tyrosine; Internal medicine; Endocrinology; Medicine; Cell biology; Biochemistry; Phosphorylation","score_opus":0.027311052924178392,"score_gpt":0.32922660250478314,"score_spread":0.30191554958060474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103370158","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000033205786,0.99622035,0.000021190777,0.00046565558,0.00077536004,0.0017119433,0.00058688276,0.000036640184,0.00017862672],"genre_scores_gemma":[0.000009557979,0.980442,0.0014123471,0.0005684903,0.0009945187,0.00173057,0.014640629,0.000103116996,0.00009880668],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99682987,0.00022024353,0.00092248904,0.0010405958,0.00054714986,0.00043963408],"domain_scores_gemma":[0.99846584,0.000045378136,0.0004834538,0.000644896,0.000108507156,0.0002519099],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029362048,0.000697993,0.0007989698,0.00022317826,0.00011479346,0.00005273731,0.0004952666,0.0004816224,0.00006501692],"category_scores_gemma":[0.00055542355,0.0006393303,0.00026065452,0.00047615624,0.00029150656,0.000029236999,0.00021306718,0.0004019357,0.000117182106],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006525749,0.0003166884,0.0000015169888,0.002140887,0.0000438162,0.0000072932307,0.000038175498,0.000070825095,0.00007371845,0.022017147,0.011315879,0.9639088],"study_design_scores_gemma":[0.00071273115,0.00021166465,0.0000010158435,0.015660502,0.0000053030685,0.000009914517,0.000008677989,0.0000011885519,0.026824336,0.0008156177,0.9551011,0.0006479805],"about_ca_topic_score_codex":0.000025224168,"about_ca_topic_score_gemma":0.000004283845,"teacher_disagreement_score":0.9632608,"about_ca_system_score_codex":0.00029196325,"about_ca_system_score_gemma":0.0013183596,"threshold_uncertainty_score":0.9996058},"labels":[],"label_agreement":null},{"id":"W2103567156","doi":"10.1517/13543784.15.8.933","title":"Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment","year":2006,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Antimicrobial Peptides and Activities","field":"Immunology and Microbiology","cited_by":432,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Cytotoxicity; Cancer cell; Lytic cycle; Cancer; Angiogenesis; Antimicrobial; Cancer research; Cytotoxic T cell; Apoptosis; Biology; Chemotherapy; Drug resistance; Drug; Pharmacology; Immunology; In vitro; Microbiology; Biochemistry","score_opus":0.08353260939165319,"score_gpt":0.36466099908877286,"score_spread":0.2811283896971197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103567156","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000102125865,0.9899548,0.00006318697,0.0007192303,0.0033387146,0.0019505118,0.002882311,0.0001236839,0.00086540123],"genre_scores_gemma":[0.00007990214,0.9649484,0.0004370156,0.0010305593,0.001099693,0.0016051438,0.014070281,0.000116032184,0.016612954],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976047,0.00014149836,0.00080242526,0.0008247766,0.000095216536,0.00053133623],"domain_scores_gemma":[0.99837655,0.0004671559,0.00061132846,0.0003617413,0.00012109419,0.00006215715],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011680291,0.000773954,0.0012940977,0.00029134448,0.0005821217,0.00007877257,0.00034975464,0.00066298665,0.00029046566],"category_scores_gemma":[0.00005865786,0.00064484455,0.00078557804,0.00017860021,0.00045766652,0.00014991994,0.00006536371,0.000291308,0.0006430728],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012331238,0.0013442016,0.0000052430937,0.0028191735,0.0017705921,0.0000014986817,0.00096843473,0.00015155831,0.0066963327,0.030638471,0.55641323,0.39906794],"study_design_scores_gemma":[0.0010218424,0.0001927073,0.000004657151,0.0047565587,0.000072415605,0.000034476398,0.000029539067,0.000002921529,0.0033103381,0.00015455032,0.98977673,0.00064326875],"about_ca_topic_score_codex":0.001134562,"about_ca_topic_score_gemma":0.000021891039,"teacher_disagreement_score":0.4333635,"about_ca_system_score_codex":0.0007025276,"about_ca_system_score_gemma":0.0013123766,"threshold_uncertainty_score":0.9996003},"labels":[],"label_agreement":null},{"id":"W2107217435","doi":"10.1517/13543784.14.9.1129","title":"The therapeutic potential of NS3 protease inhibitors in HCV infection","year":2005,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Hepatitis C virus research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"NS3; Protease; Hepatitis C virus; Virology; Viral replication; Hepatitis C; Medicine; Drug discovery; Biology; Virus; Enzyme; Immunology; Bioinformatics; Biochemistry","score_opus":0.08782441455950177,"score_gpt":0.4167827363426397,"score_spread":0.3289583217831379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107217435","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000047966605,0.9927732,0.000011269388,0.001955453,0.0007058075,0.0024814412,0.000029604971,0.00004164234,0.0019536235],"genre_scores_gemma":[0.0005141898,0.9958369,0.00012706718,0.00034834232,0.0014227998,0.0010249793,0.0003603568,0.000068955655,0.00029638773],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962933,0.00063011184,0.0010442595,0.00043866172,0.0012494778,0.00034417285],"domain_scores_gemma":[0.99833375,0.0004184914,0.0003704175,0.0004598374,0.0001908197,0.00022666204],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000788377,0.00036734133,0.0008357921,0.00056436355,0.00016176273,0.0000405464,0.00020645227,0.00036585933,0.00011453746],"category_scores_gemma":[0.0005578964,0.00024930798,0.00038382778,0.0006998676,0.00042709731,0.000109706365,0.00007581521,0.00090273755,0.00016888908],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003685339,0.00015015696,0.000057421228,0.0010401163,0.00007562438,0.0000031012394,0.00016733825,0.000010467614,0.000007585375,0.001981443,0.0037453435,0.99272454],"study_design_scores_gemma":[0.00049804425,0.00016809606,0.0001866087,0.009533659,0.000014140835,0.000010181076,0.000013495392,0.00015611714,0.000038187038,0.0002452019,0.988935,0.00020124913],"about_ca_topic_score_codex":0.00028346182,"about_ca_topic_score_gemma":0.000012159166,"teacher_disagreement_score":0.9925233,"about_ca_system_score_codex":0.00052623777,"about_ca_system_score_gemma":0.0017891502,"threshold_uncertainty_score":0.9999959},"labels":[],"label_agreement":null},{"id":"W2109977008","doi":"10.1517/13543784.9.2.383","title":"A review of clinical trials with fluoroquinolones with an emphasis on new agents","year":2000,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Pneumonia and Respiratory Infections","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital","funders":"","keywords":"Medicine; Intensive care medicine; Antimicrobial; Broad spectrum; Antibiotics; Respiratory tract infections; Clinical trial; Anti-Infective Agents; Pharmacology; Internal medicine; Respiratory system; Biology; Microbiology","score_opus":0.3822515389438884,"score_gpt":0.5327650230802695,"score_spread":0.1505134841363811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109977008","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000027985545,0.9925714,0.00000688361,0.0025452864,0.00052057876,0.0021826855,0.0000986337,0.00008788407,0.001958631],"genre_scores_gemma":[0.0000016993221,0.9827393,0.0005105541,0.012986222,0.001789727,0.00036072286,0.0010931115,0.00008899628,0.00042964212],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9938359,0.0017285879,0.0024537353,0.0007759952,0.0009451252,0.00026063801],"domain_scores_gemma":[0.9957016,0.0011162304,0.0014181564,0.0008253726,0.00019747767,0.0007411763],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015585958,0.00062524935,0.0040051676,0.00037029726,0.0001247688,0.000020611704,0.00023553197,0.00043901496,0.00068430457],"category_scores_gemma":[0.0010621297,0.00035435756,0.0008354257,0.0006022743,0.00037598453,0.000112221154,0.000019586134,0.0006777116,0.00017537919],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027666643,0.00064049143,0.000024348596,0.014206844,0.00064369146,0.000011150307,0.00009383323,0.0000029810067,5.440432e-7,0.00062420097,0.049982492,0.9334928],"study_design_scores_gemma":[0.0011433293,0.0027092125,0.000054013744,0.2398928,0.00024215614,0.0000991216,0.000007640718,0.000001913662,0.0000037275308,0.000021252425,0.7555388,0.00028599353],"about_ca_topic_score_codex":0.000025676793,"about_ca_topic_score_gemma":8.8204126e-7,"teacher_disagreement_score":0.93320674,"about_ca_system_score_codex":0.000099378296,"about_ca_system_score_gemma":0.0035764086,"threshold_uncertainty_score":0.99989086},"labels":[],"label_agreement":null},{"id":"W2112228502","doi":"10.1517/13543784.12.1.87","title":"Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes","year":2003,"lang":"en","type":"article","venue":"Expert Opinion on Investigational Drugs","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":208,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Incretin; Dipeptidyl peptidase; Aminopeptidase; Peptide; Glucagon-like peptide-1; Dipeptidyl peptidase-4; Type 2 diabetes; Sitagliptin; Chemistry; Pharmacology; Biochemistry; Endocrinology; Internal medicine; Biology; Diabetes mellitus; Medicine; Enzyme; Amino acid","score_opus":0.02959327137273806,"score_gpt":0.2913622153120864,"score_spread":0.26176894393934835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112228502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9728742,0.012396391,0.00015395648,0.006621084,0.0020091322,0.002811562,0.00005311198,0.00006273548,0.0030178023],"genre_scores_gemma":[0.9956123,0.0011397479,0.0011147123,0.00072214624,0.00023010373,0.00024559454,0.00017467173,0.000023274792,0.00073743047],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990109,0.000043462078,0.00028408383,0.00018945,0.0003070289,0.00016506133],"domain_scores_gemma":[0.9991738,0.00024922017,0.00013010584,0.00023950913,0.00012935809,0.00007799614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000113054244,0.00016372219,0.00023826964,0.00009350189,0.00007788175,0.000008051818,0.000058878675,0.000047736034,0.000093273185],"category_scores_gemma":[0.000053027525,0.00010207802,0.00017241098,0.00014981956,0.00018859886,0.000044405664,0.000007255219,0.000030120753,0.000010054607],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001957906,0.014788178,0.038770843,0.0007143906,0.0071785212,0.0000039949887,0.015425104,0.0023254815,0.12606,0.5154888,0.08388976,0.193397],"study_design_scores_gemma":[0.009369196,0.0088431295,0.016221084,0.00044873153,0.0002186479,0.000001192477,0.0013391036,0.0025281238,0.3341505,0.0066788336,0.61980194,0.0003995658],"about_ca_topic_score_codex":0.000008814109,"about_ca_topic_score_gemma":2.3245778e-7,"teacher_disagreement_score":0.53591216,"about_ca_system_score_codex":0.00007191397,"about_ca_system_score_gemma":0.000092932176,"threshold_uncertainty_score":0.41626206},"labels":[],"label_agreement":null},{"id":"W2112309322","doi":"10.1517/13543784.10.7.1265","title":"Recent advances in the management of adult myositis","year":2001,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Inflammatory Myopathies and Dermatomyositis","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Polymyositis; Medicine; Myositis; Azathioprine; Methotrexate; Inclusion body myositis; Dermatomyositis; Infliximab; Combination therapy; Tacrolimus; Immunology; Cyclophosphamide; Cytotoxic T cell; Etanercept; Pharmacology; Rheumatoid arthritis; Dermatology; Internal medicine; Chemotherapy; Tumor necrosis factor alpha; Transplantation; Disease; Biology","score_opus":0.03867655144852411,"score_gpt":0.35170777275297277,"score_spread":0.31303122130444866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112309322","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000060516,0.9763895,0.00000826198,0.0018809161,0.0005860322,0.001075308,0.000035841855,0.000026841977,0.019991199],"genre_scores_gemma":[0.0000033060417,0.99477166,0.0007036663,0.0026832847,0.00044897213,0.0005220183,0.0007083624,0.000035751546,0.0001229551],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974382,0.00021680252,0.00090116996,0.00036786954,0.00083610497,0.00023988854],"domain_scores_gemma":[0.9987719,0.00017552079,0.00036918282,0.00044989408,0.00013198609,0.00010152134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025461428,0.00035111082,0.00088459044,0.00024873012,0.00008380463,0.00001907471,0.00026298023,0.00018575718,0.00013609127],"category_scores_gemma":[0.000031991964,0.00023538967,0.00027129264,0.0006037833,0.00017424961,0.000107845735,0.000048800564,0.00036215314,0.00008429444],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020690353,0.00009469138,0.0000059765957,0.005411137,0.00006600147,0.000063638625,0.00054798985,0.0000031272557,5.3552295e-8,0.045521215,0.009377598,0.9388879],"study_design_scores_gemma":[0.00047919882,0.00007678648,0.000048627484,0.036443695,0.00002933769,0.00016066022,0.0003831304,0.000008800532,0.0000033602412,0.000500621,0.9616578,0.00020798587],"about_ca_topic_score_codex":0.0000066129846,"about_ca_topic_score_gemma":5.57069e-7,"teacher_disagreement_score":0.9522802,"about_ca_system_score_codex":0.0001645238,"about_ca_system_score_gemma":0.00019132471,"threshold_uncertainty_score":0.9598912},"labels":[],"label_agreement":null},{"id":"W2113703285","doi":"10.1517/13543784.14.1.37","title":"Nitric oxide and the angiogenic response: can we improve the results of therapeutic angiogenesis?","year":2005,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Nitric Oxide and Endothelin Effects","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Angiogenesis; Nitric oxide; Medicine; Endothelial dysfunction; Bench to bedside; Endothelium; Neovascularization; Therapeutic angiogenesis; Antiangiogenic therapy; Pharmacology; Cancer research; Bioinformatics; Biology; Internal medicine; Medical physics","score_opus":0.04957339502972656,"score_gpt":0.3434438970343578,"score_spread":0.2938705020046312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113703285","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028441372,0.98339254,0.0000039010215,0.013742724,0.0002933779,0.0017933288,0.00018269027,0.000042985248,0.00026403315],"genre_scores_gemma":[0.0008800562,0.9929968,0.0001971911,0.0029918607,0.0010935413,0.0004552807,0.0002084302,0.00007804829,0.001098806],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960827,0.0013135081,0.0009845874,0.0005341813,0.00076381036,0.00032118472],"domain_scores_gemma":[0.99221903,0.006004402,0.0006184499,0.00083175657,0.00013629324,0.00019006117],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018676968,0.00051465165,0.0012412074,0.00036739226,0.00021467816,0.000032645923,0.00036379107,0.0002997685,0.0000179987],"category_scores_gemma":[0.00093821855,0.000252975,0.000751709,0.0007521123,0.0008156848,0.000044896056,0.00009258625,0.00043870028,0.00003859],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023629786,0.00009929011,0.0000027025062,0.0010921323,0.00073254155,0.000003828987,0.0012226581,0.000004648083,0.00015801647,0.003224152,0.009465092,0.98163193],"study_design_scores_gemma":[0.003051033,0.00014533217,0.000095108866,0.003990455,0.00022363118,0.00009521442,0.0001287097,0.000051243278,0.00013477488,0.00048850186,0.99133307,0.00026290203],"about_ca_topic_score_codex":0.00010347456,"about_ca_topic_score_gemma":0.0000013548275,"teacher_disagreement_score":0.981868,"about_ca_system_score_codex":0.0001612562,"about_ca_system_score_gemma":0.00096785976,"threshold_uncertainty_score":0.99999225},"labels":[],"label_agreement":null},{"id":"W2116152202","doi":"10.1517/13543784.11.7.991","title":"Bosentan: a dual endothelin receptor antagonist","year":2002,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Pulmonary Hypertension Research and Treatments","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Bosentan; Endothelin receptor antagonist; Medicine; Endothelin receptor; Pulmonary hypertension; Tolerability; Internal medicine; Cardiology; Pharmacology; Receptor; Adverse effect","score_opus":0.10954535217521799,"score_gpt":0.38386848033004844,"score_spread":0.27432312815483045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116152202","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000060760185,0.98678213,0.0000010938658,0.0031537672,0.0010167548,0.0013194026,0.0005939015,0.00013263873,0.006994242],"genre_scores_gemma":[0.0000058590244,0.9773212,0.0010370367,0.002248589,0.0017364268,0.00056876475,0.005806365,0.00011909238,0.011156658],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99615407,0.00029518642,0.00080059323,0.00086157816,0.0013580538,0.0005304908],"domain_scores_gemma":[0.99765384,0.00042183476,0.0002676068,0.00062333076,0.00015937956,0.0008739791],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00018289211,0.0006771828,0.0015207817,0.00046338368,0.0002698973,0.000060740997,0.00020500996,0.0004075081,0.002230538],"category_scores_gemma":[0.00029841802,0.00050123106,0.00067415315,0.0004182345,0.00033494816,0.00010376239,0.00009688393,0.000722051,0.006828274],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000109840585,0.001330059,0.000012756862,0.0021822103,0.0006978691,0.0005282109,0.00011393093,2.227947e-7,0.000022418151,0.0030102187,0.3766941,0.61529815],"study_design_scores_gemma":[0.0010831967,0.0003762508,0.000005578653,0.010393469,0.000040300147,0.00061702036,0.000026462261,0.000029405921,0.000033110904,0.00009970864,0.9869014,0.0003940983],"about_ca_topic_score_codex":0.00002652132,"about_ca_topic_score_gemma":1.4856295e-7,"teacher_disagreement_score":0.61490405,"about_ca_system_score_codex":0.00044350803,"about_ca_system_score_gemma":0.000864711,"threshold_uncertainty_score":0.99974394},"labels":[],"label_agreement":null},{"id":"W2122024610","doi":"10.1517/13543784.13.4.403","title":"Ximelagatran: the first oral direct thrombin inhibitor","year":2004,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University Medical Centre","funders":"","keywords":"Ximelagatran; Direct thrombin inhibitor; Medicine; Discovery and development of direct thrombin inhibitors; Coagulation; Anticoagulant; Thrombin; Intensive care medicine; Warfarin; Pharmacology; Atrial fibrillation; Dabigatran; Internal medicine","score_opus":0.13524794000117346,"score_gpt":0.3960961936146366,"score_spread":0.26084825361346314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122024610","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000028019717,0.96970916,0.000008141767,0.018694108,0.0025861505,0.0017734607,0.000033684657,0.00017994792,0.007012564],"genre_scores_gemma":[0.000035146473,0.98849386,0.00040342743,0.0026434332,0.0049826354,0.00009883274,0.0011499035,0.000095000905,0.002097751],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99716485,0.00015707484,0.0008499642,0.0005824735,0.0009355017,0.00031011397],"domain_scores_gemma":[0.99820936,0.00057045487,0.00038054425,0.0005486564,0.00008613723,0.00020484436],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003995912,0.0005725181,0.0013036464,0.000263688,0.0003769821,0.000088441295,0.00027653467,0.0003299966,0.00036711918],"category_scores_gemma":[0.00026584102,0.0003541145,0.0008902003,0.0005698631,0.00031050734,0.0001295694,0.000099010125,0.00045165216,0.0009075643],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014044307,0.00012868023,0.00012518246,0.012292754,0.0015432817,0.000018640965,0.0021178515,0.00010942968,0.00000231896,0.1570211,0.37476158,0.45173872],"study_design_scores_gemma":[0.00078987185,0.000108487126,0.000079357545,0.012357732,0.0000943596,0.000016612608,0.000033976445,0.000009962264,0.000012487798,0.0006838754,0.9854462,0.00036706202],"about_ca_topic_score_codex":0.00003403747,"about_ca_topic_score_gemma":0.0000013911152,"teacher_disagreement_score":0.61068463,"about_ca_system_score_codex":0.00038898567,"about_ca_system_score_gemma":0.00066901714,"threshold_uncertainty_score":0.9998911},"labels":[],"label_agreement":null},{"id":"W2122461299","doi":"10.1517/13543784.17.5.811","title":"Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma","year":2008,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Phosphodiesterase function and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Foothills Medical Centre","funders":"","keywords":"Roflumilast; Medicine; COPD; Asthma; Intensive care medicine; Lung function; Internal medicine; Lung","score_opus":0.040720505888062065,"score_gpt":0.3306587140258579,"score_spread":0.2899382081377958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122461299","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013445942,0.9969251,0.00046217156,0.00024402498,0.0007966925,0.0010862437,0.00011422624,0.000014799275,0.00022227004],"genre_scores_gemma":[0.00015133091,0.9943839,0.0014620274,0.0004203236,0.00060563785,0.0004759365,0.00190895,0.000039997234,0.00055190816],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99861056,0.000116461924,0.00040930597,0.0004638793,0.00024750113,0.00015227812],"domain_scores_gemma":[0.9991176,0.00007765433,0.00028174958,0.00028342978,0.00014101806,0.00009855196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014125115,0.0002955641,0.000380839,0.0000682547,0.00022706267,0.000022587294,0.00015865624,0.00023276755,0.0000074183536],"category_scores_gemma":[0.000026779955,0.00021046214,0.00018633684,0.0001304886,0.00027330083,0.000010762179,0.000069737696,0.000108030305,0.000004175173],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022073239,0.00023807825,0.0000054734674,0.0019117603,0.00087734003,7.845607e-7,0.0005831963,0.00011477355,0.0002994327,0.006949939,0.15497223,0.83382624],"study_design_scores_gemma":[0.00045010584,0.000310785,0.000053061412,0.001164613,0.000016846012,0.000014690766,0.00008416845,0.00007844436,0.0009613765,0.00008506567,0.99654746,0.00023340377],"about_ca_topic_score_codex":0.0000069315943,"about_ca_topic_score_gemma":0.0000011655443,"teacher_disagreement_score":0.8415752,"about_ca_system_score_codex":0.000043554734,"about_ca_system_score_gemma":0.00019338865,"threshold_uncertainty_score":0.8582397},"labels":[],"label_agreement":null},{"id":"W2122631980","doi":"10.1517/13543784.11.11.1605","title":"Selective phosphodiesterase type 5 inhibition using tadalafil for the treatment of erectile dysfunction","year":2002,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Sexual function and dysfunction studies","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Centre","funders":"","keywords":"Tadalafil; Erectile dysfunction; Sildenafil; Medicine; cGMP-specific phosphodiesterase type 5; Broad spectrum; Placebo; Population; Pharmacotherapy; Pharmacology; Internal medicine; Alternative medicine; Chemistry; Pathology","score_opus":0.21173695906244597,"score_gpt":0.40449572255346905,"score_spread":0.19275876349102308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122631980","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000039609284,0.9916646,0.00041259563,0.0003625725,0.004327735,0.002264937,0.00010919313,0.00008413709,0.0007346409],"genre_scores_gemma":[0.000033847235,0.99287605,0.0005557368,0.000653381,0.0018208999,0.0008488119,0.00086825696,0.00006915389,0.0022738588],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99793875,0.0001207548,0.00072589796,0.00051474996,0.00047645776,0.0002233984],"domain_scores_gemma":[0.9973864,0.0011189115,0.0004920451,0.00032728538,0.0005426997,0.00013268519],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014415332,0.0004829396,0.0010814589,0.00029123278,0.0004042302,0.000026024434,0.000050070474,0.00026057998,0.00026200773],"category_scores_gemma":[0.00026615866,0.00030795805,0.0004998595,0.00061456056,0.00021011801,0.00008626212,0.000014926912,0.0001860325,0.00006908366],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088805455,0.0013515906,0.000024155128,0.0026361286,0.0019163431,0.0000016893505,0.0028857435,0.00016106767,0.000041084004,0.0025470296,0.12773527,0.85981184],"study_design_scores_gemma":[0.0013345863,0.0017938132,0.000016869148,0.0027765953,0.00023536438,0.000036379428,0.0002837992,0.00045027223,0.00018401907,0.000053022148,0.99258363,0.00025165474],"about_ca_topic_score_codex":0.00007900925,"about_ca_topic_score_gemma":0.0000011689128,"teacher_disagreement_score":0.8648484,"about_ca_system_score_codex":0.00076785823,"about_ca_system_score_gemma":0.00042070917,"threshold_uncertainty_score":0.99993724},"labels":[],"label_agreement":null},{"id":"W2126896835","doi":"10.1517/13543784.9.3.457","title":"Platelet substitutes and novel platelet products","year":2000,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Queen's University","funders":"","keywords":"Platelet; Business; Chemistry; Medicine; Internal medicine","score_opus":0.06310912037077193,"score_gpt":0.3306338903687579,"score_spread":0.26752476999798597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126896835","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014812761,0.9956774,0.000013727388,0.0006935885,0.0005788211,0.0012385864,0.00018327785,0.0001515113,0.0013149717],"genre_scores_gemma":[0.000029022338,0.99156487,0.000682015,0.0014350951,0.0018985231,0.0002668985,0.0034882512,0.00010762775,0.0005276749],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99712265,0.00012284725,0.00066388684,0.0009270318,0.00079844956,0.00036513992],"domain_scores_gemma":[0.99849045,0.00020335248,0.00020901645,0.0005809417,0.00010209604,0.0004141703],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002490311,0.0006846728,0.0016515291,0.00031193148,0.00021539512,0.00006848086,0.00018398986,0.00043447185,0.00025227922],"category_scores_gemma":[0.00014375117,0.0005481132,0.00059332524,0.00039576727,0.00043510896,0.00015554867,0.000045197794,0.00052144856,0.00025197104],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000111819165,0.00021685699,0.0000017652147,0.0036220746,0.0009660956,0.00003939551,0.00019801472,0.0000060850666,0.0000045375355,0.0061978586,0.014330016,0.97430545],"study_design_scores_gemma":[0.0013071133,0.00011315613,0.00001701346,0.011582191,0.00008084073,0.0006477366,0.000018126277,0.000009271667,0.00008440639,0.00015514153,0.98544055,0.0005444345],"about_ca_topic_score_codex":0.000011555269,"about_ca_topic_score_gemma":8.760753e-8,"teacher_disagreement_score":0.973761,"about_ca_system_score_codex":0.00010642375,"about_ca_system_score_gemma":0.00089499325,"threshold_uncertainty_score":0.999697},"labels":[],"label_agreement":null},{"id":"W2127275456","doi":"10.1517/13543784.17.8.1247","title":"Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor","year":2008,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Fondation de France","keywords":"Pharmacodynamics; Histone; Cancer research; Histone deacetylase; Pharmacokinetics; Pharmacology; Histone deacetylase inhibitor; Medicine; Cancer; Gene; Chemistry; Biology; Internal medicine; Biochemistry","score_opus":0.04875667779882451,"score_gpt":0.3654440281644459,"score_spread":0.31668735036562135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127275456","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002906105,0.99235225,0.00029036665,0.0002624021,0.0006904775,0.0017053062,0.0002589899,0.00007904796,0.0014550587],"genre_scores_gemma":[0.0005178009,0.9902443,0.00227946,0.0002789765,0.002277353,0.00075196166,0.0020273218,0.000231895,0.0013908908],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959329,0.00034922306,0.00061737426,0.0014278874,0.0010545626,0.0006180486],"domain_scores_gemma":[0.9977709,0.00014359236,0.00051007705,0.0007714129,0.00036141684,0.0004425979],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024534945,0.00086118496,0.0011002545,0.00039506413,0.0004734408,0.00006380751,0.00046013953,0.00065570045,0.000024958716],"category_scores_gemma":[0.00043214616,0.000745632,0.00043848416,0.00058545877,0.0007958893,0.000026843572,0.00019874102,0.0008970221,0.00014963906],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017524408,0.003932209,0.000007712631,0.005901781,0.0018136811,0.00011648171,0.0019353882,0.00014803499,0.089404024,0.0013873092,0.4358952,0.45770574],"study_design_scores_gemma":[0.0008612019,0.00057501136,0.0000045487245,0.0036786553,0.000013089889,0.00027342184,0.000015054515,0.000023187315,0.036108747,0.0000061637134,0.95758146,0.00085942954],"about_ca_topic_score_codex":0.0000732276,"about_ca_topic_score_gemma":0.00000835886,"teacher_disagreement_score":0.5216863,"about_ca_system_score_codex":0.0006551568,"about_ca_system_score_gemma":0.003506542,"threshold_uncertainty_score":0.9994995},"labels":[],"label_agreement":null},{"id":"W2129376177","doi":"10.1517/13543784.2014.998334","title":"Novel investigational drugs targeting IL-6 signaling for the treatment of depression","year":2015,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Tryptophan and brain disorders","field":"Neuroscience","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Major depressive disorder; Antidepressant; Signal transduction; Neuroscience; Drug development; Medicine; Function (biology); Bioinformatics; Pharmacology; Drug; Psychology; Biology; Psychiatry; Cognition; Anxiety; Cell biology","score_opus":0.15072664658707133,"score_gpt":0.37481996680945256,"score_spread":0.22409332022238124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129376177","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000045159537,0.9931707,0.0005360561,0.00096484256,0.0016703465,0.0022782206,0.00076020113,0.000103856524,0.00047063283],"genre_scores_gemma":[0.00011662049,0.99018604,0.004020354,0.0011713298,0.0014925099,0.0016167028,0.0009549974,0.00011969507,0.0003217631],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961449,0.00030100334,0.0010560703,0.00093243463,0.001156493,0.00040911115],"domain_scores_gemma":[0.9937524,0.004402179,0.0009066635,0.00046002676,0.0001910773,0.00028762245],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048304378,0.00065396604,0.00096889155,0.0002661726,0.00050221337,0.00008749402,0.0006626263,0.00030637512,0.00006341342],"category_scores_gemma":[0.0013044701,0.00042723652,0.0007457358,0.00051826896,0.0006365072,0.00018968398,0.00007403452,0.00024738623,0.00004261725],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011348134,0.0011708066,0.0000031506238,0.0022586475,0.00024025362,0.0000012345428,0.00794488,0.0015447895,0.004256363,0.054231767,0.05587293,0.8723617],"study_design_scores_gemma":[0.00093979173,0.00018174743,0.0000013628835,0.0026390802,0.00002457171,0.000008326073,0.00020881726,0.00076636253,0.0052821557,0.002508902,0.98699063,0.0004482626],"about_ca_topic_score_codex":0.000027375127,"about_ca_topic_score_gemma":2.6898863e-7,"teacher_disagreement_score":0.9311177,"about_ca_system_score_codex":0.00030912328,"about_ca_system_score_gemma":0.0011984864,"threshold_uncertainty_score":0.99981797},"labels":[],"label_agreement":null},{"id":"W2130229333","doi":"10.1517/13543784.2013.795945","title":"Investigational drugs for schizophrenia targeting the dopamine receptor: Phase II trials","year":2013,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre for Addiction and Mental Health","funders":"","keywords":"Schizophrenia (object-oriented programming); Pharmacology; Medicine; Dopamine; Dopamine receptor D2; Dopamine receptor; Investigational Drugs; Dopamine receptor D3; Psychiatry; Clinical trial; Neuroscience; Biology; Internal medicine","score_opus":0.1547790096082772,"score_gpt":0.43139162373715595,"score_spread":0.2766126141288787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130229333","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000143865,0.9716023,0.00003955891,0.01661922,0.0018155855,0.00814567,0.0011320355,0.00018701119,0.00031475225],"genre_scores_gemma":[0.000026950085,0.9327182,0.021574233,0.0016501895,0.00770322,0.010884266,0.02371234,0.00020377444,0.0015268036],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9922526,0.001215592,0.002437787,0.0012589954,0.0020087338,0.0008262878],"domain_scores_gemma":[0.99054027,0.005512571,0.0013144079,0.00089918444,0.0006401175,0.001093478],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0029573264,0.0011459365,0.0029062782,0.00061800214,0.0012162641,0.00020746415,0.00063775165,0.0005655557,0.0012377911],"category_scores_gemma":[0.006681912,0.00068817654,0.0015888718,0.000728239,0.00076446,0.0002636763,0.00022359497,0.0010675176,0.0008014175],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012761643,0.0006259431,5.3495984e-7,0.0014731825,0.0009309993,0.0000019616227,0.0005054969,0.0000019984097,0.000041318446,0.027148487,0.30303496,0.66495895],"study_design_scores_gemma":[0.009427155,0.0012384797,0.000001373614,0.009372183,0.00017372113,0.000027655191,0.000102637816,0.00019797767,0.00027970213,0.004696826,0.97386307,0.00061921816],"about_ca_topic_score_codex":0.000045837456,"about_ca_topic_score_gemma":7.428185e-7,"teacher_disagreement_score":0.6708281,"about_ca_system_score_codex":0.0007219182,"about_ca_system_score_gemma":0.0045148176,"threshold_uncertainty_score":0.9999766},"labels":[],"label_agreement":null},{"id":"W2130413670","doi":"10.1517/13543784.9.5.1099","title":"Pharmacology and clinical assessment of cariporide for the treatment coronary artery diseases","year":2000,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Cardiac Ischemia and Reperfusion","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Myocardial infarction; Cardiology; Internal medicine; Clinical trial; Placebo; Coronary artery disease; Thrombolysis; Pharmacology","score_opus":0.07327883999910648,"score_gpt":0.44735957193004305,"score_spread":0.3740807319309366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130413670","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00041750006,0.99362785,0.0000076092824,0.0013709898,0.0018811692,0.002059719,0.0002930088,0.000023283766,0.0003188529],"genre_scores_gemma":[0.00009278528,0.9935357,0.00032117456,0.00079128746,0.0023188095,0.0008697748,0.0016986756,0.000036027785,0.0003357605],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981641,0.00016844431,0.0007563758,0.00043408183,0.00031683745,0.00016012801],"domain_scores_gemma":[0.9970439,0.0021226131,0.00026877696,0.00027349527,0.000069135094,0.00022205208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018769053,0.0003215991,0.0012246243,0.0000926061,0.00013902089,0.000009398586,0.00008227111,0.00024181089,0.00011586756],"category_scores_gemma":[0.000038812515,0.00018011607,0.00084366376,0.00008245579,0.0004129825,0.0000264936,0.0000282242,0.00021855946,0.000004772735],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001375473,0.00056991144,0.00022452451,0.0011790098,0.001067688,0.0000060053994,0.00010785924,0.0000032536823,0.0000070293804,0.00047475268,0.036145344,0.96007705],"study_design_scores_gemma":[0.0015064368,0.000750007,0.0005748594,0.002489252,0.0006613461,0.0000662045,0.000027605378,0.00012305724,0.000017264827,0.00003450569,0.9935873,0.00016217455],"about_ca_topic_score_codex":0.000009769271,"about_ca_topic_score_gemma":1.1099962e-7,"teacher_disagreement_score":0.9599149,"about_ca_system_score_codex":0.00018772413,"about_ca_system_score_gemma":0.0012437565,"threshold_uncertainty_score":0.734492},"labels":[],"label_agreement":null},{"id":"W2132420892","doi":"10.1517/13543784.17.5.619","title":"Osteoarthritic pain: a review of current, theoretical and emerging therapeutics","year":2008,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Chronic pain; Tolerability; Intensive care medicine; Osteoarthritis; Clinical trial; Population; Etiology; Bioinformatics; Alternative medicine; Physical therapy; Psychiatry; Pathology; Biology","score_opus":0.06397579900833963,"score_gpt":0.3767876863065986,"score_spread":0.31281188729825893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132420892","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000034204204,0.99619746,0.00001264823,0.0009936726,0.00051750016,0.0012977724,0.00005771889,0.000047293404,0.0008725146],"genre_scores_gemma":[0.0000064218784,0.99435794,0.00051660446,0.0030402297,0.00047444683,0.00030465797,0.0011923267,0.000065461216,0.000041885185],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99742776,0.0004069409,0.0008257185,0.0004618542,0.00063021074,0.00024750945],"domain_scores_gemma":[0.9982756,0.00065232755,0.00031794453,0.00035656686,0.00014525959,0.0002523217],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003311115,0.00047142117,0.0014920529,0.0002030458,0.00010155994,0.000010379687,0.00010751332,0.00020153169,0.00015631581],"category_scores_gemma":[0.00033832557,0.00036270372,0.00043741232,0.00025134766,0.00055044435,0.000053313677,0.000049552284,0.00036857522,0.000038678674],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008927926,0.00009765739,0.0000010795288,0.022230016,0.000057104255,0.0000049122295,0.00015670407,5.9264313e-9,0.0000017070375,0.06262047,0.0021298728,0.91269153],"study_design_scores_gemma":[0.00054377504,0.0005545113,3.1361301e-7,0.27533215,0.0000662451,0.00010499305,0.000013708453,0.000002635608,0.000012202992,0.0007742984,0.72238725,0.00020792849],"about_ca_topic_score_codex":5.5723115e-7,"about_ca_topic_score_gemma":4.624272e-8,"teacher_disagreement_score":0.91248363,"about_ca_system_score_codex":0.00007308769,"about_ca_system_score_gemma":0.0006553063,"threshold_uncertainty_score":0.9998825},"labels":[],"label_agreement":null},{"id":"W2135873884","doi":"10.1517/13543784.14.11.1435","title":"MC-1 (pyridoxal 5′-phosphate): novel therapeutic applications to reduce ischaemic injury","year":2005,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Medicure (Canada); University of Alberta","funders":"","keywords":"Medicine; Percutaneous coronary intervention; Cardiology; Ischemia; Internal medicine; Artery; Creatine kinase; Myocardial infarction","score_opus":0.06470835044174862,"score_gpt":0.3829273831335289,"score_spread":0.3182190326917803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135873884","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000014567067,0.99447733,0.001992696,0.001006298,0.00049746037,0.001015036,0.00020086626,0.00004409633,0.00075165206],"genre_scores_gemma":[0.00010498788,0.9810209,0.0024970905,0.004603499,0.0053821173,0.001661231,0.0032973988,0.00011391362,0.0013188372],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976509,0.00008924847,0.0006531516,0.0008675026,0.0003910346,0.00034813856],"domain_scores_gemma":[0.99859625,0.00006955269,0.00027893847,0.00062750926,0.00012425115,0.00030348447],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019079467,0.0005441759,0.00058141944,0.00018414736,0.00024947652,0.000066884575,0.00056818215,0.00046085136,0.00009402336],"category_scores_gemma":[0.000053396383,0.00049914105,0.00032760247,0.00034922897,0.00015787632,0.000009146187,0.00016520284,0.00032174503,0.00032973808],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046602352,0.00023578956,8.8644003e-7,0.00042515635,0.0002634149,4.6965275e-7,0.00021165425,0.00018501427,0.0024090204,0.010988295,0.2117339,0.7734998],"study_design_scores_gemma":[0.00019349602,0.00011613019,9.710848e-7,0.001105429,0.000018306047,0.000019268284,0.000018863546,0.000009800022,0.0015245205,0.000101268204,0.9963294,0.00056253286],"about_ca_topic_score_codex":0.00001380759,"about_ca_topic_score_gemma":2.17889e-7,"teacher_disagreement_score":0.78459555,"about_ca_system_score_codex":0.000093695904,"about_ca_system_score_gemma":0.00079625787,"threshold_uncertainty_score":0.999746},"labels":[],"label_agreement":null},{"id":"W2136699790","doi":"10.1517/13543784.9.6.1293","title":"The parathyroid hormone, its fragments and analogues - potent bone-builders for treating osteoporosis","year":2000,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Bone health and treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada","funders":"","keywords":"Osteoporosis; Calcitonin; Medicine; Parathyroid hormone; Bone remodeling; Menopause; Endocrinology; Internal medicine; Osteoblast; Bone disease; Chemistry; Calcium","score_opus":0.06713230053955255,"score_gpt":0.3736084107162686,"score_spread":0.30647611017671605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136699790","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010793122,0.9941589,0.0000036469094,0.0019446607,0.00028902804,0.0025216383,0.00025236918,0.00006042128,0.0006613756],"genre_scores_gemma":[0.00004971558,0.99123263,0.0010135723,0.0015496328,0.00040610338,0.0019559301,0.0025277322,0.00007789371,0.0011868088],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99728864,0.0001527606,0.0008804944,0.000643788,0.00056278665,0.00047151145],"domain_scores_gemma":[0.9979667,0.00068072835,0.0003870742,0.00034759048,0.00009677479,0.00052114105],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002664312,0.000554389,0.0010682084,0.00018502183,0.0007731764,0.00007540296,0.0001183471,0.00031738097,0.000011906535],"category_scores_gemma":[0.00017177395,0.00035565096,0.00036343554,0.00021648854,0.00019173487,0.00009295175,0.000033258875,0.00030984404,0.000066596214],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015065185,0.00016494341,0.000009459516,0.0012218406,0.00032849595,0.00000370504,0.00054551783,0.0000014642033,0.0000021833778,0.00094937446,0.03213252,0.9644898],"study_design_scores_gemma":[0.0016206001,0.00055065245,0.00015523197,0.0045027407,0.000104424355,0.00005221984,0.00008995359,0.000047349567,0.000007231686,0.00024991698,0.9923267,0.00029302534],"about_ca_topic_score_codex":0.00007372306,"about_ca_topic_score_gemma":0.0000021787055,"teacher_disagreement_score":0.9641968,"about_ca_system_score_codex":0.00025864618,"about_ca_system_score_gemma":0.00075898535,"threshold_uncertainty_score":0.99988955},"labels":[],"label_agreement":null},{"id":"W2137885383","doi":"10.1517/13543784.15.12.1479","title":"Can statins put the brakes on Alzheimer’s disease?","year":2006,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Biological Sciences","funders":"","keywords":"Disease; Medicine; Alzheimer's disease; Neuroscience; Intensive care medicine; Pharmacology; Psychology; Internal medicine","score_opus":0.0906705833483172,"score_gpt":0.37082078246105105,"score_spread":0.28015019911273387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137885383","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000045389934,0.9812988,0.0000072639514,0.011610753,0.0009822546,0.0021379062,0.00037691105,0.0001016612,0.0034798898],"genre_scores_gemma":[0.000039591247,0.9809234,0.00017617164,0.0079372525,0.0043210536,0.0010304335,0.004823052,0.00011866837,0.00063038425],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99597925,0.00047532356,0.0007418288,0.00071219367,0.0016896087,0.00040178222],"domain_scores_gemma":[0.9974448,0.00044457472,0.0003302279,0.0010929733,0.00012331389,0.000564121],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004998179,0.000591915,0.0011994889,0.0002099778,0.00036030228,0.00006492537,0.000286701,0.00023549375,0.00009698944],"category_scores_gemma":[0.0002097434,0.00035853818,0.0010336089,0.0003530572,0.00028389832,0.000045963392,0.000051820894,0.0007024602,0.00021199146],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025881704,0.00016410956,0.0000057008447,0.0017089006,0.0005208524,0.000013840384,0.00020611324,0.000014421363,7.6911235e-8,0.024023967,0.12234044,0.8509757],"study_design_scores_gemma":[0.00040123626,0.00013062407,0.00024300232,0.009636169,0.00016696572,0.000022495422,0.000028529117,0.000020888412,0.0000027303277,0.0006249228,0.98837143,0.00035102278],"about_ca_topic_score_codex":0.0004023615,"about_ca_topic_score_gemma":0.000004466736,"teacher_disagreement_score":0.866031,"about_ca_system_score_codex":0.00029926197,"about_ca_system_score_gemma":0.0025054524,"threshold_uncertainty_score":0.99988663},"labels":[],"label_agreement":null},{"id":"W2139097056","doi":"10.1517/13543784.9.4.807","title":"Influence of photodynamic therapy on immunological aspects of disease - an update","year":2000,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Photodynamic Therapy Research Studies","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"QLT (Canada)","funders":"","keywords":"Photodynamic therapy; Immune system; Immunity; Disease; Medicine; Immunology; Cancer research; Biology; Chemistry; Pathology","score_opus":0.05403188043651019,"score_gpt":0.38844002780130515,"score_spread":0.33440814736479496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139097056","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.056208607,0.940526,3.4148988e-7,0.00039703338,0.0001199718,0.0015564043,0.00039648905,0.00006691628,0.0007282321],"genre_scores_gemma":[0.006493231,0.9905192,0.000070337286,0.0007950929,0.00016923601,0.00040345982,0.0014194471,0.00006719238,0.00006280701],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963463,0.00046577243,0.00096720504,0.0006803866,0.0011919116,0.00034845],"domain_scores_gemma":[0.9975559,0.0005026414,0.00050081493,0.00086206186,0.00020048552,0.00037807264],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030880116,0.00057500374,0.001701696,0.0005036998,0.00010147575,0.000012184407,0.00049144553,0.00025645897,0.0002854634],"category_scores_gemma":[0.00028919335,0.00040701337,0.00048060605,0.00048830657,0.0010411517,0.00011504929,0.000066496286,0.0006290555,0.000058932612],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043948526,0.0034808118,0.000010883636,0.0056462125,0.0017118851,0.000035571644,0.0013472518,0.00048069438,0.0018505674,0.03468194,0.0010098229,0.9453495],"study_design_scores_gemma":[0.0017298299,0.0025854656,0.0016536762,0.025035514,0.00003372456,0.0000119042725,0.000027384487,0.00006783524,0.000691109,0.0033454131,0.96423864,0.0005795122],"about_ca_topic_score_codex":0.00004985167,"about_ca_topic_score_gemma":3.768192e-7,"teacher_disagreement_score":0.9632288,"about_ca_system_score_codex":0.00025407693,"about_ca_system_score_gemma":0.0013207819,"threshold_uncertainty_score":0.9998382},"labels":[],"label_agreement":null},{"id":"W2140368374","doi":"10.1517/13543784.15.11.1337","title":"Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia","year":2006,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Cholesterol and Lipid Metabolism","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials; Western University","funders":"","keywords":"Ezetimibe; Sterol O-acyltransferase; Medicine; Cholesterol; Microsomal triglyceride transfer protein; Pharmacology; Bile acid; Drug; Internal medicine; Lipoprotein; Very low-density lipoprotein","score_opus":0.07968378855267716,"score_gpt":0.38652787534824584,"score_spread":0.3068440867955687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140368374","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027906336,0.9893365,0.00019035298,0.0017603479,0.0033084478,0.0036590414,0.00015199283,0.000249583,0.0010646597],"genre_scores_gemma":[0.00013586898,0.9739582,0.00081277965,0.005535756,0.008417605,0.0024342488,0.006492051,0.00024328924,0.0019701782],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957907,0.0002506638,0.0013486053,0.0010932941,0.0009834295,0.0005332596],"domain_scores_gemma":[0.99763083,0.00035691357,0.00064334046,0.00069371687,0.00024465707,0.00043052624],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047916846,0.00092994823,0.0018039901,0.00067829154,0.00023514521,0.00014758132,0.00027978167,0.0008728766,0.000046468034],"category_scores_gemma":[0.00013735674,0.00076565036,0.0010512873,0.0004084319,0.00024148996,0.00027723456,0.000059030564,0.00079093006,0.00046686025],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001012647,0.00037583502,0.000008228826,0.0041326196,0.00020788056,0.0000011731672,0.00038187904,0.000010855128,0.00009284999,0.0075369,0.015573853,0.9715767],"study_design_scores_gemma":[0.002021397,0.0003396919,0.0001899457,0.013288595,0.00016220864,0.00012309037,0.00003330468,0.000055586723,0.00006140976,0.0007972814,0.98230284,0.0006246189],"about_ca_topic_score_codex":0.0000441301,"about_ca_topic_score_gemma":8.131673e-7,"teacher_disagreement_score":0.97095203,"about_ca_system_score_codex":0.0004644929,"about_ca_system_score_gemma":0.0007514813,"threshold_uncertainty_score":0.9994795},"labels":[],"label_agreement":null},{"id":"W2143820646","doi":"10.1517/13543784.10.5.835","title":"Therapeutic potential of Na-H exchange inhibitors for the treatment of heart failure","year":2001,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Cardiac electrophysiology and arrhythmias","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Heart failure; Cardioprotection; Antiporter; Sodium–hydrogen antiporter; Intracellular pH; Intracellular; Pharmacology; In vivo; Gene isoform; Muscle hypertrophy; Medicine; Internal medicine; Ischemia; Chemistry; Biology; Cell biology; Sodium; Biochemistry; Membrane","score_opus":0.04920125121892773,"score_gpt":0.34811311058962807,"score_spread":0.29891185937070036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143820646","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008955133,0.9946982,0.000030974148,0.0026005073,0.0007910737,0.0016241024,0.00010397511,0.00001790427,0.000043690456],"genre_scores_gemma":[0.00029544643,0.9949276,0.0003107302,0.00044602976,0.0022886964,0.00071034353,0.00076368026,0.00004234181,0.00021513997],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985203,0.00013943293,0.00053395936,0.00030426373,0.00030715976,0.00019484569],"domain_scores_gemma":[0.99856067,0.00057319546,0.00032031015,0.00034159338,0.0001210877,0.00008314896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011343919,0.0003224259,0.0011862303,0.00015648144,0.000104078004,0.000004619859,0.00008362608,0.0002713039,0.000072624316],"category_scores_gemma":[0.000033988792,0.00019028464,0.0010663508,0.00023630046,0.00032341975,0.000025447787,0.000013022934,0.00015151288,0.000011473063],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025419315,0.0005028738,0.0000032623784,0.003047871,0.0013796753,0.0000030816566,0.00080827984,0.000033952725,0.00028444536,0.003925637,0.031467643,0.9582891],"study_design_scores_gemma":[0.0007212378,0.0014360802,0.000016726171,0.0026967921,0.00015628271,0.00006437965,0.00004439793,0.000020876521,0.00041285573,0.00022477689,0.9940611,0.00014447185],"about_ca_topic_score_codex":0.000019746742,"about_ca_topic_score_gemma":2.8370616e-7,"teacher_disagreement_score":0.9625935,"about_ca_system_score_codex":0.000119216624,"about_ca_system_score_gemma":0.0004457954,"threshold_uncertainty_score":0.77595824},"labels":[],"label_agreement":null},{"id":"W2145333806","doi":"10.1517/13543784.13.12.1593","title":"Amyotrophic lateral sclerosis: contemporary concepts in etiopathogenesis and pharmacotherapy","year":2004,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Amyotrophic Lateral Sclerosis Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Muscular Dystrophy Association","keywords":"Amyotrophic lateral sclerosis; Disease; Context (archaeology); Neuroscience; Clinical trial; Medicine; Degenerative Disorder; Neurochemical; Pharmacotherapy; Psychology; Pathology; Psychiatry; Biology","score_opus":0.16599653782673643,"score_gpt":0.4263400610695118,"score_spread":0.2603435232427753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145333806","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001117861,0.9935228,0.000002830828,0.0025448152,0.000450901,0.0018121719,0.000098340155,0.00009697468,0.00035329213],"genre_scores_gemma":[0.0029031835,0.99137706,0.00042654682,0.0024115706,0.0008345322,0.00086391997,0.0007999904,0.00014699402,0.0002361844],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958202,0.0005297457,0.0010969115,0.0009947303,0.0010455514,0.0005128517],"domain_scores_gemma":[0.9983157,0.00024473254,0.00031631405,0.00041697026,0.00012472426,0.00058157626],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043563818,0.00071558886,0.0017096018,0.0006448622,0.00014296875,0.00008346161,0.0002723928,0.0005211331,0.0002710862],"category_scores_gemma":[0.00009495979,0.0005754457,0.00035682018,0.0006208508,0.00060514844,0.00021268243,0.00010954908,0.0009103391,0.00015752407],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006499404,0.0010428773,0.0005104663,0.016164452,0.0006902938,0.0001786538,0.0031532554,0.000034841087,0.0018131628,0.006430155,0.010155267,0.95917666],"study_design_scores_gemma":[0.0038688804,0.0003829566,0.002354269,0.07034276,0.000019893072,0.00007168057,0.000024656674,0.00004445968,0.00005316827,0.00038527712,0.9217389,0.00071311183],"about_ca_topic_score_codex":0.00017507368,"about_ca_topic_score_gemma":5.852917e-7,"teacher_disagreement_score":0.95846355,"about_ca_system_score_codex":0.00074299186,"about_ca_system_score_gemma":0.0018474736,"threshold_uncertainty_score":0.9996697},"labels":[],"label_agreement":null},{"id":"W2147648095","doi":"10.1517/13543784.9.12.2873","title":"Therapeutic potential of endothelin receptor antagonists in diabetes","year":2000,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Nitric Oxide and Endothelin Effects","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Diabetes mellitus; Medicine; Pathogenesis; Endothelins; Endothelin receptor; Bioinformatics; Receptor; Internal medicine; Endocrinology; Biology","score_opus":0.039939073131632696,"score_gpt":0.3417029854520782,"score_spread":0.3017639123204455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147648095","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022113435,0.996203,0.0000026515202,0.00053026434,0.00077829446,0.0009570197,0.00015960402,0.000050601746,0.001097446],"genre_scores_gemma":[0.00019698628,0.99519145,0.00058884156,0.0010944225,0.0010277118,0.00026224004,0.0010283206,0.000087423236,0.00052260415],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972108,0.0003440339,0.0009602162,0.00050655764,0.00063677924,0.00034163028],"domain_scores_gemma":[0.9984587,0.0005537194,0.0003271876,0.0004046937,0.00005982604,0.00019591626],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033641275,0.00046956615,0.0015256833,0.0005796127,0.00004950488,0.000016230846,0.0002142346,0.00038456218,0.00062117964],"category_scores_gemma":[0.00012230115,0.00037384225,0.00048422685,0.00043141952,0.00022782272,0.000065681656,0.000030237437,0.00052197394,0.000357749],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008774215,0.0003736232,0.000040600185,0.00459438,0.0002081992,0.0000065360623,0.00025057534,0.000008804985,0.00041070383,0.0012632898,0.0036602388,0.98909533],"study_design_scores_gemma":[0.0010085371,0.0002312391,0.000023002223,0.016334493,0.000038209117,0.0000141932205,0.000018094746,0.000044104407,0.00068525,0.00041148,0.98086965,0.00032173033],"about_ca_topic_score_codex":0.000025747044,"about_ca_topic_score_gemma":1.6156262e-7,"teacher_disagreement_score":0.9887736,"about_ca_system_score_codex":0.00017921637,"about_ca_system_score_gemma":0.0007089644,"threshold_uncertainty_score":0.9998714},"labels":[],"label_agreement":null},{"id":"W2148507562","doi":"10.1517/13543784.17.5.679","title":"Pharmacotherapy for erectile dysfunction","year":2008,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Sexual function and dysfunction studies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Erectile dysfunction; Medicine; cGMP-specific phosphodiesterase type 5; Pharmacotherapy; Sildenafil; Pharmacology; Bioinformatics; Internal medicine; Biology","score_opus":0.17929959699025913,"score_gpt":0.4393145557107627,"score_spread":0.2600149587205036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148507562","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[8.96062e-7,0.98375964,0.0005145393,0.0009584704,0.0073185847,0.0018892714,0.00009845317,0.0003145857,0.0051455414],"genre_scores_gemma":[4.3372538e-7,0.97442293,0.0009324741,0.007200632,0.005345005,0.0021731162,0.0022342342,0.00012798027,0.007563176],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973158,0.00012196994,0.000794918,0.00076880155,0.00068016176,0.0003183247],"domain_scores_gemma":[0.9979141,0.00072416593,0.00037001062,0.00035143728,0.00032549287,0.0003148127],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015216901,0.0006177186,0.001363373,0.0005069619,0.00045407945,0.000030432051,0.00010654113,0.00036886352,0.000701722],"category_scores_gemma":[0.00026638302,0.0004924909,0.0007790146,0.00047558994,0.00019862075,0.00010772024,0.000026029671,0.00043182922,0.0006527689],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014713111,0.00013584936,0.0000014537832,0.00081042934,0.00030610646,9.1602413e-7,0.00017115219,0.000002177213,0.0000032395276,0.0016099506,0.48454955,0.51226205],"study_design_scores_gemma":[0.0017814283,0.00048669122,0.000005230731,0.0030716453,0.000049146525,0.00015027312,0.00006957753,0.000037659567,0.000027536678,0.00009041894,0.9938006,0.00042982242],"about_ca_topic_score_codex":0.000012767264,"about_ca_topic_score_gemma":1.3368032e-7,"teacher_disagreement_score":0.51183224,"about_ca_system_score_codex":0.00037342263,"about_ca_system_score_gemma":0.00072914595,"threshold_uncertainty_score":0.9997527},"labels":[],"label_agreement":null},{"id":"W2149879542","doi":"10.1517/13543784.15.5.507","title":"The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer","year":2006,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Clusterin; Prostate cancer; Prostate; Gene silencing; Cancer research; Medicine; Cancer; Apoptosis; Oncology; Internal medicine; Biology; Gene","score_opus":0.05709997216926325,"score_gpt":0.3872571996764856,"score_spread":0.3301572275072223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149879542","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00061374716,0.99172676,0.00003569165,0.0020525048,0.001497895,0.0030607602,0.00062913954,0.00006318777,0.0003203192],"genre_scores_gemma":[0.00015464236,0.99251175,0.00089911296,0.0009093072,0.0016609203,0.0017844229,0.0013992703,0.00012842985,0.0005521264],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99710006,0.00024704981,0.0011398069,0.00057179213,0.00055304583,0.00038822705],"domain_scores_gemma":[0.9976243,0.0006858951,0.00079183443,0.0004434014,0.00028193192,0.00017266553],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039673352,0.00047725334,0.001132808,0.00020058193,0.0002681382,0.00003973453,0.00022464902,0.00026249315,0.00003243132],"category_scores_gemma":[0.0002435212,0.00032950842,0.0006246889,0.00022781875,0.0005454027,0.000051548144,0.0001058929,0.00027576645,0.0000115277635],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004051393,0.00019879085,0.000018517087,0.005702801,0.00028686167,0.000011560736,0.00032019618,0.000078812685,0.00029313102,0.0019830603,0.044517577,0.94618356],"study_design_scores_gemma":[0.0013746505,0.00021981032,0.0001261779,0.010831661,0.000048150978,0.000065859975,0.000051091385,0.00036882915,0.00012332105,0.0003850682,0.98609424,0.00031111535],"about_ca_topic_score_codex":0.00006298684,"about_ca_topic_score_gemma":0.0000024199076,"teacher_disagreement_score":0.9458724,"about_ca_system_score_codex":0.0001933797,"about_ca_system_score_gemma":0.0011198734,"threshold_uncertainty_score":0.9999157},"labels":[],"label_agreement":null},{"id":"W2150692587","doi":"10.1517/13543784.2013.769957","title":"5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders","year":2013,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Obsessive-Compulsive Spectrum Disorders","field":"Psychology","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto Western Hospital","funders":"","keywords":"Schizophrenia (object-oriented programming); Psychiatry; Antipsychotic; Psychosis; Anxiety; Mood disorders; Dementia; Psychology; Management of schizophrenia; Depression (economics); 5-HT2A receptor; Medicine; Disease; Serotonin; 5-HT receptor; Internal medicine","score_opus":0.03747977311721774,"score_gpt":0.3762715629305328,"score_spread":0.3387917898133151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150692587","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000033807173,0.96981514,0.00015390251,0.0039539365,0.013042962,0.004982347,0.0006417072,0.00024078578,0.0071354206],"genre_scores_gemma":[0.00003242855,0.9720803,0.0026026992,0.0008961342,0.003393817,0.007333589,0.008662015,0.00031416325,0.0046848734],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99476326,0.0005343544,0.0013492561,0.0017495869,0.00069970073,0.0009038663],"domain_scores_gemma":[0.99668175,0.0006416828,0.0010554217,0.0009889405,0.00013166916,0.0005005331],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.00016182117,0.0013533641,0.0018181755,0.00077451864,0.00050271256,0.00014463477,0.0007768424,0.0008289555,0.0052252],"category_scores_gemma":[0.0001264134,0.0011578738,0.0013930175,0.00066044065,0.0004517689,0.00018082341,0.00007986891,0.00048594162,0.0064540915],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006832925,0.0008752931,0.0000063623497,0.0006658573,0.00071436196,0.0000013203224,0.0007659003,0.000011577455,0.0000017706126,0.052301925,0.14533536,0.799252],"study_design_scores_gemma":[0.0022220958,0.0013019157,0.000021953221,0.0011523847,0.000083145016,0.000018942064,0.00026434092,0.000031333577,0.0000039413626,0.004806125,0.9889614,0.0011324342],"about_ca_topic_score_codex":0.00045623683,"about_ca_topic_score_gemma":0.0000050591602,"teacher_disagreement_score":0.843626,"about_ca_system_score_codex":0.00070523046,"about_ca_system_score_gemma":0.00082525355,"threshold_uncertainty_score":0.99992174},"labels":[],"label_agreement":null},{"id":"W2152749001","doi":"10.1517/13543784.12.3.353","title":"Aromatase inhibitors for the treatment of infertility","year":2003,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Ovarian function and disorders","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"","keywords":"Ovarian hyperstimulation syndrome; Ovulation induction; Infertility; Ovulation; Medicine; Aromatase; Follicular phase; Internal medicine; Endocrinology; Polycystic ovary; Letrozole; Anovulation; Pregnancy; Hormone; Biology; In vitro fertilisation; Insulin; Insulin resistance","score_opus":0.10719836975608356,"score_gpt":0.3850609297580475,"score_spread":0.27786256000196397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152749001","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000028334248,0.9938554,0.00006747869,0.0012394949,0.0014401367,0.0020882434,0.00022204695,0.00003415935,0.0010502177],"genre_scores_gemma":[0.0000052707496,0.9942351,0.00046909263,0.0011471433,0.0004860764,0.0010506418,0.0019963777,0.000038274102,0.00057204976],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99836504,0.00011006592,0.0006504706,0.00035392828,0.00035815375,0.00016235998],"domain_scores_gemma":[0.99820334,0.00076336,0.00029246515,0.00046744762,0.000104585924,0.0001688051],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001711438,0.00033876218,0.00082390127,0.00015334475,0.00012638573,0.000013876781,0.00008233202,0.00021132371,0.0002161239],"category_scores_gemma":[0.00023712033,0.00019803236,0.000635543,0.00024027668,0.00022932218,0.00003512939,0.000008050213,0.00011018107,0.000056808123],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013463642,0.0011483046,0.000018561861,0.0026038273,0.00051027763,5.7556167e-7,0.00064753776,0.000005236588,9.541236e-7,0.015851296,0.12551554,0.85356325],"study_design_scores_gemma":[0.0011795794,0.0005275815,0.00002236137,0.0019254261,0.0000833211,0.0000064395317,0.00008484134,0.000017566726,0.00002014421,0.0003486712,0.99562705,0.00015699698],"about_ca_topic_score_codex":0.000022782035,"about_ca_topic_score_gemma":3.5437455e-7,"teacher_disagreement_score":0.8701115,"about_ca_system_score_codex":0.00020669431,"about_ca_system_score_gemma":0.00081532705,"threshold_uncertainty_score":0.8075525},"labels":[],"label_agreement":null},{"id":"W2152775636","doi":"10.1517/13543784.12.4.663","title":"Pregabalin: a new anxiolytic","year":2003,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Neuroscience and Neuropharmacology Research","field":"Neuroscience","cited_by":316,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Pregabalin; Gabapentin; Anticonvulsant; Pharmacology; Anxiolytic; Neuropathic pain; Medicine; Epilepsy; Anesthesia; Anxiety; Psychiatry","score_opus":0.2469151906030161,"score_gpt":0.4506774258193225,"score_spread":0.20376223521630643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152775636","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008507431,0.9885571,0.0000082783545,0.0012208782,0.0037456972,0.0012893903,0.000059372738,0.00017051738,0.004940277],"genre_scores_gemma":[0.000004401425,0.9790453,0.000060985833,0.011807989,0.0008936191,0.00031057195,0.000022789163,0.0000975023,0.0077568684],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944822,0.0012198662,0.00072758354,0.001561541,0.0013003544,0.0007084214],"domain_scores_gemma":[0.9966946,0.0015803828,0.0003426429,0.00060585083,0.000043674307,0.0007328245],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029893883,0.0006452852,0.00094034226,0.0005530118,0.0004347152,0.00016444988,0.0011536808,0.00030877942,0.00055180443],"category_scores_gemma":[0.0013269167,0.0005340384,0.0004224822,0.0013305839,0.0007111566,0.00028657942,0.00018538885,0.0010909117,0.0025830707],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031755437,0.00036377792,6.21915e-7,0.0013043429,0.000025067586,0.000090681424,0.00032331634,0.00001340984,0.003159684,0.044120856,0.3546812,0.5958853],"study_design_scores_gemma":[0.0002969068,0.0001510948,2.0567232e-7,0.0017710763,0.000006630872,0.00013110365,0.0000031866728,0.000029209328,0.004144611,0.0008655617,0.9921332,0.00046720618],"about_ca_topic_score_codex":0.0000048136844,"about_ca_topic_score_gemma":4.8525365e-8,"teacher_disagreement_score":0.637452,"about_ca_system_score_codex":0.00017529375,"about_ca_system_score_gemma":0.0024436046,"threshold_uncertainty_score":0.9997111},"labels":[],"label_agreement":null},{"id":"W2156708079","doi":"10.1517/13543784.15.6.649","title":"Pharmacological treatment of attention-deficit/hyperactivity disorder in adults","year":2006,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Peter's Hospital; Montreal Children's Hospital; Calgary Laboratory Services","funders":"","keywords":"Atomoxetine; Attention deficit hyperactivity disorder; Medicine; Guanfacine; Desipramine; Adverse effect; Psychiatry; Clinical trial; Psychosocial; Methylphenidate; Psychology; Antidepressant; Pharmacology; Anxiety; Clonidine; Internal medicine","score_opus":0.08516280517309431,"score_gpt":0.4026321275527526,"score_spread":0.31746932237965825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156708079","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.026643004,0.967777,0.000017496888,0.00078645215,0.000683731,0.0022530865,0.000189698,0.00008749142,0.0015620284],"genre_scores_gemma":[0.0037214933,0.9903943,0.00034081106,0.00011592264,0.00048302207,0.00096239266,0.0032615056,0.000094801886,0.00062577066],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99616826,0.00042673133,0.0012677845,0.00089677155,0.0008515182,0.00038893105],"domain_scores_gemma":[0.9977895,0.000738303,0.0006810664,0.0004209848,0.00016672492,0.00020342132],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017470845,0.00073155534,0.0021269077,0.0006532878,0.00010101182,0.000019516949,0.00015694695,0.00052251597,0.00042819217],"category_scores_gemma":[0.00016743432,0.0005829179,0.0008803835,0.000693516,0.00027839615,0.00017498224,0.00004774276,0.00048092453,0.00021732289],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003945183,0.01369556,0.01407278,0.00561722,0.0006883595,0.000046208075,0.00025064766,0.00011934095,0.000040116243,0.0024651412,0.0015812624,0.9610289],"study_design_scores_gemma":[0.004299632,0.0007045258,0.007995014,0.011589006,0.00014189653,0.000057765898,0.0002210001,0.000190108,0.0000026668222,0.00004271431,0.9741115,0.0006441656],"about_ca_topic_score_codex":0.00032645874,"about_ca_topic_score_gemma":0.000009458981,"teacher_disagreement_score":0.97253025,"about_ca_system_score_codex":0.0006872678,"about_ca_system_score_gemma":0.0006552824,"threshold_uncertainty_score":0.9996622},"labels":[],"label_agreement":null},{"id":"W2160247377","doi":"10.1517/13543784.17.2.217","title":"The use of dexrazoxane for the prevention of anthracycline extravasation injury","year":2008,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Chemotherapy-related skin toxicity","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Canada Research Chairs","keywords":"Dexrazoxane; Anthracycline; Cardiotoxicity; Extravasation; Doxorubicin; Epirubicin; Medicine; Daunorubicin; Pharmacology; Idarubicin; Chemotherapy; Internal medicine; Pathology; Cancer; Cyclophosphamide; Breast cancer","score_opus":0.18770641767915827,"score_gpt":0.419788730279666,"score_spread":0.23208231260050774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160247377","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008072577,0.99384755,0.00080819847,0.0016601327,0.0006738445,0.00270908,0.00014564797,0.00003140793,0.000043407217],"genre_scores_gemma":[0.00007359933,0.99436235,0.0028358984,0.00030121976,0.0005630137,0.00039137097,0.0008888803,0.00006695224,0.00051669695],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99721694,0.00022944938,0.0012954886,0.00034658678,0.0007215408,0.00018997474],"domain_scores_gemma":[0.99410015,0.0035920518,0.0012251349,0.00065004104,0.00034331586,0.000089303234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043721488,0.00034596655,0.0009027494,0.00017049981,0.00024908484,0.000016097763,0.00025486838,0.00035471466,0.000039837003],"category_scores_gemma":[0.001193169,0.0001982695,0.0006800198,0.00038532793,0.0006734563,0.00010663452,0.000036188725,0.0003864053,0.0000065057534],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002382994,0.00027745045,0.000004146843,0.0014124648,0.0005316696,2.3357403e-7,0.00046967718,0.000033178807,0.00016687461,0.0035591,0.037609745,0.9556972],"study_design_scores_gemma":[0.0006072324,0.0002804777,0.00004994458,0.008869588,0.000075717035,0.000024031942,0.000020611142,0.00035156877,0.001572518,0.00047936378,0.98750246,0.00016649667],"about_ca_topic_score_codex":0.000030259742,"about_ca_topic_score_gemma":0.0000011572298,"teacher_disagreement_score":0.95553064,"about_ca_system_score_codex":0.00015207527,"about_ca_system_score_gemma":0.0007933875,"threshold_uncertainty_score":0.80851954},"labels":[],"label_agreement":null},{"id":"W2165059215","doi":"10.1517/13543780902762827","title":"Caprospinol: moving from a neuroactive steroid to a neurotropic drug","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Alzheimer's disease research and treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Neuroactive steroid; Neuroprotection; Pharmacology; Neurotoxicity; Drug; Respiratory chain; Hippocampus; Neurodegeneration; Neuroscience; Amyloid beta; Medicine; Disease; Chemistry; Mitochondrion; Psychology; Internal medicine; Biochemistry; Receptor; Toxicity; GABAA receptor","score_opus":0.08218918296770682,"score_gpt":0.38739984561135765,"score_spread":0.3052106626436508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165059215","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027807822,0.99266946,0.0000073888395,0.0023374204,0.00050052314,0.0026784018,0.0003870958,0.00015406728,0.000987591],"genre_scores_gemma":[0.00020148193,0.9880632,0.00092465937,0.0049739196,0.001464133,0.0010343589,0.003007185,0.00013389051,0.00019716646],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958963,0.00036605974,0.00069121947,0.0011628272,0.0013191984,0.00056438596],"domain_scores_gemma":[0.99709195,0.00036242593,0.00026437154,0.0007458557,0.00016673555,0.0013686508],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008819268,0.0007522906,0.0014252893,0.0004940991,0.00021390062,0.00010138214,0.00032264623,0.00021087695,0.0001609027],"category_scores_gemma":[0.00023925598,0.00061098975,0.0005583824,0.00051259785,0.00013716795,0.0001582058,0.00013400888,0.0007056733,0.0011773556],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031605831,0.0012169121,0.00005845359,0.0013540054,0.0054751174,0.0002646078,0.0012568773,0.000007400013,0.0000070863484,0.0012118941,0.044077992,0.9447536],"study_design_scores_gemma":[0.0011266081,0.0005498787,0.00088040263,0.013641807,0.00019734443,0.00002678671,0.000042461947,0.000030080102,0.00003030176,0.00045765008,0.982473,0.0005436766],"about_ca_topic_score_codex":0.00020220534,"about_ca_topic_score_gemma":0.0000010683781,"teacher_disagreement_score":0.94420993,"about_ca_system_score_codex":0.00047539335,"about_ca_system_score_gemma":0.0015076413,"threshold_uncertainty_score":0.99963415},"labels":[],"label_agreement":null},{"id":"W2165328648","doi":"10.1517/13543784.15.1.47","title":"Exogenous surfactant therapy for ARDS","year":2005,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Neonatal Respiratory Health Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Centre","funders":"","keywords":"ARDS; Medicine; Surfactant therapy; Intensive care medicine; Acute respiratory distress; Respiratory distress; Pulmonary surfactant; Pathophysiology; Neonatal respiratory distress syndrome; Clinical trial; Lung; Internal medicine; Anesthesia","score_opus":0.255999150866969,"score_gpt":0.4965203684000783,"score_spread":0.2405212175331093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165328648","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000048630163,0.9907144,0.000022288017,0.0025465135,0.000849634,0.004271471,0.00031931762,0.00011438227,0.0011571395],"genre_scores_gemma":[0.0000013552838,0.9826761,0.0021456042,0.0063609513,0.0034825276,0.0021987958,0.0018428091,0.00018242965,0.0011094209],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956989,0.00026793388,0.001039424,0.0008494443,0.0014819985,0.0006622962],"domain_scores_gemma":[0.99644727,0.0013114845,0.0003504975,0.0006933036,0.00036716304,0.0008302752],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00084743055,0.0006189451,0.0015635514,0.0004896575,0.00027506627,0.000045714554,0.000359386,0.0005381678,0.00040466533],"category_scores_gemma":[0.000685169,0.00047695937,0.0006717404,0.00040540838,0.00026012646,0.000092792594,0.00005648104,0.0007857371,0.00049645494],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015998012,0.00017455014,5.863817e-7,0.0041973446,0.000114321476,0.0000048047928,0.000148859,0.0000010430338,0.000005210958,0.0030449843,0.01636962,0.9757787],"study_design_scores_gemma":[0.0011931317,0.00071855925,0.0000058973756,0.0078776935,0.000009796568,0.000041884745,0.0000137685465,0.000024563697,0.000035633373,0.0001773724,0.9895131,0.00038859659],"about_ca_topic_score_codex":0.000021287204,"about_ca_topic_score_gemma":5.4682556e-7,"teacher_disagreement_score":0.9753901,"about_ca_system_score_codex":0.00089498085,"about_ca_system_score_gemma":0.0058326256,"threshold_uncertainty_score":0.99980336},"labels":[],"label_agreement":null},{"id":"W2166753714","doi":"10.1517/13543780902832661","title":"Cathepsin K inhibitors for osteoporosis and potential off-target effects","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Bone Metabolism and Diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":209,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institutes of Health; Canada Research Chairs","keywords":"Cathepsin K; Cathepsin; Osteoporosis; Medicine; Cathepsin A; Cancer research; Pharmacology; Chemistry; Biochemistry; Internal medicine; Osteoclast; Enzyme; In vitro","score_opus":0.01784050697919237,"score_gpt":0.3063636798781626,"score_spread":0.2885231728989702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166753714","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011802907,0.997381,0.00006718462,0.00022354354,0.00090154976,0.000877651,0.0002948602,0.000021305177,0.000114933995],"genre_scores_gemma":[0.00007943729,0.9879368,0.0020083217,0.001140296,0.0023881209,0.0004369887,0.0057446067,0.000056809487,0.00020859927],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998286,0.00018798398,0.00039823272,0.0006351206,0.00024662464,0.00024601643],"domain_scores_gemma":[0.9990569,0.00010577837,0.00022152494,0.000291349,0.00007284774,0.00025162823],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018284797,0.00042804255,0.00062498834,0.00011060343,0.00015892701,0.000053735424,0.00016848273,0.00037645086,0.0000069496314],"category_scores_gemma":[0.0002933358,0.00036965605,0.0003923864,0.00008629587,0.00015504293,0.0000075553417,0.00007106873,0.00010851245,0.000010060962],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007582001,0.0001706109,0.0000021348335,0.0022015995,0.00013523406,0.0000011371651,0.00010043591,0.000006935974,0.0005188991,0.0017520868,0.11355057,0.8814845],"study_design_scores_gemma":[0.000498941,0.00020786085,0.000021333337,0.0014343376,0.00003962671,0.000007511745,0.000011324059,0.000006405849,0.0010845007,0.00069170794,0.9955862,0.00041023933],"about_ca_topic_score_codex":0.0000056527842,"about_ca_topic_score_gemma":1.7553114e-7,"teacher_disagreement_score":0.8820356,"about_ca_system_score_codex":0.000019992576,"about_ca_system_score_gemma":0.00036030187,"threshold_uncertainty_score":0.99987555},"labels":[],"label_agreement":null},{"id":"W2168406738","doi":"10.1517/13543784.10.12.2157","title":"Therapeutic potential of mycobacterial cell wall-DNA complexes","year":2001,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Mycobacterium research and diagnosis","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BioPhage Pharma (Canada)","funders":"","keywords":"Cell wall; Cell; Effector; Apoptosis; Biology; DNA; Cell division; Immune system; Mechanism of action; Cell growth; Mycobacterium; Cancer cell; Mycobacterium phlei; Cancer research; Microbiology; Cancer; Chemistry; Cell biology; Bacteria; Immunology; In vitro; Biochemistry; Genetics","score_opus":0.07827342594698494,"score_gpt":0.3700735214891212,"score_spread":0.29180009554213626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168406738","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026815027,0.9935311,0.000012974212,0.0009224802,0.0012536687,0.0012574539,0.0002859346,0.00007326166,0.0023949873],"genre_scores_gemma":[0.00026267176,0.9905776,0.0003929535,0.0010582736,0.0023260235,0.00031344898,0.0045486805,0.000093091076,0.00042728163],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963151,0.00036297328,0.0010181388,0.00062441407,0.0012122784,0.0004670602],"domain_scores_gemma":[0.9976483,0.00051494694,0.00048147593,0.00056913914,0.00024775363,0.000538401],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027832369,0.0005709117,0.0016526935,0.00045255778,0.00012114062,0.000055959612,0.00035440244,0.00042765992,0.0019153922],"category_scores_gemma":[0.00015934509,0.0004488875,0.0007359505,0.00045298212,0.00035367787,0.00010658905,0.000099460114,0.00050064316,0.00038021052],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00089783274,0.0026736467,0.000115034345,0.027132362,0.0012812307,0.00006991678,0.000802706,0.000005072949,0.0036919636,0.010065584,0.17613423,0.7771304],"study_design_scores_gemma":[0.0010543986,0.0004731526,0.00016305284,0.0083544655,0.00006934414,0.00004886623,0.000023287808,0.0000136955805,0.00041785304,0.0002598214,0.98875374,0.00036830804],"about_ca_topic_score_codex":0.000074735646,"about_ca_topic_score_gemma":3.6870293e-7,"teacher_disagreement_score":0.8126195,"about_ca_system_score_codex":0.00021153834,"about_ca_system_score_gemma":0.0012581925,"threshold_uncertainty_score":0.9997963},"labels":[],"label_agreement":null},{"id":"W2287387906","doi":"10.1517/13543784.2015.1083010","title":"An evaluation of RVX-208 for the treatment of atherosclerosis","year":2015,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Bromodomain; Apolipoprotein B; Mechanism (biology); Epigenetics; Pharmacology; Reverse cholesterol transport; Lipoprotein; Mechanism of action; Drug; Medicine; Cholesterol; Bioinformatics; Biology; Internal medicine; In vitro; Biochemistry; Gene","score_opus":0.19381988199036995,"score_gpt":0.4284758641484715,"score_spread":0.23465598215810154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2287387906","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019406731,0.99707144,0.00012517121,0.00011745045,0.00051793037,0.0015819471,0.000270835,0.000005827616,0.000115342824],"genre_scores_gemma":[0.00024131614,0.99323523,0.0007726843,0.00007621524,0.000721328,0.0012316506,0.0036076384,0.00003248818,0.000081426035],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983545,0.00027171825,0.00047312657,0.00030222116,0.00049892516,0.00009953138],"domain_scores_gemma":[0.9984827,0.00007974157,0.00044656324,0.0004553498,0.0004573986,0.000078247096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059924804,0.00022732333,0.00040942404,0.000066048946,0.00006427087,0.000010671191,0.00021484082,0.00021372543,0.000019546109],"category_scores_gemma":[0.00014404522,0.00014783535,0.00029041964,0.00009882129,0.00016007813,0.000005682076,0.00001382745,0.00003658774,0.0000032555206],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030421736,0.00035371768,0.0000028984543,0.00026897906,0.00019842356,4.571079e-9,0.00036587025,0.00010417068,0.0010898752,0.0017308466,0.010297791,0.985557],"study_design_scores_gemma":[0.00054613635,0.0008934524,0.000005703225,0.0005640051,0.000048950882,4.6649726e-7,0.000050315117,0.00025116323,0.010436644,0.00018374549,0.9868758,0.00014367438],"about_ca_topic_score_codex":0.000016396447,"about_ca_topic_score_gemma":9.52351e-7,"teacher_disagreement_score":0.9854133,"about_ca_system_score_codex":0.000090822934,"about_ca_system_score_gemma":0.00076599367,"threshold_uncertainty_score":0.6028551},"labels":[],"label_agreement":null},{"id":"W2299867389","doi":"10.1517/13543784.2016.1142529","title":"Novel investigational therapies for onychomycosis: an update","year":2016,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Nail Diseases and Treatments","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mediprobe Research (Canada); University of Toronto","funders":"","keywords":"Medicine; Terbinafine; Dermatology; Adverse effect; Azole; Pharmacology; Drug; Clinical trial; Investigational Drugs; Antifungal; Internal medicine; Itraconazole","score_opus":0.11589128427420814,"score_gpt":0.4118034750595802,"score_spread":0.29591219078537206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2299867389","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000009930474,0.9904326,0.0002213451,0.0036180266,0.000992448,0.0021132806,0.0019899022,0.00015307634,0.00046934938],"genre_scores_gemma":[0.000013820225,0.97021395,0.007887541,0.004580967,0.002365747,0.0027516603,0.011289865,0.00015793988,0.0007385383],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969265,0.00011567194,0.0008246667,0.0009201952,0.0008119518,0.00040104688],"domain_scores_gemma":[0.99743474,0.00046317052,0.0004639797,0.00061350845,0.00026893578,0.0007556975],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000200928,0.00072325126,0.0012231256,0.00037381824,0.00027405928,0.00007651852,0.0002777429,0.00036970293,0.00039779764],"category_scores_gemma":[0.00022574952,0.000489728,0.00073695317,0.00024420975,0.00033190002,0.00027063212,0.000045362485,0.00022264697,0.00035735895],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013201941,0.0009399711,0.00002716226,0.002323949,0.0011422044,0.0000025712573,0.0002375595,7.781554e-7,0.000011697912,0.10230721,0.043663636,0.8492112],"study_design_scores_gemma":[0.002087037,0.00033832696,0.00014198193,0.016152894,0.00011417147,0.00003042798,0.00002234539,0.000015908878,0.000011623447,0.005438784,0.97514236,0.0005041264],"about_ca_topic_score_codex":0.000012280849,"about_ca_topic_score_gemma":3.9018647e-7,"teacher_disagreement_score":0.93147874,"about_ca_system_score_codex":0.00036425184,"about_ca_system_score_gemma":0.0016630769,"threshold_uncertainty_score":0.99975544},"labels":[],"label_agreement":null},{"id":"W2342567337","doi":"10.1080/13543784.2016.1182498","title":"Novel approaches for preventing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation","year":2016,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fonds De La Recherche Scientifique - FNRS; Terry Fox Foundation","keywords":"Immunology; Graft-versus-host disease; Hematopoietic stem cell transplantation; Transplantation; Medicine; Disease; Stem cell; Calcineurin; Pathogenesis; Immune system; Biology; Internal medicine","score_opus":0.09843819540201718,"score_gpt":0.33775760871798355,"score_spread":0.23931941331596637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2342567337","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001062745,0.97804815,0.011040383,0.00095359376,0.0017185321,0.00524954,0.0020695035,0.00019914308,0.0006148966],"genre_scores_gemma":[0.00038687853,0.98018277,0.004948001,0.00039045536,0.0009944161,0.005206944,0.006612234,0.00024379377,0.0010345342],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99575526,0.00019095348,0.0013319035,0.0011687732,0.0009917993,0.0005613024],"domain_scores_gemma":[0.9969006,0.0011122774,0.0005981874,0.000594697,0.00014242032,0.00065182627],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040270097,0.00088910654,0.0013912291,0.00041286068,0.00019710729,0.00006684484,0.00028416046,0.00047528284,0.000108418004],"category_scores_gemma":[0.000031894277,0.00069702504,0.00096589956,0.00028880054,0.00020651118,0.00021016001,0.000029433979,0.00031614548,0.00020585247],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008737883,0.0032896795,0.000096249765,0.37252387,0.0049601127,0.00019129032,0.015473164,0.000042909996,0.000911434,0.03643405,0.0061316895,0.55120766],"study_design_scores_gemma":[0.0078639,0.00041205756,0.00012214291,0.08859079,0.0017985104,0.000205434,0.00019093674,0.00012077338,0.0009715396,0.00029852512,0.89762795,0.0017974296],"about_ca_topic_score_codex":0.0000025037107,"about_ca_topic_score_gemma":3.8021008e-7,"teacher_disagreement_score":0.89149624,"about_ca_system_score_codex":0.00031343207,"about_ca_system_score_gemma":0.0010081584,"threshold_uncertainty_score":0.9995481},"labels":[],"label_agreement":null},{"id":"W2416001425","doi":"10.1080/13543784.2016.1195808","title":"Investigational targeted therapies for the treatment of testicular germ cell tumors","year":2016,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Brentuximab vedotin; Clinical trial; Oncology; Internal medicine; Targeted therapy; Germ cell tumors; Sunitinib; Disease; Ifosfamide; Chemotherapy; Cancer; Lymphoma; Etoposide; Hodgkin lymphoma","score_opus":0.06552153533269944,"score_gpt":0.36070765393514304,"score_spread":0.2951861186024436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2416001425","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004817014,0.99379486,0.00006632208,0.0014064438,0.0004945256,0.0029400783,0.0010364077,0.00006722267,0.0001459573],"genre_scores_gemma":[0.0001591646,0.9898189,0.0024568553,0.00048440593,0.0009660041,0.00266352,0.0027663969,0.0001067172,0.000578074],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973716,0.00014820155,0.0008508406,0.00059224654,0.00072301994,0.00031407943],"domain_scores_gemma":[0.9957351,0.002310206,0.00073114503,0.00060359115,0.0002693927,0.00035055424],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001281281,0.00066395773,0.0012395384,0.00021069967,0.00023358458,0.000029399587,0.00020524676,0.00021840619,0.00021343652],"category_scores_gemma":[0.00035969567,0.00033523224,0.0010507869,0.000248965,0.00051788165,0.00006015823,0.000022500835,0.00010704278,0.000106362386],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012218975,0.0022214877,0.00017906011,0.00363071,0.0022890149,0.0000122513675,0.00086570473,0.000012916908,0.000031374086,0.015115344,0.012241036,0.9632789],"study_design_scores_gemma":[0.0019159243,0.00095846184,0.0003314659,0.009005336,0.00032536103,0.000020289981,0.000028228767,0.000055981534,0.00017021403,0.0013657379,0.98549163,0.00033138492],"about_ca_topic_score_codex":0.000025741772,"about_ca_topic_score_gemma":1.5527861e-7,"teacher_disagreement_score":0.97325057,"about_ca_system_score_codex":0.00037759583,"about_ca_system_score_gemma":0.0017411239,"threshold_uncertainty_score":0.99991},"labels":[],"label_agreement":null},{"id":"W2539921642","doi":"10.1080/13543784.2016.1254187","title":"Lomitapide for the treatment of hypertriglyceridemia","year":2016,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Lipid metabolism and disorders","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Hypertriglyceridemia; Medicine; Microsomal triglyceride transfer protein; Acute pancreatitis; Triglyceride; Clinical trial; Intensive care medicine; Familial hypercholesterolemia; Internal medicine; Cholesterol; Lipoprotein","score_opus":0.10633249717807947,"score_gpt":0.40067559040270684,"score_spread":0.2943430932246274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2539921642","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000019453744,0.9917796,0.000085337626,0.003064122,0.0017741418,0.0020246885,0.0002583819,0.000034202207,0.0009775814],"genre_scores_gemma":[0.0000017654895,0.9918278,0.0008106842,0.001033155,0.0027892995,0.0014561708,0.00059638475,0.00006321253,0.0014215664],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981689,0.000089803965,0.0007056295,0.0004025692,0.00040048987,0.00023260113],"domain_scores_gemma":[0.9965817,0.0021929624,0.00036991964,0.0005470058,0.00012516326,0.0001832747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018119528,0.00040595775,0.0013246539,0.00016849453,0.00011403228,0.00001074226,0.00017284988,0.00023865855,0.00013957836],"category_scores_gemma":[0.0003736457,0.00018732989,0.0008722448,0.00016383684,0.00029223866,0.000047089903,0.00001582023,0.00008987585,0.000103045866],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007581294,0.0001805363,0.0000020896612,0.0010776392,0.000300522,2.0771023e-7,0.00026131928,5.978697e-7,0.000002902559,0.016166043,0.043226793,0.93870556],"study_design_scores_gemma":[0.0015506635,0.00035491903,0.00000845863,0.0053378614,0.00011516377,0.0000073916744,0.00003999518,0.000008723681,0.000047412344,0.0005853763,0.99175,0.00019405445],"about_ca_topic_score_codex":0.000022581235,"about_ca_topic_score_gemma":1.8104508e-7,"teacher_disagreement_score":0.94852316,"about_ca_system_score_codex":0.00016740146,"about_ca_system_score_gemma":0.0009602617,"threshold_uncertainty_score":0.76390916},"labels":[],"label_agreement":null},{"id":"W2611809642","doi":"10.1080/13543784.2017.1324847","title":"The neurogenic compound, NSI-189 phosphate: a novel multi-domain treatment capable of pro-cognitive and antidepressant effects","year":2017,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Neurogenesis and neuroplasticity mechanisms","field":"Neuroscience","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Brain and Cognition Discovery Foundation","funders":"","keywords":"Neurogenesis; Antidepressant; Neuroscience; Cognition; Subventricular zone; Psychology; Neural stem cell; Major depressive disorder; Hippocampus; Stem cell; Biology","score_opus":0.1842359574083909,"score_gpt":0.3839717961617744,"score_spread":0.1997358387533835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611809642","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019538724,0.9915688,0.00015106537,0.00017471798,0.0020357696,0.003455901,0.0004335039,0.00008050763,0.000145845],"genre_scores_gemma":[0.0018615418,0.99607575,0.00019498632,0.0004840136,0.00020829293,0.000833393,0.000057291745,0.00011330957,0.00017143278],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99609554,0.0007097374,0.00078599644,0.0011860178,0.0007539327,0.0004687939],"domain_scores_gemma":[0.9935355,0.0045039817,0.0010195777,0.0005717145,0.00009181374,0.00027741693],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025332824,0.00075463415,0.0012328706,0.00016879436,0.0011121936,0.00022321136,0.0005616098,0.00018611913,0.000005142983],"category_scores_gemma":[0.0013589748,0.00049680413,0.00039758027,0.00020020363,0.00089485524,0.00016609445,0.00023505844,0.00032181182,0.000042493626],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000518472,0.003845146,0.000016538559,0.007386033,0.00072128454,0.00026330954,0.0022413968,0.000019592293,0.10009867,0.081495754,0.0012223003,0.8021715],"study_design_scores_gemma":[0.0018666313,0.0006615368,0.000023317592,0.005486048,0.0000723261,0.00019672807,0.000021269163,0.00028132315,0.23850316,0.00014425849,0.7521598,0.0005836346],"about_ca_topic_score_codex":0.000026973597,"about_ca_topic_score_gemma":0.0000014042291,"teacher_disagreement_score":0.8015879,"about_ca_system_score_codex":0.00008143916,"about_ca_system_score_gemma":0.00045326113,"threshold_uncertainty_score":0.99974835},"labels":[],"label_agreement":null},{"id":"W2732154709","doi":"10.1080/13543784.2017.1349753","title":"Alicaforsen for the treatment of inflammatory bowel disease","year":2017,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials; Western University","funders":"","keywords":"Medicine; Pouchitis; Inflammatory bowel disease; Vedolizumab; Ulcerative colitis; Placebo; Clinical trial; Gastroenterology; Internal medicine; Crohn's disease; Disease; Immunology; Pathology","score_opus":0.17651780968923894,"score_gpt":0.4477101717914101,"score_spread":0.2711923621021711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2732154709","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000006025654,0.99276644,0.000016778306,0.0025216558,0.00046535346,0.0033602582,0.00023127094,0.000028051381,0.0006041531],"genre_scores_gemma":[0.0000051121374,0.9905079,0.00030411803,0.00028242767,0.0011971797,0.0025392973,0.0014082257,0.0000776314,0.0036781009],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976514,0.00012547038,0.0006562354,0.00046961824,0.00083240366,0.00026487568],"domain_scores_gemma":[0.99656034,0.0011686049,0.00046269997,0.0011498539,0.0002044314,0.00045408032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023558245,0.00040064557,0.0009054831,0.00022533406,0.00028558154,0.00003817258,0.0003808063,0.00019098044,0.000120483615],"category_scores_gemma":[0.0005517038,0.0002329713,0.00092064636,0.00008061753,0.00051842036,0.000042829575,0.000054439523,0.00017327504,0.00010439061],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020391108,0.00043574703,0.000018122068,0.005752192,0.00047236783,0.000008396991,0.00035733907,0.0000049844825,0.000005839827,0.007773259,0.035767462,0.9492004],"study_design_scores_gemma":[0.0007851464,0.00034709883,0.00011351392,0.0060731964,0.0000845059,0.000004891555,0.000018494324,0.00015672491,0.000036465994,0.00022584375,0.9919621,0.00019204918],"about_ca_topic_score_codex":0.000017826458,"about_ca_topic_score_gemma":3.4275692e-7,"teacher_disagreement_score":0.9561946,"about_ca_system_score_codex":0.00032716914,"about_ca_system_score_gemma":0.0019065917,"threshold_uncertainty_score":0.9500294},"labels":[],"label_agreement":null},{"id":"W2734923678","doi":"10.1080/13543784.2017.1353598","title":"Experimental and early investigational drugs for androgenetic alopecia","year":2017,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health Research Institute; University of British Columbia","funders":"Canadian Institutes of Health Research; Canadian Dermatology Foundation","keywords":"Medicine; Investigational Drugs; Hair loss; Drug development; Ruxolitinib; Clinical trial; Dermatology; Pharmacology; Bioinformatics; Drug; Internal medicine; Biology","score_opus":0.12233725084206386,"score_gpt":0.4059214545339066,"score_spread":0.28358420369184273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2734923678","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033122874,0.991668,0.000028135864,0.0013222634,0.0008798947,0.0022688617,0.00022103966,0.000087238746,0.0031933275],"genre_scores_gemma":[0.00039319467,0.9855705,0.0030973589,0.0023035265,0.0020520536,0.0020275777,0.0033021865,0.00016251397,0.001091074],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968101,0.00012177463,0.0008696915,0.0009422671,0.0008043776,0.00045181488],"domain_scores_gemma":[0.9975575,0.00039422733,0.0004862162,0.00057877536,0.00016260946,0.0008206253],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029772572,0.000711286,0.0014259903,0.0004010909,0.0005441184,0.00015601785,0.0003071663,0.0004881647,0.0001054333],"category_scores_gemma":[0.00045759522,0.00062881125,0.00051174854,0.00015200095,0.00079997873,0.00020367277,0.000106790256,0.00037222393,0.00014052044],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026695852,0.000641274,0.00026630634,0.008809805,0.00082683517,0.000011546454,0.0054930714,0.0000028699915,0.00006170972,0.06051928,0.10753709,0.81556326],"study_design_scores_gemma":[0.0018428594,0.00037695136,0.00015993611,0.0073110596,0.000053623382,0.000046399815,0.00013136576,0.000036200272,0.00010258119,0.0012313002,0.98810184,0.00060585624],"about_ca_topic_score_codex":0.000034201705,"about_ca_topic_score_gemma":4.219596e-7,"teacher_disagreement_score":0.88056475,"about_ca_system_score_codex":0.00019089207,"about_ca_system_score_gemma":0.0015436857,"threshold_uncertainty_score":0.9996163},"labels":[],"label_agreement":null},{"id":"W2902357040","doi":"10.1080/13543784.2019.1554054","title":"Therapeutic targets and early stage clinical trials for pulmonary fibrosis","year":2018,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Institute of Circulatory and Respiratory Health","keywords":"Clinical trial; Medicine; Identifier; Trial registration; Intensive care medicine; Internal medicine; Computer science","score_opus":0.264726498184007,"score_gpt":0.47917078060269047,"score_spread":0.21444428241868346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902357040","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010418147,0.9920714,0.00011218333,0.0009460756,0.0022319483,0.0028297775,0.0010781024,0.00008856845,0.00063155],"genre_scores_gemma":[0.000049629794,0.9851322,0.0012963725,0.001820936,0.006781777,0.0010037749,0.0023255518,0.00012910669,0.0014606429],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948706,0.0010175359,0.002120653,0.0010043187,0.00058823824,0.00039866669],"domain_scores_gemma":[0.99511594,0.0026043097,0.0008833571,0.0005051502,0.00025030604,0.00064095535],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002500351,0.00065217214,0.002776884,0.0002745534,0.0002606426,0.0000864369,0.00022910642,0.00069537276,0.00019977495],"category_scores_gemma":[0.0013561046,0.00048729312,0.0017237874,0.00017954073,0.000587204,0.00014287955,0.00009188669,0.00047720975,0.000094661285],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003298093,0.00066859205,0.000037900623,0.0139932865,0.001186291,0.000013939222,0.00032711506,2.2631528e-7,0.000010238631,0.01697849,0.07308884,0.890397],"study_design_scores_gemma":[0.00070761144,0.0028995946,0.00008506477,0.01720255,0.0002456678,0.000025123654,0.00003440303,0.00010218351,0.0000038612047,0.00095866295,0.97726434,0.00047093115],"about_ca_topic_score_codex":0.00002130268,"about_ca_topic_score_gemma":9.160169e-8,"teacher_disagreement_score":0.9041755,"about_ca_system_score_codex":0.00014922455,"about_ca_system_score_gemma":0.0009340766,"threshold_uncertainty_score":0.9997579},"labels":[],"label_agreement":null},{"id":"W2905977615","doi":"10.1080/13543784.2019.1559295","title":"Rapastinel - an investigational NMDA-R modulator for major depressive disorder: evidence to date","year":2018,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Major depressive disorder; Antidepressant; Treatment-resistant depression; Adverse effect; Investigational Drugs; Clinical trial; Medicine; Depression (economics); Psychiatry; Meta-analysis; Cognition; Psychology; Pharmacology; Internal medicine; Anxiety","score_opus":0.1509173299690087,"score_gpt":0.42581684556225025,"score_spread":0.27489951559324155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905977615","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033164883,0.9847115,0.0010053623,0.004699556,0.0018564385,0.006094333,0.00074873515,0.00033763138,0.00021473799],"genre_scores_gemma":[0.000089618865,0.9198373,0.048066355,0.0049332315,0.005606047,0.0070527736,0.012826161,0.00036722622,0.001221299],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940923,0.0004059983,0.0013678165,0.0019084648,0.0015784084,0.0006470472],"domain_scores_gemma":[0.9945326,0.0013510248,0.00078468176,0.0013224463,0.00059818174,0.0014110651],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00054268265,0.0011246967,0.0017782451,0.00071743235,0.00052490726,0.00013224546,0.00069575565,0.00062361016,0.00023440795],"category_scores_gemma":[0.0025521633,0.000910453,0.000634676,0.0006009561,0.00047508167,0.00057241507,0.00024316764,0.00047931218,0.0005415691],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010026516,0.0018288142,0.00036870633,0.013351477,0.001383267,0.000018466906,0.002283777,0.00017934614,0.00023797795,0.013523577,0.3513759,0.61444604],"study_design_scores_gemma":[0.0018028611,0.000996748,0.00033385522,0.04482702,0.00016176119,0.0000530244,0.00002850394,0.00044224565,0.00018747537,0.00117393,0.9491207,0.0008718897],"about_ca_topic_score_codex":0.00004926673,"about_ca_topic_score_gemma":0.0000023151845,"teacher_disagreement_score":0.61357415,"about_ca_system_score_codex":0.00038760898,"about_ca_system_score_gemma":0.001837907,"threshold_uncertainty_score":0.99933463},"labels":[],"label_agreement":null},{"id":"W2997288603","doi":"10.1080/13543784.2020.1709822","title":"Phase I/II parallel double-blind randomized controlled clinical trial of perispinal etanercept for chronic stroke: improved mobility and pain alleviation","year":2020,"lang":"en","type":"article","venue":"Expert Opinion on Investigational Drugs","topic":"Botulinum Toxin and Related Neurological Disorders","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Etanercept; Medicine; Physical therapy; Placebo; Stroke (engine); Visual analogue scale; Randomized controlled trial; Chronic pain; Clinical trial; Chronic stroke; Physical medicine and rehabilitation; Rehabilitation; Internal medicine; Tumor necrosis factor alpha","score_opus":0.1003967417263509,"score_gpt":0.3981617017785402,"score_spread":0.29776496005218933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2997288603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8458523,0.0026519378,0.008379037,0.122788586,0.0010379502,0.01855809,0.000062062994,0.0001551332,0.0005148604],"genre_scores_gemma":[0.9797888,0.0030329942,0.0028435064,0.010728384,0.0012135981,0.0017265856,0.0004577699,0.000033311404,0.0001750615],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99648577,0.00080467947,0.0014900643,0.00057400676,0.00042006082,0.00022544122],"domain_scores_gemma":[0.9966119,0.002115786,0.0005012897,0.00018860122,0.00018493125,0.00039748388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024212126,0.00027513612,0.0014947221,0.00006895689,0.00015376217,0.000018332299,0.00010438307,0.00037076554,0.00013178067],"category_scores_gemma":[0.0037227373,0.00019054426,0.0006968183,0.00011744944,0.0006962757,0.00007772425,0.000040715924,0.00042904858,0.0000035877924],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98579925,0.0017443238,0.0000053510166,0.00006321733,0.00033218926,5.202612e-7,0.00063137943,0.00011121258,0.0025258851,0.0035853144,0.001070528,0.0041308217],"study_design_scores_gemma":[0.8552068,0.018073339,0.000024490797,0.00005029224,0.000057308283,0.0000010988526,0.00007339477,0.121144004,0.00019235178,0.0005870677,0.0044328496,0.00015701434],"about_ca_topic_score_codex":0.00000647407,"about_ca_topic_score_gemma":2.7914274e-7,"teacher_disagreement_score":0.13393645,"about_ca_system_score_codex":0.00003528977,"about_ca_system_score_gemma":0.0003640455,"threshold_uncertainty_score":0.77701694},"labels":[],"label_agreement":null},{"id":"W3014880052","doi":"10.1080/13543784.2020.1751121","title":"Investigational non-JAK inhibitors for chronic phase myelofibrosis","year":2020,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Princess Margaret Cancer Foundation","keywords":"Myelofibrosis; Ruxolitinib; Medicine; Clinical trial; Phases of clinical research; Tofacitinib; Pharmacology; Internal medicine; Oncology; Bone marrow","score_opus":0.08566006386425828,"score_gpt":0.41308605949262,"score_spread":0.3274259956283617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014880052","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000020390864,0.98106766,0.00011778667,0.010445269,0.0014967626,0.004869463,0.001099442,0.00015834448,0.00072485727],"genre_scores_gemma":[0.00003670474,0.9598016,0.0057015554,0.0038329165,0.006342826,0.0076426403,0.016120648,0.00020358343,0.00031749596],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99533695,0.00017809715,0.0014471745,0.0013552259,0.0011439217,0.0005386286],"domain_scores_gemma":[0.9963454,0.0010950029,0.0007010503,0.0005074431,0.00032292778,0.0010281886],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024711562,0.0011013494,0.0023227502,0.00045168374,0.00039676513,0.00010568407,0.00026734459,0.00056601956,0.00033684325],"category_scores_gemma":[0.0005675917,0.0008958563,0.0011468236,0.0006319278,0.0004032136,0.00018283055,0.00009734107,0.0006009189,0.0005474523],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014453327,0.00096994836,0.000019760564,0.0075718663,0.0011296972,0.0000149880125,0.0007429563,0.000011577842,0.000038689523,0.019313948,0.2587409,0.71130115],"study_design_scores_gemma":[0.0040597455,0.0018589229,0.000014054095,0.022930669,0.000182532,0.000040304767,0.00002420402,0.00035295903,0.0006406146,0.00058259984,0.96859473,0.00071865466],"about_ca_topic_score_codex":0.000015087048,"about_ca_topic_score_gemma":8.461382e-7,"teacher_disagreement_score":0.7105825,"about_ca_system_score_codex":0.0013786147,"about_ca_system_score_gemma":0.004733,"threshold_uncertainty_score":0.99934924},"labels":[],"label_agreement":null},{"id":"W4211020510","doi":"10.1080/13543784.2022.2040479","title":"Emerging neuroprotective interventions in periventricular leukomalacia - A systematic review of preclinical studies","year":2022,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Neonatal and fetal brain pathology","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Neuroprotection; Psychological intervention; Clinical trial; Context (archaeology); Periventricular leukomalacia; Cerebral palsy; Intensive care medicine; Pathology; Pharmacology; Physical therapy; Pregnancy; Psychiatry","score_opus":0.1825023867716277,"score_gpt":0.4551623112909132,"score_spread":0.27265992451928556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4211020510","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000029498754,0.9944436,0.000008313209,0.0008192746,0.0005966152,0.003804674,0.000052293475,0.00003438605,0.00023789916],"genre_scores_gemma":[0.000004632195,0.9940937,0.00027847552,0.0013280188,0.0001340117,0.0034350655,0.00047071467,0.00004428189,0.00021110817],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9948923,0.0014435843,0.0021864597,0.0005895951,0.0006813908,0.00020667005],"domain_scores_gemma":[0.9970699,0.0012419801,0.0009966358,0.00043986697,0.00013347362,0.000118157746],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011825074,0.00040050817,0.0032880637,0.0004938187,0.00009048322,0.0000050506123,0.00024905693,0.00014194073,0.0002521147],"category_scores_gemma":[0.0060033947,0.00030411064,0.0013200793,0.00078189926,0.0002757891,0.000057545876,0.00025609139,0.0007788731,0.000039014016],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012752836,0.00022005064,0.000001262625,0.97394294,0.00033736954,0.000052256815,0.00058684795,9.74161e-7,4.0264152e-7,0.0017290249,0.00050213694,0.022614006],"study_design_scores_gemma":[0.00027054935,0.00032180094,0.0000063271896,0.7531483,0.00019084405,0.00019724327,0.00021356558,0.000007026938,0.0000010488711,0.00020707052,0.24524596,0.00019026693],"about_ca_topic_score_codex":0.0000060774723,"about_ca_topic_score_gemma":2.038798e-7,"teacher_disagreement_score":0.24474382,"about_ca_system_score_codex":0.0003193725,"about_ca_system_score_gemma":0.00039754107,"threshold_uncertainty_score":0.9999411},"labels":[],"label_agreement":null},{"id":"W4211244827","doi":"10.1517/13543784.11.2.189","title":"The macrolides","year":2002,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Pneumonia and Respiratory Infections","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; St. Paul's Hospital; Royal University Hospital","funders":"","keywords":"Clarithromycin; Azithromycin; Erythromycin; Medicine; Macrolide Antibiotics; Antimicrobial; Antibiotics; Intensive care medicine; Dosing; Adverse effect; Antibiotic resistance; Clinical trial; Pharmacology; Biology; Internal medicine; Microbiology","score_opus":0.10257103055064343,"score_gpt":0.3915771278110502,"score_spread":0.28900609726040677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4211244827","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[7.3801107e-7,0.98028404,0.0000027077804,0.0050463085,0.001706281,0.0006338014,0.000029603249,0.00011157501,0.012184961],"genre_scores_gemma":[0.000002015711,0.9901853,0.000040373012,0.003352636,0.0019590028,0.0005066166,0.00020202178,0.000059493042,0.0036925385],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99802375,0.00018974561,0.00058538356,0.00037691463,0.00054615195,0.00027804062],"domain_scores_gemma":[0.9982404,0.0006545871,0.00024263895,0.00049067056,0.000095990465,0.0002757058],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019189701,0.00037939672,0.0007048056,0.00018701467,0.00062502257,0.00006949522,0.00019986759,0.00029501072,0.00018981192],"category_scores_gemma":[0.00027980763,0.0002168917,0.0005318286,0.0003438343,0.00037208552,0.00004942972,0.00004444004,0.00061183266,0.0013713196],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000033340932,0.00008637416,0.0000034159254,0.00078641064,0.00018383421,0.0000052588675,0.0001404031,0.0000012732191,0.000002619235,0.016865978,0.1372622,0.8446589],"study_design_scores_gemma":[0.00017530071,0.00008875007,0.000010676895,0.006180749,0.000026852007,0.00013742856,0.000017717126,0.000014291245,0.0000028469592,0.00029087576,0.99283457,0.00021994855],"about_ca_topic_score_codex":0.0000043044392,"about_ca_topic_score_gemma":2.2522849e-7,"teacher_disagreement_score":0.85557234,"about_ca_system_score_codex":0.0002018568,"about_ca_system_score_gemma":0.0004861495,"threshold_uncertainty_score":0.9994062},"labels":[],"label_agreement":null},{"id":"W4230784343","doi":"10.1517/13543784.14.7.905","title":"Stiripentol","year":2005,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dravet syndrome; Medicine; Carbamazepine; Epilepsy; Felbamate; CYP2C19; Tolerability; Clobazam; Pharmacology; Myoclonic epilepsy; Orphan drug; Adjunctive treatment; Clinical trial; Pediatrics; Adverse effect; Internal medicine; Bioinformatics; Psychiatry","score_opus":0.13481690479529249,"score_gpt":0.4447422447116589,"score_spread":0.3099253399163664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230784343","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[8.190287e-7,0.9819657,0.0000042891543,0.002763856,0.0004595782,0.0012246852,0.00008369398,0.00010129205,0.013396052],"genre_scores_gemma":[0.000002552695,0.98652947,0.0014027073,0.0014642123,0.0023887048,0.00076865935,0.0033739118,0.00007552181,0.003994241],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99718875,0.00016533722,0.00059758493,0.0005975952,0.0010633974,0.0003873545],"domain_scores_gemma":[0.99816555,0.0003423677,0.0001883471,0.0005138976,0.000112750364,0.00067711016],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0001893046,0.00048343884,0.0011291935,0.00037177268,0.00013094768,0.000042708347,0.0001899557,0.00029102305,0.0010262623],"category_scores_gemma":[0.00022115158,0.00035065308,0.0005356738,0.0003091277,0.00019762215,0.00007694261,0.00006164113,0.00056388497,0.0031026257],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019537174,0.0002627527,0.000006089483,0.0011107932,0.00022381723,0.000015433894,0.00008793945,4.6537576e-7,1.8789851e-7,0.0066647376,0.09344421,0.89816403],"study_design_scores_gemma":[0.0006509213,0.00026740294,0.000020027506,0.013305155,0.000031047537,0.0000684055,0.000012190003,0.000011874392,0.0000047355934,0.00015033539,0.9852111,0.0002668299],"about_ca_topic_score_codex":0.00001705623,"about_ca_topic_score_gemma":3.9958786e-7,"teacher_disagreement_score":0.8978972,"about_ca_system_score_codex":0.00054505037,"about_ca_system_score_gemma":0.0014497355,"threshold_uncertainty_score":0.99989456},"labels":[],"label_agreement":null},{"id":"W4232214719","doi":"10.1517/13543784.9.7.1511","title":"Psoriatic arthritis","year":2000,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"","keywords":"Psoriatic arthritis; Medicine; Rheumatoid arthritis; Arthritis; Psoriasis; Dactylitis; Inflammatory arthritis; Immunology; Osteolysis; Cytokine; Pathogenesis; Dermatology; Enthesitis; Surgery","score_opus":0.05957936896122606,"score_gpt":0.36995000607833156,"score_spread":0.3103706371171055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232214719","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000021438702,0.9881025,0.0000039846486,0.0015101545,0.00068884913,0.0009568244,0.00009265661,0.00013724863,0.008505638],"genre_scores_gemma":[0.0000031639177,0.9929734,0.0004916731,0.0015978634,0.0013908437,0.00062001264,0.0019587972,0.00010113508,0.00086311984],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996873,0.00026013024,0.000788024,0.0005865391,0.0010571203,0.00043514013],"domain_scores_gemma":[0.99832433,0.00035403998,0.00018139971,0.0005030251,0.00008914719,0.00054805237],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002263992,0.0004995594,0.0014211178,0.00043185233,0.0002037565,0.00008450356,0.00022096527,0.0003124998,0.0024688344],"category_scores_gemma":[0.00023462558,0.0004106381,0.00055095204,0.0003682209,0.00032824554,0.000114622875,0.00003842039,0.00065155467,0.002852284],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000205179,0.000093872186,2.7438878e-7,0.00069897185,0.00013994188,0.000012010807,0.00021051025,3.3631954e-7,1.4812406e-7,0.006016375,0.06263646,0.9301706],"study_design_scores_gemma":[0.0008435919,0.000222513,0.0000022877068,0.04244386,0.0000029328064,0.0001714521,0.000019502171,0.000012075805,0.000003242182,0.0014581985,0.95448005,0.00034029086],"about_ca_topic_score_codex":0.00003286445,"about_ca_topic_score_gemma":6.080753e-7,"teacher_disagreement_score":0.9298303,"about_ca_system_score_codex":0.00016951236,"about_ca_system_score_gemma":0.0012110559,"threshold_uncertainty_score":0.99983454},"labels":[],"label_agreement":null},{"id":"W4233825669","doi":"10.1517/eoid.12.10.1655.21840","title":"Targeting cellular energy production in neurological disorders","year":2003,"lang":"en","type":"article","venue":"Expert Opinion on Investigational Drugs","topic":"Diet and metabolism studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Production (economics); Medicine; Neuroscience; Biology","score_opus":0.022253948457351243,"score_gpt":0.26888812325229017,"score_spread":0.24663417479493893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233825669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8556685,0.014742883,0.00037921584,0.06689632,0.009272077,0.00092062156,0.000005283758,0.00031627208,0.051798847],"genre_scores_gemma":[0.99040574,0.0022235508,0.0015845227,0.0043709446,0.0006355637,0.00012084211,0.0000867734,0.000020253656,0.0005517817],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99876666,0.00011845766,0.000248829,0.0003366811,0.00032359024,0.0002057848],"domain_scores_gemma":[0.9996082,0.000064165324,0.00005471532,0.00012181178,0.000048166155,0.00010291866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021962357,0.00014554514,0.00018873975,0.00013005336,0.00009672653,0.000008618487,0.00004294262,0.0000689253,0.00006819578],"category_scores_gemma":[0.0007688957,0.00012234008,0.00005461008,0.00024181358,0.00014000355,0.000077447025,0.000016489219,0.00015068777,0.00002138363],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044283818,0.0016663978,0.08377711,0.00007008714,0.000096915974,0.0000138726555,0.0074584307,0.0019645344,0.038891666,0.70489824,0.14215988,0.018560005],"study_design_scores_gemma":[0.001265216,0.00021383156,0.03963969,0.0000843728,0.0000033562794,0.0000031214254,0.0005545834,0.00043125864,0.00953375,0.017199872,0.93078595,0.000285024],"about_ca_topic_score_codex":0.000029183188,"about_ca_topic_score_gemma":0.0000014525581,"teacher_disagreement_score":0.788626,"about_ca_system_score_codex":0.00002043868,"about_ca_system_score_gemma":0.00007161275,"threshold_uncertainty_score":0.49888837},"labels":[],"label_agreement":null},{"id":"W4238239896","doi":"10.1517/eoid.13.2.139.26339","title":"Current and investigational treatment of psoriatic arthritis","year":2004,"lang":"en","type":"article","venue":"Expert Opinion on Investigational Drugs","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Investigational Drugs; Psoriatic arthritis; Medicine; Psoriasis; Dermatology; Intensive care medicine; Internal medicine; Clinical trial","score_opus":0.0353861475486092,"score_gpt":0.31567753421729017,"score_spread":0.280291386668681,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238239896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9241381,0.05590125,0.000054279706,0.016406242,0.0012074538,0.0008799269,0.00012945963,0.00008192513,0.001201323],"genre_scores_gemma":[0.9662672,0.02683733,0.0042192684,0.0011894063,0.00062866014,0.0002612501,0.000519963,0.000028426368,0.000048456666],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987085,0.00002584022,0.00034692537,0.00030878707,0.0004365893,0.00017335606],"domain_scores_gemma":[0.9992961,0.00008101251,0.0001100787,0.00016292532,0.00010625374,0.00024360375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000046063313,0.00020864919,0.0003151021,0.0001257397,0.00014056738,0.000011778434,0.00003231028,0.000054642525,0.00005496521],"category_scores_gemma":[0.00008142154,0.00017701495,0.00008929288,0.0001505944,0.00033755004,0.00007529242,0.000018251529,0.000061013194,0.0000350261],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006286846,0.005001175,0.028159615,0.00016610579,0.00082638994,0.00003936118,0.016815523,0.0002823965,0.002355842,0.45653155,0.0067870547,0.4824063],"study_design_scores_gemma":[0.061787277,0.010110529,0.35634404,0.005294599,0.00006626994,0.000316935,0.0012376402,0.00027070256,0.04241678,0.12171561,0.39926374,0.0011758915],"about_ca_topic_score_codex":0.00012978843,"about_ca_topic_score_gemma":0.000004737194,"teacher_disagreement_score":0.4812304,"about_ca_system_score_codex":0.00019817986,"about_ca_system_score_gemma":0.00026441144,"threshold_uncertainty_score":0.72184604},"labels":[],"label_agreement":null},{"id":"W4241182179","doi":"10.1517/13543784.10.10.1869","title":"Eletriptan","year":2001,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Sumatriptan; Triptans; Migraine; Zolmitriptan; Medicine; Pharmacology; Onset of action; Rizatriptan; Anesthesia; Agonist; Adverse effect; Internal medicine; Receptor","score_opus":0.1467284620387652,"score_gpt":0.4242388683436477,"score_spread":0.27751040630488255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241182179","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[4.837482e-7,0.9505532,0.000006233583,0.0028028016,0.00029709263,0.00067086116,0.000034862926,0.00011087633,0.04552363],"genre_scores_gemma":[6.6299157e-7,0.97577035,0.00067810534,0.0038507346,0.0031853986,0.00030077415,0.0013708689,0.00007257208,0.014770546],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99766487,0.00010419929,0.0006853796,0.0005380255,0.0006919612,0.00031553832],"domain_scores_gemma":[0.99862504,0.0002809927,0.00023684588,0.00042148537,0.0001240962,0.00031151832],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019696969,0.0004964312,0.0014459435,0.00038815028,0.00017310966,0.000022698026,0.00015552835,0.0003274847,0.00062204676],"category_scores_gemma":[0.00035988714,0.0003762289,0.00065146707,0.0005860434,0.00019556348,0.000049770766,0.000060722272,0.00057783705,0.00097214506],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008034554,0.00008418944,0.000003875513,0.0019054736,0.00018404686,0.00000787637,0.00027676136,7.8437154e-8,2.6794453e-7,0.010796879,0.6860122,0.30072033],"study_design_scores_gemma":[0.00033121454,0.00014636687,0.000013581602,0.014663844,0.00004092574,0.00008535468,0.00006494238,0.0000033689691,0.0000013541907,0.00033717573,0.9839836,0.0003283102],"about_ca_topic_score_codex":0.000030124509,"about_ca_topic_score_gemma":6.138059e-7,"teacher_disagreement_score":0.30039203,"about_ca_system_score_codex":0.00024113119,"about_ca_system_score_gemma":0.0007354627,"threshold_uncertainty_score":0.999869},"labels":[],"label_agreement":null},{"id":"W4244867483","doi":"10.1517/eoid.12.11.1855.21883","title":"Experimental and clinical studies show that the probucol derivative AGI-1067 prevents vascular growth","year":2003,"lang":"en","type":"article","venue":"Expert Opinion on Investigational Drugs","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Probucol; Restenosis; Medicine; Internal medicine; Endocrinology; Lipoprotein; Cholesterol; Stent","score_opus":0.052125097192935115,"score_gpt":0.3499731531585472,"score_spread":0.2978480559656121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244867483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8996001,0.07510175,0.00043616642,0.0041265255,0.01673871,0.0017316388,0.000040600447,0.000048885504,0.0021756296],"genre_scores_gemma":[0.96166927,0.0144474385,0.0023468444,0.009472449,0.010384476,0.0006919565,0.00019680303,0.000058469228,0.0007322725],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99844646,0.00032993493,0.0002692413,0.00045066356,0.00030944502,0.00019423365],"domain_scores_gemma":[0.9993281,0.00008363009,0.00011073305,0.0002485657,0.00009854186,0.00013044427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040845442,0.00020881453,0.00019962546,0.000029397675,0.00023383525,0.00003048938,0.00014539,0.00011403144,0.000018303188],"category_scores_gemma":[0.00037261998,0.00015312513,0.00012702284,0.00006811514,0.00054564065,0.000014358335,0.000090329195,0.00012504826,0.000005709193],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033244176,0.0010687399,0.015302486,0.00007198119,0.0017957763,3.9879876e-7,0.012595868,0.000050506904,0.23253681,0.0889015,0.6440691,0.0032743982],"study_design_scores_gemma":[0.0014558759,0.0002712381,0.00463565,0.0000632574,0.000007528465,0.000008644662,0.002576729,0.000017459066,0.1931423,0.0016218424,0.7958888,0.000310678],"about_ca_topic_score_codex":0.000010938313,"about_ca_topic_score_gemma":0.0000010869682,"teacher_disagreement_score":0.15181972,"about_ca_system_score_codex":0.000027351682,"about_ca_system_score_gemma":0.00014601498,"threshold_uncertainty_score":0.6244262},"labels":[],"label_agreement":null},{"id":"W4246532558","doi":"10.1517/eoid.13.3.199.27347","title":"Recent advances in protein tyrosine phosphatase 1B inhibitors","year":2004,"lang":"en","type":"article","venue":"Expert Opinion on Investigational Drugs","topic":"Protein Tyrosine Phosphatases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Insulin resistance; Downregulation and upregulation; Protein tyrosine phosphatase; Leptin; Type 2 diabetes; Insulin; Diabetes mellitus; Obesity; Insulin receptor; Biology; Phosphatase; Internal medicine; Endocrinology; Tyrosine; Medicine; Cell biology; Biochemistry; Phosphorylation","score_opus":0.01315410682153738,"score_gpt":0.2786591131533658,"score_spread":0.2655050063318284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246532558","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14189714,0.8245666,0.0007240032,0.025603546,0.0021178767,0.0027438272,0.00056117726,0.00015301698,0.0016328199],"genre_scores_gemma":[0.9053534,0.053377643,0.015929297,0.011554506,0.002430289,0.0018191414,0.009170381,0.00014482223,0.00022046665],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984272,0.000059454967,0.0003550696,0.0005143737,0.0003611194,0.00028279383],"domain_scores_gemma":[0.9992859,0.000014356031,0.00012220694,0.00032394673,0.0000875077,0.00016611593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017821541,0.00024135514,0.00014884793,0.00008894987,0.000097320066,0.00002837356,0.00021472434,0.00012625869,0.000039581948],"category_scores_gemma":[0.0003690077,0.00023914379,0.000054189535,0.00025002784,0.00020463174,0.000032865562,0.000093215305,0.00013845455,0.000054512337],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014236332,0.0020630222,0.0009964613,0.000108071225,0.00006435216,0.000023734561,0.0008173243,0.011265295,0.32677874,0.48478413,0.04857293,0.12310234],"study_design_scores_gemma":[0.0011054868,0.00017416208,0.00017606371,0.0001462762,2.8328384e-7,0.000002361743,0.000027571296,0.0000063640014,0.6029854,0.0035975748,0.39158675,0.00019171454],"about_ca_topic_score_codex":0.000042498566,"about_ca_topic_score_gemma":0.000010809695,"teacher_disagreement_score":0.771189,"about_ca_system_score_codex":0.000103832615,"about_ca_system_score_gemma":0.00028168978,"threshold_uncertainty_score":0.9752001},"labels":[],"label_agreement":null},{"id":"W4322763591","doi":"10.1080/13543784.2023.2187286","title":"The potential role of opioid vaccines and monoclonal antibodies in the opioid overdose crisis","year":2023,"lang":"en","type":"editorial","venue":"Expert Opinion on Investigational Drugs","topic":"Opioid Use Disorder Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute on Drug Abuse; National Institutes of Health; World Health Organization","keywords":"Opioid; Monoclonal antibody; Opioid overdose; Medicine; Virology; Antibody; Immunology; (+)-Naloxone; Internal medicine; Receptor","score_opus":0.011568094082562333,"score_gpt":0.29870801845156664,"score_spread":0.2871399243690043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322763591","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05077197,0.05211032,0.0000044462504,0.026662162,0.865886,0.002536346,0.0011437059,0.00018423612,0.0007008296],"genre_scores_gemma":[0.027554719,0.14929998,0.0011142581,0.0022160825,0.8055126,0.0011957163,0.011772853,0.0003568437,0.0009769744],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963781,0.00020669977,0.00072085013,0.0005984894,0.0017286915,0.00036713076],"domain_scores_gemma":[0.99647176,0.0022057113,0.00031881334,0.0005784004,0.0002921527,0.00013317107],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00050903397,0.0004745047,0.00056161487,0.00027125093,0.00031194856,0.00009567486,0.00038423293,0.0004260044,0.00002017195],"category_scores_gemma":[0.0010597358,0.00029099485,0.00020223417,0.0003453141,0.00029873673,0.00010150504,0.00015895761,0.00065844774,0.000031283624],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029714534,0.00022008835,0.00044575872,0.00012292463,0.00017654906,0.000006623671,0.0075389463,0.000027230686,0.0001252675,0.0022415256,0.9875288,0.0012691297],"study_design_scores_gemma":[0.002322589,0.00042953045,0.016108489,0.0008341569,0.00004212883,0.0000055505593,0.009476402,0.00035644515,0.0004620551,0.011232529,0.9583533,0.00037686864],"about_ca_topic_score_codex":0.0008531136,"about_ca_topic_score_gemma":0.00001641533,"teacher_disagreement_score":0.09718965,"about_ca_system_score_codex":0.00013006527,"about_ca_system_score_gemma":0.0008296982,"threshold_uncertainty_score":0.9999542},"labels":[],"label_agreement":null},{"id":"W4366990971","doi":"10.1080/13543784.2023.2206559","title":"Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials","year":2023,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Brain and Cognition Discovery Foundation; University Health Network","funders":"","keywords":"Tolerability; Adverse effect; Schizophrenia (object-oriented programming); Clinical trial; Medicine; Psychiatry; Systematic review; Antipsychotic; Pharmacology; Psychology; MEDLINE; Internal medicine","score_opus":0.22589218821859425,"score_gpt":0.493442865454273,"score_spread":0.26755067723567877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366990971","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000509327,0.98416114,0.0000037348634,0.0017834401,0.00016896604,0.012264272,0.0010709502,0.000022443426,0.000015753223],"genre_scores_gemma":[0.00009146103,0.9971388,0.00071716093,0.000057121862,0.00013646302,0.0011969575,0.00044433225,0.00006547521,0.00015220205],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9932217,0.0020115306,0.0033911818,0.0005802617,0.0005950866,0.00020022018],"domain_scores_gemma":[0.9800842,0.017247118,0.0017754606,0.0004751328,0.00013133835,0.0002867419],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0041235713,0.00043697536,0.004842831,0.00012895513,0.00008710725,0.0000135173295,0.00012720961,0.00026425044,0.00004169405],"category_scores_gemma":[0.0098339245,0.00023817687,0.0008839534,0.00022273889,0.0008187604,0.00002697526,0.00005605094,0.00017536935,0.0000033949004],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008206479,0.0042707976,0.00020896751,0.5749007,0.008084115,7.1505616e-7,0.00096634653,1.4792417e-7,0.000002089856,0.0019592436,0.0016175734,0.39978287],"study_design_scores_gemma":[0.021209849,0.008120493,0.0014276305,0.82133293,0.0031314383,0.000014008745,0.00016618807,0.00018310832,0.000013200955,0.00038684983,0.14356562,0.00044867076],"about_ca_topic_score_codex":0.00007872634,"about_ca_topic_score_gemma":0.000022704662,"teacher_disagreement_score":0.3993342,"about_ca_system_score_codex":0.00015787901,"about_ca_system_score_gemma":0.0006505734,"threshold_uncertainty_score":0.99850667},"labels":[],"label_agreement":null},{"id":"W4378347895","doi":"10.1080/13543784.2023.2212155","title":"Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study","year":2023,"lang":"en","type":"article","venue":"Expert Opinion on Investigational Drugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Celltrion","keywords":"Tocilizumab; Medicine; Bioequivalence; Clinical endpoint; Cmax; Pharmacokinetics; Adverse effect; Internal medicine; Confidence interval; Pharmacology; Randomized controlled trial; European union; Area under the curve; Rheumatoid arthritis; Gastroenterology","score_opus":0.11854610921628209,"score_gpt":0.39229762798865775,"score_spread":0.2737515187723757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378347895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9388909,0.010353015,0.00027779563,0.02342641,0.008124186,0.007672591,0.00129491,0.00063371466,0.009326501],"genre_scores_gemma":[0.9949911,0.0019031417,0.000603562,0.0008583356,0.00013632607,0.0002611595,0.0006416105,0.0000341703,0.0005705427],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971442,0.0007680795,0.0008337185,0.0006163443,0.00023905876,0.00039857387],"domain_scores_gemma":[0.9975952,0.001463035,0.0002707266,0.0003521128,0.00018900089,0.00012992883],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011032177,0.00036126273,0.0007388143,0.00028722172,0.00026403708,0.000031573494,0.0002849498,0.0001878562,0.00047117606],"category_scores_gemma":[0.00044202394,0.00029089773,0.00015371834,0.0005472699,0.0011204333,0.00010635315,0.00018710959,0.00038433753,0.00007378054],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83804905,0.0025549876,0.00010024087,0.00008500206,0.0016881347,0.000019723213,0.0046398235,0.000056176308,0.065806754,0.031211177,0.028403966,0.02738496],"study_design_scores_gemma":[0.82020605,0.002203794,0.00017518623,0.0001759269,0.00010047864,0.000016404643,0.0016328099,0.00058785256,0.08821864,0.0012752292,0.084756,0.0006516436],"about_ca_topic_score_codex":0.00014749248,"about_ca_topic_score_gemma":0.000007716559,"teacher_disagreement_score":0.05635204,"about_ca_system_score_codex":0.000078134544,"about_ca_system_score_gemma":0.00015583805,"threshold_uncertainty_score":0.99995434},"labels":[],"label_agreement":null},{"id":"W4383186645","doi":"10.1080/13543784.2023.2233892","title":"Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies","year":2023,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Alzheimer's disease research and treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Health, British Columbia","keywords":"Primary (astronomy); Medicine; Neuroscience; Internal medicine; Oncology; Psychology; Physics","score_opus":0.1588989828028061,"score_gpt":0.443967261644877,"score_spread":0.28506827884207087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383186645","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000843241,0.99699473,0.000053821066,0.00027253418,0.00023381045,0.0017604141,0.00036111704,0.0000602796,0.0001789847],"genre_scores_gemma":[0.000027175209,0.9793936,0.012093507,0.0005521011,0.00035732865,0.0012813319,0.0061170277,0.00010021879,0.000077694385],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972235,0.00020564774,0.0011699613,0.0005145303,0.0006053738,0.00028101358],"domain_scores_gemma":[0.9968235,0.0018363015,0.000515768,0.00027882028,0.00020978363,0.00033583102],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043784786,0.00040149933,0.0013360244,0.00030028712,0.00020036416,0.000022505963,0.000117898526,0.00027860346,0.0000276484],"category_scores_gemma":[0.00025999692,0.00030965285,0.00043004993,0.0002156798,0.00039442428,0.00005304514,0.00006276668,0.0003273017,0.000031007505],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016788678,0.0003675832,0.00006571745,0.009863532,0.0052299793,0.000005840609,0.00032320755,3.7808408e-7,0.0000010915847,0.00061333,0.0016541043,0.98170733],"study_design_scores_gemma":[0.003390449,0.0006566895,0.0008933669,0.031219069,0.00030352906,0.000007947341,0.0001242137,0.000075975135,0.000074356525,0.00031880784,0.9625026,0.00043301767],"about_ca_topic_score_codex":0.0000047748567,"about_ca_topic_score_gemma":2.8379552e-7,"teacher_disagreement_score":0.9812743,"about_ca_system_score_codex":0.00020201597,"about_ca_system_score_gemma":0.005632508,"threshold_uncertainty_score":0.99993557},"labels":[],"label_agreement":null},{"id":"W4386347132","doi":"10.1080/13543784.2023.2254684","title":"Investigational monoclonal antibodies in early development for psoriatic arthritis: beyond the biosimilars","year":2023,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Memorial University of Newfoundland","funders":"","keywords":"Psoriatic arthritis; Biosimilar; Medicine; Psoriasis; Investigational Drugs; Clinical trial; Ixekizumab; Monoclonal antibody; Arthritis; Intensive care medicine; Immunology; Secukinumab; Internal medicine; Antibody","score_opus":0.11954500560529793,"score_gpt":0.3821567219202426,"score_spread":0.2626117163149446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386347132","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003531208,0.9902495,0.000048535065,0.004612428,0.0027847579,0.0015457466,0.00045205763,0.00009898523,0.00017269004],"genre_scores_gemma":[0.0000067160045,0.98467946,0.0064931214,0.0034508058,0.0004722227,0.0016793623,0.0023857856,0.00008805288,0.0007444468],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99611324,0.00069899525,0.0014670906,0.0008498597,0.0002621221,0.00060871465],"domain_scores_gemma":[0.9960557,0.0028626379,0.00046668848,0.00037462937,0.00013954242,0.0001007784],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013108731,0.00067391095,0.0013011219,0.0004836533,0.0005070143,0.00008080976,0.0006372579,0.0008371205,0.00011375719],"category_scores_gemma":[0.0008547608,0.0004667492,0.00046312762,0.0006469689,0.00093000603,0.0001051935,0.00017418565,0.0008115233,0.00037626651],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058805508,0.00021788856,0.000042427982,0.0016969901,0.001048193,0.000003230957,0.0017270584,0.000007878712,0.000027330241,0.07154204,0.14662388,0.77700424],"study_design_scores_gemma":[0.0006495447,0.000091118694,0.00023482711,0.0076949145,0.000027434467,0.000012026507,0.00006872201,0.000012590485,0.00020602542,0.010737905,0.9796986,0.0005663171],"about_ca_topic_score_codex":0.000015781972,"about_ca_topic_score_gemma":0.00000942375,"teacher_disagreement_score":0.8330747,"about_ca_system_score_codex":0.00021638797,"about_ca_system_score_gemma":0.001211631,"threshold_uncertainty_score":0.99977845},"labels":[],"label_agreement":null},{"id":"W4390744560","doi":"10.1080/13543784.2024.2305136","title":"Approaches to combating methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) biofilm infections","year":2024,"lang":"en","type":"editorial","venue":"Expert Opinion on Investigational Drugs","topic":"Bacterial biofilms and quorum sensing","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; School of Medicine; National Institutes of Health; NYU Grossman School of Medicine; York University; New York University","keywords":"Methicillin-resistant Staphylococcus aureus; Microbiology; Staphylococcus aureus; Biofilm; Medicine; Biology; Bacteria","score_opus":0.04675818851187052,"score_gpt":0.2883816623992882,"score_spread":0.24162347388741767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390744560","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012326094,0.0038452845,0.00015453127,0.008429638,0.9668798,0.0010092524,0.002458478,0.00021607937,0.0046808603],"genre_scores_gemma":[0.0059815603,0.0007106145,0.0046645445,0.0033117628,0.9652213,0.00033595605,0.017347729,0.00027365173,0.0021528671],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99644464,0.00023239988,0.0006780014,0.0012596285,0.0008808285,0.00050448754],"domain_scores_gemma":[0.9981738,0.00028900456,0.00024763402,0.0006456306,0.00025566,0.0003882735],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0005640332,0.0006667328,0.00046390158,0.00027845346,0.00038748738,0.0002801218,0.00037639486,0.0013677216,0.000032917575],"category_scores_gemma":[0.0010676032,0.0006368161,0.00031575604,0.00036388935,0.000247756,0.000011376671,0.00032024895,0.0008938578,0.00021657941],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052002626,0.000049628823,9.366085e-7,0.00004554322,0.00009629965,9.013488e-7,0.00019003564,0.00010570797,0.396371,0.0012741167,0.60157657,0.00023723209],"study_design_scores_gemma":[0.00026982697,0.0004062938,0.0000050299213,0.00042213433,0.000011120211,3.0955584e-7,0.000083194536,0.000052730782,0.11390891,0.00023744655,0.88393265,0.0006703801],"about_ca_topic_score_codex":0.00016391202,"about_ca_topic_score_gemma":0.000024946165,"teacher_disagreement_score":0.2824621,"about_ca_system_score_codex":0.00013520324,"about_ca_system_score_gemma":0.00088828773,"threshold_uncertainty_score":0.9999287},"labels":[],"label_agreement":null},{"id":"W4391399172","doi":"10.1080/13543784.2024.2313105","title":"Duchenne muscular dystrophy: promising early-stage clinical trials to watch","year":2024,"lang":"en","type":"article","venue":"Expert Opinion on Investigational Drugs","topic":"Muscle Physiology and Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Duchenne muscular dystrophy; Muscular dystrophy; Medicine; Clinical trial; Disease; Physical therapy; Physical medicine and rehabilitation; Pediatrics; Intensive care medicine; Internal medicine","score_opus":0.10370736443026966,"score_gpt":0.43758176156918466,"score_spread":0.333874397138915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391399172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805246,0.0016000081,0.0013734568,0.012562494,0.0022825005,0.0005482074,0.00006303164,0.00007575722,0.00096992485],"genre_scores_gemma":[0.98779356,0.00055923034,0.0020919123,0.0050717364,0.0026436343,0.00017987817,0.0006729899,0.000045116263,0.000941917],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99771535,0.0005630457,0.0005842557,0.000657026,0.00023469186,0.00024562725],"domain_scores_gemma":[0.9990565,0.00020349315,0.000076440534,0.00032984835,0.00007376248,0.0002599155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014056878,0.0002102393,0.00027840404,0.000061337305,0.00012289712,0.00006473301,0.00019253507,0.00023959765,0.00011898112],"category_scores_gemma":[0.0012150386,0.00018167231,0.00027102776,0.00013640142,0.00017100522,0.000011397415,0.000087226996,0.00019721758,0.00019038767],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012852418,0.00038826893,0.0007626183,0.00010958582,0.0005979832,0.000010278618,0.0017254843,0.0018552212,0.657033,0.06262269,0.24885586,0.02475374],"study_design_scores_gemma":[0.00086724566,0.00073405786,0.004661828,0.00014848342,0.0000056700683,0.0000022639822,0.00013130631,0.00046258877,0.045868147,0.0026673537,0.9440293,0.0004217792],"about_ca_topic_score_codex":0.000043479973,"about_ca_topic_score_gemma":0.0000010423714,"teacher_disagreement_score":0.6951734,"about_ca_system_score_codex":0.000020232073,"about_ca_system_score_gemma":0.00019895841,"threshold_uncertainty_score":0.74083817},"labels":[],"label_agreement":null},{"id":"W4392096159","doi":"10.1080/13543784.2024.2323528","title":"A modest proposal: targeting αv integrin-mediated activation of latent TGFbeta as a novel therapeutic approach to treat scleroderma fibrosis","year":2024,"lang":"en","type":"article","venue":"Expert Opinion on Investigational Drugs","topic":"Connective Tissue Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Scleroderma (fungus); Fibrosis; Integrin; Cancer research; Medicine; Immunology; Internal medicine; Receptor","score_opus":0.044870518804165045,"score_gpt":0.31950002056080734,"score_spread":0.2746295017566423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392096159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9683874,0.0017656576,0.016490871,0.0077917,0.00039742334,0.0015125159,0.00018056267,0.00013525097,0.0033386096],"genre_scores_gemma":[0.9950296,0.00007867464,0.0024017273,0.0005309034,0.00030196636,0.00025670996,0.0011706109,0.000052307227,0.00017747375],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99826556,0.00011243969,0.0002965256,0.00057967356,0.0004933206,0.00025245216],"domain_scores_gemma":[0.99919367,0.0001190253,0.000060122595,0.00024531127,0.00020725813,0.00017459648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025164784,0.00022597483,0.00016731575,0.00020386692,0.000084203566,0.000060782884,0.00021760474,0.00014466458,0.00003068253],"category_scores_gemma":[0.00035693217,0.00019774355,0.00009712296,0.00036770265,0.00013387608,0.000021570602,0.000115577415,0.00018311216,0.000037241447],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014793624,0.00016963064,0.00018219846,0.000073918076,0.00006815827,1.9238868e-7,0.0012634987,0.00087215437,0.98306495,0.009319414,0.0023424898,0.002495443],"study_design_scores_gemma":[0.00059107755,0.00050408044,0.0021142433,0.00027184366,0.0000036653846,0.0000049109567,0.0002707228,0.019951144,0.9551757,0.0007963863,0.019955907,0.00036032643],"about_ca_topic_score_codex":0.00015177921,"about_ca_topic_score_gemma":7.118916e-7,"teacher_disagreement_score":0.027889272,"about_ca_system_score_codex":0.000100666126,"about_ca_system_score_gemma":0.00035032374,"threshold_uncertainty_score":0.8063748},"labels":[],"label_agreement":null},{"id":"W4407232469","doi":"10.1080/13543784.2025.2462592","title":"Investigational gene expression inhibitors for the treatment of idiopathic pulmonary fibrosis","year":2025,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Pirfenidone; Nintedanib; Idiopathic pulmonary fibrosis; Medicine; Genetic enhancement; Tolerability; Clinical trial; Disease; Pulmonary fibrosis; Bioinformatics; Intensive care medicine; Fibrosis; Lung; Immunology; Adverse effect; Internal medicine; Gene; Biology; Genetics","score_opus":0.04677634943419064,"score_gpt":0.34750848443140736,"score_spread":0.30073213499721674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407232469","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010642629,0.9918504,0.00012157371,0.0015865333,0.0018704655,0.0029363863,0.0012361612,0.00006694529,0.0003208872],"genre_scores_gemma":[0.00011084159,0.98618895,0.0015359032,0.00057211367,0.0031349033,0.003073145,0.004557364,0.00008134439,0.00074541307],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99646705,0.00023195278,0.0013071704,0.0007992592,0.0008421533,0.00035239846],"domain_scores_gemma":[0.99669194,0.0013153277,0.0006473097,0.00069823116,0.00031584923,0.00033136335],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002640121,0.00072695035,0.0015891925,0.0004131813,0.0003988605,0.000037454247,0.00031520528,0.0004904927,0.000057696285],"category_scores_gemma":[0.00030014841,0.00046739576,0.0015814666,0.0004626768,0.0005084942,0.00010907162,0.00006918065,0.00026639173,0.000021817774],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00258513,0.0027393824,0.000026262289,0.04679014,0.0011622367,0.000016058335,0.0011942635,0.000074674244,0.00092574436,0.013219185,0.049956217,0.8813107],"study_design_scores_gemma":[0.0006089944,0.002002294,0.000012939578,0.06508518,0.0002819301,0.000026473801,0.000057543995,0.00021454656,0.001160675,0.00068299705,0.9294847,0.00038167968],"about_ca_topic_score_codex":0.000032036634,"about_ca_topic_score_gemma":1.3249759e-7,"teacher_disagreement_score":0.880929,"about_ca_system_score_codex":0.00053167064,"about_ca_system_score_gemma":0.0023634513,"threshold_uncertainty_score":0.9997778},"labels":[],"label_agreement":null},{"id":"W4410591077","doi":"10.1080/13543784.2025.2510664","title":"A randomized, Phase I study of the safety, tolerability, and pharmacokinetics of BI 764198, a transient receptor potential channel 6 (TRPC6) inhibitor, in healthy Japanese men","year":2025,"lang":"en","type":"article","venue":"Expert Opinion on Investigational Drugs","topic":"Ion Channels and Receptors","field":"Neuroscience","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"Boehringer Ingelheim","keywords":"Tolerability; Pharmacokinetics; TRPC6; Pharmacology; Transient receptor potential channel; Medicine; Receptor; Internal medicine; Adverse effect","score_opus":0.030759186528401816,"score_gpt":0.3303914103887965,"score_spread":0.2996322238603947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410591077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98250073,0.00032174806,0.000031326173,0.01200553,0.0023770125,0.0021401523,0.00006200395,0.00002037749,0.00054112775],"genre_scores_gemma":[0.9976033,0.00071538,0.000029022567,0.0011940303,0.00014551598,0.00017239548,0.000010733889,0.000013785767,0.00011580955],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99666595,0.0010097296,0.00095813454,0.00048018433,0.00067246525,0.00021354338],"domain_scores_gemma":[0.99872386,0.00059078744,0.00027430314,0.00019775765,0.00010292561,0.00011037583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007668729,0.00021983967,0.00052838225,0.00026889052,0.00017041988,0.000016731681,0.0002742449,0.000086791384,0.00004254738],"category_scores_gemma":[0.00044811092,0.00015450669,0.00012852724,0.000672771,0.00067507115,0.00009486652,0.00012461383,0.00023470794,0.0000014141619],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19066726,0.021758255,0.00016433172,0.0006702426,0.00017767605,0.0000030383778,0.24857962,0.017629066,0.48545948,0.011373621,0.0172178,0.0062996075],"study_design_scores_gemma":[0.42526534,0.002185885,0.00028385338,0.0009772948,0.000023180619,0.000005913741,0.013346877,0.038968332,0.5101205,0.0028623822,0.0053341016,0.0006263411],"about_ca_topic_score_codex":0.00027731917,"about_ca_topic_score_gemma":0.0000034184714,"teacher_disagreement_score":0.23523274,"about_ca_system_score_codex":0.000064618136,"about_ca_system_score_gemma":0.00019535482,"threshold_uncertainty_score":0.63006},"labels":[],"label_agreement":null},{"id":"W4410639051","doi":"10.1080/13543784.2025.2511177","title":"Prospects for multi-focal motor neuropathy treatment by complement inhibition","year":2025,"lang":"en","type":"editorial","venue":"Expert Opinion on Investigational Drugs","topic":"Peripheral Neuropathies and Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Neuroscience; Multifocal motor neuropathy; Complement (music); Medicine; Physical medicine and rehabilitation; Psychology; Biology; Genetics; Mismatch negativity","score_opus":0.03560388577186867,"score_gpt":0.3361237313942681,"score_spread":0.3005198456223994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410639051","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00085499324,0.0038016918,0.0009905335,0.011282076,0.9678388,0.006295653,0.0072257463,0.00039760707,0.0013128949],"genre_scores_gemma":[0.00081820117,0.00641255,0.0088424105,0.015680306,0.86388993,0.0074139917,0.0767971,0.0003231073,0.019822408],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99694365,0.00010951688,0.00063177664,0.0009242156,0.0009895375,0.00040129802],"domain_scores_gemma":[0.9982516,0.00045666128,0.00024682417,0.00036970948,0.00035590123,0.00031931626],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001313433,0.00059471995,0.0006270146,0.000191548,0.00029020998,0.000066859444,0.00012168256,0.00041810938,0.00007335294],"category_scores_gemma":[0.0007141293,0.00052479224,0.00033086547,0.0001588834,0.00018606539,0.00008004581,0.00005537711,0.00038752618,0.000023414423],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006714603,0.00080301607,0.000009967935,0.00017202985,0.00006488936,0.0000045997804,0.0002927843,0.000008948778,0.0015671396,0.00090674637,0.9942102,0.0012882184],"study_design_scores_gemma":[0.007217436,0.0028799889,0.000039090435,0.00065308774,0.000019161074,0.0000012532183,0.00009250033,0.001490752,0.0016141821,0.00019909522,0.9853957,0.00039771627],"about_ca_topic_score_codex":0.00014305227,"about_ca_topic_score_gemma":0.00000817007,"teacher_disagreement_score":0.103948876,"about_ca_system_score_codex":0.0006349402,"about_ca_system_score_gemma":0.00095524435,"threshold_uncertainty_score":0.99972034},"labels":[],"label_agreement":null},{"id":"W4411413756","doi":"10.1080/13543784.2025.2522885","title":"Acetylcholine and muscarinic receptor targeting in bipolar disorder: does xanomeline-trospium chloride and other investigational muscarinic agonists hold promise as mechanistically informed treatments for manic episodes, mixed features and cognitive deficits in bipolar disorder?","year":2025,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Receptor Mechanisms and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Muscarinic acetylcholine receptor; Mania; Bipolar disorder; Pharmacology; Medicine; Muscarinic acetylcholine receptor M4; Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M3; Investigational Drugs; Acetylcholine; Cognition; Internal medicine; Psychiatry; Receptor; Clinical trial","score_opus":0.018240322109553266,"score_gpt":0.31328305457724753,"score_spread":0.29504273246769425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411413756","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.028885411,0.96656823,0.0001909708,0.00033780525,0.0004725576,0.002515204,0.0009787234,0.000026362495,0.00002473979],"genre_scores_gemma":[0.0019742197,0.98461473,0.0032530369,0.00072285975,0.0003878657,0.0016781057,0.007026775,0.00010653974,0.00023584455],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99663204,0.00026698294,0.0010485465,0.001207836,0.00034917786,0.00049540726],"domain_scores_gemma":[0.9982916,0.0006115809,0.00044255567,0.00023266532,0.00014013602,0.0002814646],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00055821537,0.0007890905,0.0010584602,0.00043283016,0.00025972768,0.00016658906,0.00023337599,0.00075477234,0.000020757512],"category_scores_gemma":[0.001687053,0.0006575173,0.00019511992,0.00030369114,0.00029431004,0.000047721252,0.0002638983,0.00044548165,0.0000024727835],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014737432,0.0010791615,0.003972447,0.013918656,0.0016558216,0.0000066086604,0.0024958944,0.00005619201,0.010871381,0.040910218,0.0015137935,0.92204607],"study_design_scores_gemma":[0.0063537643,0.00094001484,0.00061535515,0.014112606,0.00017539682,0.000024427143,0.0006035986,0.00036694683,0.0059217666,0.0048060725,0.96425676,0.0018232662],"about_ca_topic_score_codex":0.00024774772,"about_ca_topic_score_gemma":0.00014237451,"teacher_disagreement_score":0.962743,"about_ca_system_score_codex":0.000111712856,"about_ca_system_score_gemma":0.00079330325,"threshold_uncertainty_score":0.9995876},"labels":[],"label_agreement":null},{"id":"W4412394230","doi":"10.1080/13543784.2025.2532446","title":"Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions","year":2025,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Kite Pharma; Chugai Pharmaceutical; Genentech; Juno Therapeutics; Incyte; BeiGene; Adaptive Biotechnologies; Regeneron Pharmaceuticals; Array BioPharma; Karyopharm Therapeutics; Exelixis; Sanofi; GlaxoSmithKline; Johns Hopkins University; Amgen; Pfizer; Legend Biotech; MorphoSys; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Multiple myeloma; Current (fluid); Medicine; Intensive care medicine; Immunology; Engineering","score_opus":0.11858936609891704,"score_gpt":0.4678993425352598,"score_spread":0.34930997643634276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412394230","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000004283419,0.99228823,0.000024254352,0.0017311315,0.002071742,0.0030577888,0.0005925051,0.000033981476,0.00019605717],"genre_scores_gemma":[0.0000039185693,0.9915379,0.001258321,0.00009199565,0.0024314132,0.0026464208,0.0015896682,0.000029341614,0.0004110144],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99784106,0.00020139583,0.0007586474,0.0005427533,0.0004136245,0.00024249252],"domain_scores_gemma":[0.9950331,0.003846404,0.00028382332,0.00041101137,0.00017687619,0.0002487786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018723389,0.00040108527,0.0012141838,0.00021509544,0.00027286055,0.000020916506,0.00012329766,0.0002024429,0.000022832353],"category_scores_gemma":[0.00046262195,0.00022165789,0.0006882091,0.00026390937,0.00036895688,0.000055639382,0.00003272118,0.00023282661,0.000009407769],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013482275,0.0008597694,0.000105940046,0.0033242896,0.00046338834,6.479767e-7,0.0001694938,2.0575453e-7,5.3515606e-8,0.0010230874,0.002661234,0.9912571],"study_design_scores_gemma":[0.002770239,0.0007736812,0.000343631,0.0054143146,0.00014265541,0.000006658874,0.0000621627,0.00008775344,0.0000041561316,0.000101520076,0.99014175,0.00015147164],"about_ca_topic_score_codex":0.000015781674,"about_ca_topic_score_gemma":0.00000318591,"teacher_disagreement_score":0.9911056,"about_ca_system_score_codex":0.00020433009,"about_ca_system_score_gemma":0.0009227757,"threshold_uncertainty_score":0.90389466},"labels":[],"label_agreement":null},{"id":"W4416026301","doi":"10.1080/13543784.2025.2587276","title":"Diffuse large B-cell lymphoma: what clinical progress have we seen in the last 5 years?","year":2025,"lang":"en","type":"article","venue":"Expert Opinion on Investigational Drugs","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Refractory (planetary science); Primary tumor; Clinical trial; Targeted therapy; First line treatment; Brentuximab vedotin","score_opus":0.03428570444146658,"score_gpt":0.3572830119342453,"score_spread":0.3229973074927787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416026301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8819282,0.014259107,0.000009836661,0.09537145,0.0016725102,0.001321453,0.000032436314,0.00008864168,0.0053163697],"genre_scores_gemma":[0.9690723,0.0054728254,0.00055212365,0.022953155,0.00050256535,0.00053977827,0.00032922978,0.000020810907,0.0005572558],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981014,0.00022758586,0.00047194396,0.00041160863,0.00052004925,0.00026741598],"domain_scores_gemma":[0.99873626,0.00057292846,0.00009563654,0.00039278285,0.00006126515,0.00014112731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043587576,0.00020115853,0.00028805347,0.00015041213,0.00010681482,0.00010977281,0.00018455049,0.00014773928,0.000031850395],"category_scores_gemma":[0.00010694686,0.00013812906,0.00015982363,0.00025663714,0.00022476433,0.000168109,0.000069873844,0.00014132465,0.00013396409],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004529952,0.03964679,0.48568302,0.000120601464,0.0002533905,0.00014853915,0.012597626,0.000005060803,0.000019189998,0.10411419,0.25100076,0.10595785],"study_design_scores_gemma":[0.01970587,0.0002470545,0.5089105,0.0009804544,0.000011262183,0.000008419383,0.0023539553,0.00024328913,0.00042722235,0.0015086043,0.46543565,0.00016772018],"about_ca_topic_score_codex":0.000026973836,"about_ca_topic_score_gemma":0.000007732224,"teacher_disagreement_score":0.2144349,"about_ca_system_score_codex":0.00019057782,"about_ca_system_score_gemma":0.00036963736,"threshold_uncertainty_score":0.56327397},"labels":[],"label_agreement":null}]}